pfnx-10q_20190930.htm

0001564590-19-041772.txt : 20191107 0001564590-19-041772.hdr.sgml : 20191107 20191107162133 ACCESSION NUMBER: 0001564590-19-041772 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191107 DATE AS OF CHANGE: 20191107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pfenex Inc. CENTRAL INDEX KEY: 0001478121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271356759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36540 FILM NUMBER: 191200675 BUSINESS ADDRESS: STREET 1: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-352-4400 MAIL ADDRESS: STREET 1: 10790 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 pfnx-10q_20190930.htm 10-Q pfnx-10q_20190930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36540

PFENEX INC.

(Exact name of registrant as specified in its charter)

Delaware

27-1356759

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)


10790 Roselle Street, San Diego, CA	92121
(Address of Principal Executive Offices)	(Zip Code)

(858) 352-4400

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

PFNX

NYSE American

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒

Non-accelerated filer	☐	Smaller reporting company	☒

		Emerging Growth Company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of November 1, 2019, the registrant had 31,675,903 shares of Common Stock ($0.001 par value) outstanding.

PFENEX INC.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	3
	Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018	3
	Consolidated Statements of Operations for the three and nine months ended September 30, 2019 and 2018	4
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018	5
	Consolidated Statements of Stockholders’ Equity for the nine months ended September 30, 2019 and 2018	6
	Notes to Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	33
Item 4.	Controls and Procedures	33
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	35
Item 1A.	Risk Factors	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	73
Item 3.	Defaults Upon Senior Securities	73
Item 4.	Mine Safety Disclosures	73
Item 5.	Other Information	73
Item 6.	Exhibits	74
EXHIBIT INDEX		74
SIGNATURES		75

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

PFENEX INC.

Consolidated Balance Sheets

	September 30, 2019 (unaudited)			December 31, 2018
	(in thousands)
Assets
Current assets
Cash and cash equivalents	$	32,518		$	56,220
Restricted cash		200			200
Accounts and unbilled receivables, net		16,215			5,171
Income tax receivable		53			207
Other current assets		2,357			1,851
Total current assets		51,343			63,649
Property and equipment, net		8,374			7,671
Other long-term assets		170			133
Intangible assets, net		3,859			4,248
Goodwill		5,577			5,577
Total assets	$	69,323		$	81,278
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	2,233		$	2,005
Accrued liabilities		8,352			9,812
Current portion of deferred revenue		105			5,317
Current portion of capital lease obligations		269			316
Total current liabilities		10,959			17,450
Deferred revenue, less current portion		2,500			2,500
Capital lease obligations, less current portion		29			191
Total liabilities		13,488			20,141
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding		—			—
Common stock, par value $0.001, 200,000,000 shares authorized; 31,622,914 and 31,467,580 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively		32			32
Additional paid-in capital		265,311			262,405
Accumulated deficit		(209,508	)		(201,300	)
Total stockholders’ equity		55,835			61,137
Total liabilities and stockholders’ equity	$	69,323		$	81,278

The accompanying notes are an integral part of these unaudited consolidated financial statements.

PFENEX INC.

Consolidated Statements of Operations

(unaudited)

	Three Months Ended September 30,					Nine Months Ended September 30,
(in thousands, except per share data)	2019		2018			2019			2018
Revenue
License revenue	$	11,562	$	1,874		$	20,430		$	6,869
Service revenue		733		1,339			3,155			3,821
Product revenue		2,953		357			4,836			816
Total revenue		15,248		3,570			28,421			11,506
Cost of revenue		1,143		1,479			3,837			3,923
Gross profit		14,105		2,091			24,584			7,583
Operating expense
Research and development		6,931		9,045			19,691			28,590
Selling, general and administrative		4,147		3,823			13,296			11,920
Total operating expense		11,078		12,868			32,987			40,510
Net income (loss) from operations		3,027		(10,777	)		(8,403	)		(32,927	)
Other income, net		55		115			195			157
Net income (loss)	$	3,082	$	(10,662	)	$	(8,208	)	$	(32,770	)
Net income (loss) per common share:
Basic	$	0.10	$	(0.34	)	$	(0.26	)	$	(1.20	)
Diluted	$	0.09	$	(0.34	)	$	(0.26	)	$	(1.20	)
Weighted-average common shares used in calculating net income (loss) per share:
Basic		31,595		31,437			31,534			27,288
Diluted		32,498		31,437			31,534			27,288

The accompanying notes are an integral part of these unaudited consolidated financial statements.

PFENEX INC.

Consolidated Statements of Cash Flows

(unaudited)

	Nine Months Ended September 30,
	2019			2018
	(in thousands)
Cash flows from operating activities
Net loss	$	(8,208	)	$	(32,770	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		968			849
Amortization of intangible assets		389			400
Stock-based compensation expense		2,381			2,551
Loss on disposal of property and equipment		—			8
Changes in operating assets and liabilities
Accounts and unbilled receivables		(11,044	)		(439	)
Other assets		(596	)		(268	)
Accounts payable		100			(560	)
Accrued liabilities		(1,887	)		2,031
Deferred revenue		(5,212	)		(522	)
Income tax receivable		207			432
Net cash used in operating activities		(22,902	)		(28,288	)
Cash flows from investing activities
Acquisitions of property and equipment		(1,076	)		(1,010	)
Purchase of intangible asset		—			(10	)
Net cash used in investing activities		(1,076	)		(1,020	)
Cash flows from financing activities
Proceeds from issuance of common stock		—			39,522
Repayments of capital lease obligations		(249	)		(212	)
Proceeds from exercise of stock options and other stock issuances		525			197
Payment for taxes related to net share settlement of equity award		—			(38	)
Net cash provided by financing activities		276			39,469
Net (decrease) increase in cash, cash equivalents and restricted cash		(23,702	)		10,161
Cash, cash equivalents and restricted cash
Beginning of period		56,420			57,864
End of period	$	32,718		$	68,025
Supplemental disclosures of non-cash investing and financing activities
Asset acquisitions in accounts payable and accrued expenses	$	747		$	92
Acquisitions under capital lease obligations	$	—		$	154
Restricted stock issuance for bonus accrual	$	—		$	56
Supplemental schedule of cash flow information
Cash paid for interest	$	18		$	36
Cash paid for taxes	$	1		$	48

The accompanying notes are an integral part of these unaudited consolidated financial statements.

PFENEX INC.

Consolidated Statements of Stockholders’ Equity

(unaudited)

(in thousands)

					Additional					Total
	Common Stock				Paid		Accumulated			Stockholders’
	Shares		Amount		in Capital		Deficit			Equity
Balance at December 31, 2017		23,548	$	24	$	219,446	$	(161,707	)	$	57,763
Restricted stock units		17		—		57		—			57
Issuance of common stock under employee stock purchase plan		19		—		55		—			55
Stock-based compensation expense		—		—		909		—			909
Net loss		—		—		—		(11,027	)		(11,027	)
Balance at March 31, 2018		23,584	$	24	$	220,467	$	(172,734	)	$	47,757
Issuance of common stock, net of offering costs		7,820		8		39,514		—			39,522
Exercise of stock options		17		—		14		—			14
Stock-based compensation expense		—		—		849		—			849
Net loss		—		—		—		(11,081	)		(11,081	)
Balance at June 30, 2018		31,421	$	32	$	260,844	$	(183,815	)	$	77,061
Exercise of stock options		20		—		65		—			65
Issuance of common stock under employee stock purchase plan		20		—		60		—			60
Stock-based compensation expense		—		—		794		—			794
Offering costs		—		—		1		—			1
Net loss		—		—		—		(10,662	)		(10,662	)
Balance at September 30, 2018		31,461	$	32	$	261,764	$	(194,477	)	$	67,319

Balance at December 31, 2018		31,468	$	32	$	262,405	$	(201,300	)	$	61,137
Exercise of stock options		15		—		60		—			60
Issuance of common stock under employee stock purchase plan		17		—		53		—			53
Stock-based compensation expense		—		—		880		—			880
Net loss		—		—		—		(3,661	)		(3,661	)
Balance at March 31, 2019		31,500	$	32	$	263,398	$	(204,961	)	$	58,469
Exercise of stock options		58		—		142		—			142
Stock-based compensation expense		—		—		830		—			830
Net loss		—		—		—		(7,629	)		(7,629	)
Balance at June 30, 2019		31,558	$	32	$	264,370	$	(212,590	)	$	51,812
Exercise of stock options		47		—		214		—			214
Issuance of common stock under employee stock purchase plan		18		—		56		—			56
Stock-based compensation expense		—		—		671		—			671
Net income		—		—		—		3,082			3,082
Balance at September 30, 2019		31,623	$	32	$	265,311	$	(209,508	)	$	55,835

The accompanying notes are an integral part of these consolidated financial statements

PFENEX INC.

Notes to Consolidated Financial Statements

1. Organization and Summary of Significant Accounting Policies

Business Activities and Organization

Pfenex Inc. (the Company or Pfenex) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology^® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of potential therapeutic equivalents, vaccines, biologics, and biosimilars. On October 4, 2019, the U.S. Food and Drug Administration (FDA) approved the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo^® (teriparatide injection) as the reference drug. Like Forteo, this FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. M arketing authorization applications are pending in other jurisdictions. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals Ireland Limited (Jazz) including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. Both PF743 and PF745 are being develop ed for the treatment of Acute Lymphoblastic Leukemia (ALL) and other hematological malignancies. The Company also uses its Pfēnex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vac cine candidates under development by Merck & Co, Inc. (Merck) and Serum Institute of India Private Ltd. (SIIPL). Both have licenses to the Pf ēnex Expression Technology for the production of CRM197 for use in conjugate vaccine products. The Company is focused developing its portfolio of partnered as well as wholly-owned peptides and complex proteins. Currently, the Company is exploring opportunities to develop novel modalities through an assessment program designed to evaluate and pursue validated biologic pathways that are differentially druggable via a selected modality in specific diseases. In addition, the Company is exploring a range of modality platforms and targets that are potentially compatible with its Pfēnex Expression Technology.

FDA-Approved PF708 Product

On October 4, 2019, the FDA approved the NDA for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug. The FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. The Company is currently in the process of transferring the NDA to Alvogen pursuant to the Alvogen Agreement, described below, between the companies. In addition, the Company has been continuing its efforts to obtain an “A” therapeutic equivalence designation for the product relative to its reference drug, Forteo. A determination of therapeutic equivalence may permit the FDA-approved PF708 product to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states. Consistent with the Company’s interactions with the FDA and the agency’s draft guidance document on demonstrating the therapeutic equivalence of drug-device combination products, the Company has completed a comparative human factors study comparing the FDA-approved PF708 product and Forteo. This human factors study was designed to further support a finding that the FDA-approved PF708 product is therapeutically equivalent to Forteo. On October 14, 2019, the Company announced the successful completion of its PF708 comparative use human factors study and its submission of the final study report to the FDA. The study data demonstrate that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo for each critical user task evaluated in the study based on pre-specified statistical analysis of critical patient and caregiver tasks. The Company believes this submission completes the information package required by the FDA to evaluate the therapeutic equivalence of the PF708 product. The Company’s collaboration partner, Alvogen, intends to launch the FDA-approved PF708 product in the U.S. upon an FDA decision on the therapeutic equivalence evaluation of the product.

In April 2018, the Company and China NT Pharma Group Company Ltd. (NT Pharma) entered into a Development and License Agreement (NT Pharma Agreement), pursuant to which the Company granted an exclusive license to NT Pharma to commercialize PF708 in Mainland China, Hong Kong, Singapore, Malaysia and Thailand and a non-exclusive license to conduct development activities in such territories with respect to PF708. The Company will be responsible for commercial manufacturing and providing product for commercial sale to NT Pharma. The Company will facilitate this obligation via its commercial partner Alvogen. NT Pharma is responsible for all regulatory submissions, development costs and costs associated with regulatory approvals in such territories.

In June 2018, the Company and Alvogen Malta Operations Ltd. (Alvogen) entered into a Development and License Agreement (Alvogen Agreement) pursuant to which Alvogen has the exclusive right to commercialize and manufacture PF708 in the United States. The Company expects Alvogen to launch FDA-approved PF708 in the U.S. upon an FDA rating decision on the therapeutic equivalence evaluation of the product. Following the FDA approval of the NDA for PF708, the FDA-approved PF708 product will be commercialized and manufactured in the U.S. by Alvogen. The Company is currently in the process of transferring the NDA to Alvogen pursuant to its collaboration agreement.

activities and for overseeing any clinical development, regulatory, litigation, commercial manufacturing and commercialization activities in these jurisdictions.

Collaboration Partner: Jazz Pharmaceuticals Ireland Limited

In July 2016, the Company and Jazz announced an agreement under which the Company granted Jazz worldwide rights to develop and commercialize multiple early stage hematology/oncology product candidates, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. In December 2017, the parties amended the Jazz agreement, bringing the total value of payments and potential payments associated with the collaboration to $224.5 million. In addition, the Company may be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement.

Pfēnex Expression Technology Licenses: CRM197

The Company has both licenses and supply agreements in place for CRM197, which is a non-toxic mutant of diphtheria toxin. It is a well-characterized protein and functions as a carrier for polysaccharides and haptens, making them immunogenic. The Company has developed unique CRM197 production strains based on its Pfēnex Expression Technology platform. As a result of these development efforts, the Company previously entered into commercial licenses for production strains capable of producing CRM197 with both Merck & Co., Inc. and Serum Institute of India Private Ltd. Merck and SIIPL are using the CRM197 produced via the licensed production strain in multiple clinical stage products. Those products currently include Merck’s 15-valent pneumococcal conjugate vaccine, PCV-15 (V114) currently in several ongoing Phase 3 clinical studies and SIIPL’s 10-valent pneumococcal conjugate vaccine Pneumosil® currently in WHO Prequalification and a pentavalent meningococcal conjugate vaccine currently in a Phase 3 clinical study. The CRM197 production strains utilized by both Merck and SIIPL are unique and exclusively licensed to each party. These commercial license agreements with Merck and SIIPL contemplate potential maintenance and milestone fees as well as royalties on net sales. Additionally, as part of the SIIPL commercial license agreement, SIIPL supplies both reagent grade and cGMP CRM197 to Pfenex, which supplies the product to vaccine development-focused pharmaceutical partners.

Arcellx Development, Evaluation and License Agreement

The Company previously entered into a development, evaluation and license agreement with Arcellx which provides access to the Pfēnex Expression Technology platform to advance Arcellx’s proprietary sparX proteins that activate, silence and reprogram Antigen- Receptor Complex T cell-based therapies. Under the terms of the agreement, Pfenex is eligible to receive development funding in addition to development, regulatory and commercial milestones ranging from $2.6 million to $18 million for each product incorporating a sparX protein expressed using the Pfēnex Expression Technology, as well as royalties on worldwide sales of any such products. The Company currently has two sparX proteins in development with Arcellx. As of September 30, 2019, the Company has recorded $1.8 million in revenue related to development for Arcellx.

Additional Novel Vaccine and Biosimilar Pipeline Products

The Company’s pipeline includes biosimilar candidates to certain reference products, including biosimilar candidates to Lucentis (PF582) and Neulasta (PF529) and two novel anthrax vaccine candidates, Px563L and RPA563, which are funded by the Biomedical Advanced Research and Development Authority (BARDA). In November of 2017, the Company paused development on both PF582 and PF529 and it does not intend to advance PF582 or PF529 without development and commercial collaboration partners. In March 2019 the Company received a notice from BARDA advising it of BARDA’s decision not to exercise development options for cGMP manufacturing, preclinical studies and Phase 1/2b study readiness in connection with the Company’s Px563L and RPA563 novel anthrax vaccine program. Following the receipt of the notice from BARDA and pursuant to discussions with BARDA, the Company deprioritized this program in its portfolio.

At the Market Offering Program

In March 2018, the Company entered into an equity sales agreement (Sales Agreement) with William Blair & Company, L.L.C. (William Blair) to sell shares of the Company’s common stock having aggregate sales proceeds of up to $20.0 million, from time to time, through an “at the market” equity offering program under which William Blair will act as sales agent. Under the Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. As of September 30, 2019, the Company had not sold any shares under the Sales Agreement.

Follow-on Public Offering

In May 2018, the Company completed a public offering of common stock in which it sold 7,820,000 shares of its common stock at an offering price of $5.50 per share, which included the full exercise by the underwriters of their option to purchase an additional 1,020,000 shares, pursuant to the Company’s prior shelf registration statement. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $39.5 million.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

Use of Estimates

The preparation of the accompanying unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.

Risk and Uncertainties

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the performance of the Company’s commercial partner Alvogen, uncertainty of results of clinical trials and reaching milestones, uncertainty of timing and types of regulatory approval of the Company’s product candidates, uncertainty of market acceptance of the Company’s products if approved for sale, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals.

Products developed by the Company require clearances from international and domestic regulatory agencies prior to commercial sales in such jurisdictions. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company.

As of September 30, 2019, the Company had an accumulated deficit of $209.5 million and expects to incur substantial operating losses for the next several years. The Company believes that its existing cash and cash equivalents and cash inflow from operations will be sufficient to meet its anticipated cash needs for at least the next 12 months from the date these unaudited consolidated financial statements are issued.

The Company will require substantial cash to achieve its objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. The Company may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. It will need to obtain significant funds under its existing collaborations and license agreements, under new collaboration, licensing or other commercial agreements for one or more of its product candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that it does not obtain additional funding, the Company will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on its ability to achieve its intended business objectives.

Cash and Cash Equivalents

The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash amounts that are restricted as to withdrawal or usage are presented as restricted cash. In January 2017, the Company entered into a Borrower’s Pledge Agreement, which required $0.2 million in restricted cash to be provided as security for its commercial credit card arrangement with one of the Company’s banks.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at three major financial institutions as of September 30, 2019 and December 31, 2018. For the Company’s cash position of $32.7 million as of September 30, 2019, which included restricted cash of $0.2 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance. Additional credit risk is related to the Company’s concentration of receivables. As of September 30, 2019, and December 31, 2018, receivables were concentrated among two and three customers representing 91% and 87% of total net receivables, respectively. No allowance for doubtful accounts was recorded at September 30, 2019 or December 31, 2018. For the three months ended September 30, 2019 and 2018, revenue was concentrated among two customers and/or collaboration partners representing 89% of total revenues for both periods. Revenue from two customers and/or collaboration partners represented 70% and 87% of total revenue for the nine months ended September 30, 2019 and 2018, respectively.

A portion of revenue is earned from entities located outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s revenue from U.S. and non-U.S. based sources for the nine months ended September 30, 2019 and 2018 is as follows:

	Three Months Ended September 30,				Nine months Ended September 30,
(in thousands)	2019		2018		2019		2018
US Revenue	$	877	$	1,371	$	4,172	$	3,877
Non-US Revenue		14,371		2,199		24,249		7,629
	$	15,248	$	3,570	$	28,421	$	11,506

During the three and nine months ended September 30, 2019, entities located in Ireland and Malta accounted for more than 10% of the Company’s revenue. During the three and nine months ended September 30, 2018, entities located in Ireland accounted for more than 10% of the Company’s revenue.

Fair Value of Financial Instruments

Financial instruments, including cash, cash equivalents, restricted cash and the lines of credit, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:

•

Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at September 30, 2019 and December 31, 2018 included the Company’s cash, cash equivalents and restricted cash. There were no Level 1 liabilities;

•

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at September 30, 2019 or December 31, 2018; and

•

Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at September 30, 2019 or December 31, 2018.

Revenue

The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, license agreements, government contracts and sales of reagent protein products, which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving development and sales milestones and for product royalties. The specifics of the Company’s significant agreements are detailed in Note 7—Significant Research and Development Agreements.

The Company’s revenue is reported into one of three categories, including: license revenue, service revenue, and product revenue. License revenue generally includes providing customers with access to the Company’s intellectual property and achievement of development milestones during the period or a portion of contractual payments that are recognized during the reporting period. Service revenue is derived from performing activities for customers related to the Company’s Pfēnex Expression Technology platform. Product revenue generally includes sales of CMR197 and other materials. The three-months ended September 30, 2019 is the first period revenue has been reported into these three categories, and prior periods have been disaggregated to conform to this current presentation.

The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement. On a quarterly basis, the Company evaluates the period of performance to determine if a change should be made.

Upfront, nonrefundable licensing payments are assessed to determine whether or not the licensee is able to obtain standalone value from the license. Where the license does not have standalone value, non-refundable license fees are recorded as deferred revenue and recognized as revenue as the Company performs under the applicable agreement. Where the level of effort is relatively consistent over the performance period, the Company recognizes fixed or determined revenue on a straight-line basis over the estimated period of performance. Where the license has standalone value, the Company recognizes total license revenue at the time all revenue recognition criteria have been met.

Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.

Revenue under service agreements are recorded as services are performed. These agreements do not require development achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement.

The Company recognizes revenue for its cost-plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under the Company’s government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred.

The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. For the three and nine months ended September 30, 2019, $11.0 million and $17.1 million in revenue was recognized in connection with the achievement of milestones, respectively.

recognizes reagent product revenue from product sales when it is realized or realizable and earned. As of September 30, 2019, the Company has had minimal product returns related to reagent protein product sales. Therefore, no reserve for warranty and return rights was recorded as of September 30, 2019 and December 31, 2018.

Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent.

Recently Issued Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Numerous updates were issued in 2016 that provide clarification on a number of specific issues as well as requiring additional disclosures. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of January 1, 2019 in that filing. However, the Company will continue to account for revenue recognition under ASC Topic 605 for interim periods in 2019 and will not be required to amend its Form 10-Q filings filed throughout 2019 to reflect the January 1, 2019 adoption date. The guidance allows for the use of one of two retrospective application methods: the full retrospective method or the modified retrospective method. The Company plans to adopt the standard in fiscal year 2019 using the modified retrospective method. The Company does not expect the new standard to have a material impact on the recognition of revenue from its services or reagent protein product sales. The Company is currently evaluating the impact of the new standard on historical revenue recorded for its collaboration agreements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which was subsequently amended by ASU No. 2018-10, ASU No. 2018-11, ASU No. 2018-20 and ASU No. 2019-01. This ASU, as amended, increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as right-of-use assets and lease liabilities. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification dictates whether lease expense is to be recognized based on an effective interest method or on a straight-line basis over the term of the lease. Additional qualitative and quantitative disclosures will be required to give financial statement users information on the amount, timing and judgments related to a reporting entity’s cash flows arising from leases. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of January 1, 2019 in that filing. However, the Company will continue to account for leases under ASC Topic 840 for interim periods in 2019 and will not be required to amend its Form 10-Q filings filed throughout 2019 to reflect the January 1, 2019 adoption date. The Company plans on adopting this standard using the modified retrospective transition approach by applying the new standard to leases existing at the date of initial adoption. The Company plans to use the package of practical expedients, which permit the Company to not reassess prior conclusions about lease identification, lease classification and initial direct costs determined under ASC Topic 840.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. This updated guidance eliminates Step 2 from the current two-step quantitative model for goodwill impairment tests. Step 2 required an entity to calculate an implied fair value, which included a hypothetical purchase price allocation requirement, for reporting units that failed Step 1. Per this updated guidance, a goodwill impairment will instead be measured as the amount by which a reporting unit’s carrying value exceeds its fair value as identified in Step 1. This guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this guidance is not expected to have a material impact on the consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718), which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of

January 1, 2019 in that filing. The adoption of this guidance is not expected to have a material impact on the consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. ASU 2018-15 is effective for the Company beginning in the first quarter of fiscal year 2020, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact on its financial statements and related disclosures.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. ASU No. 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in ASU No. 2018-18 are required to be applied retrospectively to the date of initial application of ASC 606. The Company is currently evaluating the impact of ASU No. 2018-08 on its consolidated financial statements.

2. Fair Value Measurements

The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of September 30, 2019 and December 31, 2018, were determined using the inputs described above and are as follows:

			Fair Value Measurements at Reporting Date Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(in thousands)
September 30, 2019
Cash and money market funds	$	32,718	$	32,718	$	—	$	—
Total assets measured at fair value	$	32,718	$	32,718	$	—	$	—
December 31, 2018
Cash and money market funds	$	56,420	$	56,420	$	—	$	—
Total assets measured at fair value	$	56,420	$	56,420	$	—	$	—

Cash and money market funds at September 30, 2019 and December 31, 2018 include restricted cash, which is included in current assets on the balance sheet.

3. Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows.

	September 30, 2019		December 31, 2018
	(in thousands)
Cash and cash equivalents	$	32,518	$	56,220
Restricted cash		200		200
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$	32,718	$	56,420

The Company’s restricted cash balance of $0.2 million is bank collateral for its corporate credit card program.

4. Property and Equipment

Property and equipment consisted of the following:

	September 30, 2019			December 31, 2018
	(in thousands)
Furniture and equipment	$	372		$	367
Computers and IT equipment		498			451
Purchased software		464			375
Lab and research equipment		9,801			9,154
Leasehold improvements		951			876
Construction in progress		1,128			328
Other fixed assets		83			83
Total property and equipment, gross		13,297			11,634
Less: accumulated depreciation and amortization		(4,923	)		(3,963	)
Total property and equipment, net	$	8,374		$	7,671

Total property and equipment assets under capital lease were $1.0 million at both September 30, 2019 and December 31, 2018. Accumulated depreciation related to assets under capital lease as of both dates was $0.2 million. For the three and nine months ended September 30, 2019 and 2018, total depreciation and amortization expense is included in research and development, selling, general and administrative expenses and cost of sales in the accompanying consolidated statements of operations was as follows:

	Three Months Ended September 30,				Nine months Ended September 30,
(in thousands)	2019		2018		2019		2018
Cost of revenue	$	88	$	8	$	105	$	23
Research and development		197		242		664		709
Selling, general and administrative		53		41		199		117
Total depreciation and amortization expense	$	338	$	291	$	968	$	849

5. Intangible Assets

Intangible assets consisted of the following:

	September 30, 2019			December 31, 2018
	(in thousands)
Customer relationships	$	3,750		$	3,750
Developed technology		4,400			4,400
Trade names		920			920
Total intangible assets, gross		9,070			9,070
Less: Accumulated amortization		(5,211	)		(4,822	)
Total intangible assets, net	$	3,859		$	4,248

Amortization expense related to intangible assets was $0.1 million for both the three months ended September 30, 2019 and 2018, and $0.4 million for both the nine months ended September 30, 2019 and 2018. Amortization expense is included within selling, general and administrative expense in the accompanying consolidated statements of operations. As of September 30, 2019, estimated amortization expense for the next five years amounts to approximately $0.5 million per year.

6. Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2019		December 31, 2018
	(in thousands)
Accrued vacation	$	522	$	493
Deferred rent		549		589
Accrued bonuses		1,618		1,748
Other accrued employee-related liabilities		525		302
Accrued professional fees		855		1,524
Accrued supplier liability		615		387
Accrued subcontractor costs		1,949		4,265
Obligation to Alvogen for raw materials		713		—
Other accrued liabilities		1,006		504
Total accrued liabilities	$	8,352	$	9,812

In May 2019, the Company received a $1.7 million cash payment from Alvogen for raw materials. As of September 30, 2019, the Company had shipped approximately $1.0 million of raw materials due to Alvogen related to this agreement which was recorded as an offset to R&D expense, and the remaining $0.7 million is recorded as part of accrued liabilities.

7. Significant Research and Development Agreements

The Company has two types of research and development agreements (i) those for which the Company co-develops or assists customers in developing their products (Collaboration Agreements), and (ii) those for which the Company receives funding to advance its own products (Funding Agreements).

Collaboration Agreements

Alvogen

In June 2018, the Company entered into an agreement with Alvogen in which the Company granted Alvogen exclusive rights to commercialize and manufacture PF708 in the United States. The Company expects Alvogen to launch the FDA-approved PF708 product in the U.S. upon an FDA rating decision on the therapeutic equivalence evaluation of the product. Prior to the FDA approval of the NDA for PF708, the Company was responsible for development and registration of PF708, while Alvogen was and continues to provide additional regulatory and development expertise. Following the FDA approval of the NDA for PF708, Alvogen has assumed responsibility for costs related to litigation, commercial manufacturing and supply chain, and commercialization of the FDA-approved PF708 product and the Company is currently in the process of transferring the NDA to Alvogen. In consideration for the licenses and other rights granted to Alvogen under the agreement, the Company received an upfront payment of $2.5 million, achieved two development milestone for $2.5 million each, one of which was the milestone achievement for FDA approval of PF708 in October 2019, and may be eligible to receive an additional $20 million in support and regulatory milestone payments. The Company may also be eligible to receive a 50% gross profit split on sales if the product is rated as Therapeutically Equivalent (AP) to Forteo and up to 40% if rated differently. The Company deems that the support and regulatory milestones are substantive.

In February 2019, the Company and Alvogen entered into agreements expanding the Company’s and Alvogen’s collaboration to develop and commercialize PF708 to the EU, to certain countries in the MENA and to the ROW territories (the latter defined as all countries outside of the EU, US and MENA, excluding Mainland China, Hong Kong, Singapore, Malaysia and Thailand). Under the agreements, Alvogen has exclusive rights to develop, commercialize and manufacture PF708 in such territories. As of September 30, 2019, the Company has earned $1.0 million in upfront and milestone payments and may be eligible to receive an additional $1.5 million in milestone payments under the terms of the expanded agreements with Alvogen. For EU, MENA and ROW, Pfenex may also be eligible to receive up to 60% of Alvogen’s gross profit derived from product sales, depending on geography and cost of goods sold.

In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the Alvogen Agreement. The significant deliverables were determined to be the development and regulatory services up through the NDA filing and ultimate approval related to the PF708 product and the exclusive license granted to Alvogen to commercialize PF708 in the United States. The Company has determined that the license and the development and regulatory activities meet the separation criteria; therefore, they are each treated as separate units of accounting.

To determine the stand-alone value of the license, the Company considered its negotiation discussions with Alvogen that led to the final terms of the agreement and other information. The Company determined a selling price for the services by estimating costs expected to be incurred for internal labor, burden rates, internal margins, and subcontractors.

The upfront payment of $2.5 million received in 2018 is not fixed and determinable due to a contract clause that $2.5 million may be payable to Alvogen if the NDA approval is not transferred to Alvogen by a specified date; therefore, the upfront payment has been recorded as deferred revenue in the accompanying consolidated balance sheet as of September 30, 2019. In the nine months ended September 30, 2019, a one-time support payment of $2.5 million was received by the Company from Alvogen upon FDA acceptance of the NDA in consideration of the Company’s production of consistency batches of PF708 product and related development and support activities. The payment was recorded as revenue during the first quarter of 2019.

In February 2019, Alvogen also agreed to support certain costs incurred by the Company for PF708 related to the preparation and filing of the NDA and costs related to regulatory affairs, quality, manufacturing and supply chain during 2019. Alvogen agreed to pay a total of $1.6 million for said costs, and the Company recognized the entire $1.6 million as an offset to R&D expense in 2019. As of September 30, 2019, the Company invoiced Alvogen approximately $1.2 million, and the remaining $0.4 million is recorded as an unbilled receivable.

The Company is currently in the process of transferring internally managed manufacturing activities to Alvogen. In April 2019, the Company entered into an agreement with Alvogen where the Company acted as the liaison between Alvogen and the Company’s established raw materials supplier/manufacturer. In May 2019, the Company received a $1.7 million cash payment from Alvogen for raw materials. As of September 30, 2019, the Company had shipped approximately $1.0 million of raw materials due to Alvogen related to this agreement which was recorded as an offset to R&D expense, and the remaining $0.7 million is recorded as part of accrued liabilities.

In May 2019, the Company entered into an agreement with Alvogen for the Company to provide PF708 drug substance batches and pen components in exchange for $2.3 million. This product sold to Alvogen was initially manufactured by Company’s CMO for manufacturing process validation purposes as part of the PF708 NDA submission to the FDA for approval. The Company does not expect to have similar transactions with its collaboration partners in the future. The $2.3 million was recorded as product revenue in the accompanying consolidated statements of operations during the three and nine months ended September 30, 2019.

In October 2019, the FDA approved the NDA for PF708 under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug. In connection with the FDA approval of PF708, the Company earned a $2.5 million milestone payment under the collaboration agreement with Alvogen, payable upon Alvogen’s receipt of notice of NDA approval, and will be recognized as revenue in the fourth quarter of 2019.

NT Pharma

In April 2018, the Company entered into an agreement with NT Pharma under which the Company granted NT Pharma non-exclusive development and exclusive commercialization rights to PF708 in Mainland China, Hong Kong, Singapore, Malaysia and Thailand. In accordance with the agreement, the Company received an upfront payment of $2.5 million and may be eligible to receive up to $22.5 million in payments based on the achievement of certain development, regulatory, and sales-related milestones. In addition, the Company is eligible to receive double-digit royalties on net product sales. NT Pharma is responsible for any further development required to achieve regulatory approval as well as commercialization activities in the applicable territories. The Company deems that none of the non-sales milestones are substantive. Milestones that are not considered substantive would be recognized as revenue over the remaining period of performance, assuming all other revenue recognition criteria are met.

In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the NT Pharma Agreement. The significant deliverables were determined to be the license and research and development services up through the NDA filing related to the PF708 product. The Company has determined that these deliverables meet the separation criteria and therefore are each treated as separate units of accounting.

Therefore, the upfront payment was recorded as deferred revenue as of December 31, 2018. The deliverables were satisfied during the first quarter of 2019, at which time the upfront payment was recognized as revenue.

Jazz

In July 2016, the Company entered into a development and license agreement with Jazz Pharmaceuticals for the development and commercialization of multiple early stage hematology/oncology product candidates, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. Jazz has the exclusive right to manufacture and commercialize such products throughout the world. In addition, pursuant to the agreement, the Company has granted Jazz certain other rights to negotiate the exclusive right to develop, manufacture and commercialize throughout the world other hematology/oncology products that are currently or in the future may be developed by the Company. In the third quarter of 2017, the Company achieved a process development milestone associated with this collaboration.

In December 2017, the Company and Jazz entered into an amended and restated agreement (as amended, the Amended Jazz Agreement). As part of the Amended Jazz Agreement, the Company received a total payment of $18.5 million, consisting of an upfront payment of $5.0 million and a payment of $13.5 million for development achievement. In 2018, the Company achieved two development milestones and received $0.8 million in recognized revenue for successful achievement of process development milestones for PF745. In September 2019, the Company achieved a development milestone and recognized $11.0 million in revenue for successful achievement of a process development milestone for PF745. In October 2019, the Company received an $11.0 million cash payment for this PF745 milestone achievement. The Company may be eligible to receive additional payments under the Amended Jazz Agreement of up to $177.5 million based on achievement of certain research and development, regulatory and sales-related milestones. As of September 30, 2019, the total remaining milestones are categorized as follows: $18.5 million based on achievement of certain research and development milestones; $34.0 million for certain regulatory milestones; and $125.0 million for sales milestones. For the non-sales-related milestones totaling $52.5 million, the Company conducted an evaluation as to whether they will be recorded using the milestone method and, as a result of this evaluation, estimates approximately $18.5 million of these non-sales-related milestones are deemed to be substantive. The Company may also be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement. Both Jazz and the Company are contributing to the development efforts. Unless terminated earlier, the Amended Jazz Agreement will continue on a product-by-product basis for as long as Jazz is commercializing or having commercialized the products under the Amended Jazz Agreement.

In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the Jazz Agreement and again upon entering into the Amended Jazz Agreement. The deliverables have not changed under the amendment. The significant deliverables were determined to be the research and development services related to the pegaspargase product candidate option and for license and research and development activities of the other hematology/oncology products. The Company has determined that the license, together with the research and development activities, represent one unit of accounting for each product under license, as the license does not have standalone value from the respective development activities. The research and development activities related to the pegaspargase option were determined to have standalone value apart from the license and development activities for the other hematology/oncology products. The estimated selling price for the pegaspargase product candidate and the hematology/oncology products was determined using an income approach. In determining the estimated selling price, the Company considered costs expected to be incurred for internal labor, burden rates, internal margins, and subcontractors. Based on the Company’s considerations of estimated selling price, the Company allocated the original $15.0 million upfront and option payment as follows: $10.0 million to the pegaspargase product candidate and $2.5 million to each of the hematology/oncology products. For the $5.0 million upfront payment received under the terms of the Amended Jazz Agreement, the Company determined that $0.8 million represented development services performed prior to the amendment, which had been reimbursable under the original agreement. The remaining $4.2 million of the upfront payment was allocated to the remaining hematology product; the amount was deferred and is being recognized over the period of performance. The Amended Jazz Agreement provisions allow for Jazz to halt the advancement of one of the products under development and replace with others wherein the Company could potentially earn milestone revenue on those products. However, the Company believes it is unlikely Jazz would halt the advancement of the product under development and replace with other products. Therefore, none of the upfront payments were allocated to this option.

The upfront and option payment for the original Jazz agreement and the amendment were being deferred and being recognized as revenue ratably over the period in which the Company expects services to be rendered for each respective unit of accounting, concluded by June 30, 2019. As previously disclosed, the estimated period of revenue recognition approximates a range of 15 to 32 months. Based on changes to this estimate that occurred during the quarter ended June 30, 2017, the Company modified the period of revenue recognition to range from 15 to 35 months. During the year ended December 31, 2017, the Company completed the service period related to one of the hematology products. During the three months ended September 30, 2019 and 2018, the Company recorded revenue of approximately $11.0 million and $1.8 million related to the Jazz Collaboration, respectively. During the nine months ended September 30, 2019 and 2018, the Company recorded revenue of approximately $13.7 million and $6.3 million related

to the Jazz collaboration, respectively. As of December 31, 2018, deferred revenue associated with the Jazz collaboration was $2.7 million. As of September 30, 2019, all deferred revenue related to the collaboration had been recognized.

Funding Agreements

The U.S. Department of Health and Human Services

In August 2015, the Company completed a development contract with the BARDA within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services for Px563L and RPA563 as a novel vaccine candidate for the prevention of anthrax infection. The Company entered into a follow-on contract with BARDA in August 2015 for the advanced development of Px563L and RPA563. This agreement is a cost-plus fixed fee development contract valued at up to approximately $143.5 million, including a 30-month base period of performance of approximately $15.9 million, and eight option periods valued at a total of approximately $127.6 million. The base period of performance was initially from August 2015 through February 2018 and later extended through September 2018. BARDA exercised additional phases of the development contract effective January 2017, totaling $4.9 million and allowing for the continuing development of Px563L and RPA563. The period of performance for the two option periods was extended through September 2018 and December 2019. In May 2018, BARDA increased the funding for one of the option periods by approximately $1.7 million. On March 29, 2019, the Company received notice from BARDA advising the Company of its decision not to exercise development options for cGMP manufacturing and potential Phase 1/2b study readiness for Px563L and RPA563. Following the receipt of the notice from BARDA and pursuant to discussions with BARDA, the Company deprioritized this program in its portfolio.

Revenue is recognized in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under this government contract primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under the BARDA contract, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under this BARDA contract, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable. The billing of any overage in indirect cost rates over the approved provisional rates in the contract is not allowed. Any such overage is expensed as incurred. When and if final rates with Defense Contract Audit Agency are approved, the Company will recognize any change in revenue resulting from the rate change in the period such revised rates are approved and as such this would be considered a change in estimate. This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 whereupon BARDA may immediately terminate the agreement early for convenience or request the Company to stop all or any part of the work for a period of at least 90 days. During the three months ended September 30, 2019 and 2018, revenue from BARDA was $0.2 million and $1.3 million, respectively. During the nine months ended September 30, 2019 and 2018, revenue from BARDA was $1.2 million and $3.8 million, respectively.

8. Commitments and Contingencies

Capital Lease Agreements

Payment commitments for the Company’s capital leases are summarized as follows:

	September 30, 2019
	(in thousands)
2019	$	92
2020		202
2021		1
Total future minimum lease payments	$	295

The Company has operating and capital lease agreements for office and lab equipment that expire at various dates through 2021.

Clinical Study and Development Activity Commitments

The Company has entered into agreements with contract research organizations and subcontractors to further develop its product candidates. These contracts can be cancelled at any time, with some having certain cancellation fees associated with the termination of the contract, and others that only obligate the Company through the termination date.

9. Stock-Based Compensation

Summary Stock-Based Compensation Information

The following table summarizes stock-based compensation expense:

	Three Months Ended September 30,				Nine months Ended September 30,
(in thousands)	2019		2018		2019		2018
Cost of revenue	$	44	$	50	$	133	$	143
Research and development		219		339		999		1,149
Selling, general and administrative		408		404		1,249		1,259
Total	$	671	$	793	$	2,381	$	2,551
Stock-based compensation from:
Stock options	$	646	$	752	$	2,320	$	2,395
Employee stock purchase plan		25		41		61		156
Total	$	671	$	793	$	2,381	$	2,551

The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2019:

	Number of Options (in thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2018		4,155		$	6.13
Granted		1,282			4.57
Exercised		(120	)		3.47
Cancelled (forfeited)		(522	)		6.52
Outstanding at September 30, 2019		4,795		$	5.73		6.92	$	15,431
Vested and expected to vest at September 30, 2019		4,245		$	5.92		6.66	$	13,156
Vested and exercisable at September 30, 2019		2,458		$	7.04		5.08	$	5,865

The Company received approximately $0.4 million and $0.1 million from stock option exercises during the nine months ended September 30, 2019 and September 30, 2018, respectively. Options outstanding at September 30, 2019 have a weighted average remaining contractual term of 6.92 years.

The exercise price of all options granted during the nine months ended September 30, 2019 and 2018 was equal to the closing price of the Company’s common stock on the date of grant. The fair value of each stock option granted is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair values of the stock option, including the effect of estimated forfeitures, are then expensed over the requisite service period which is generally the vesting period. The table below sets forth the weighted-average assumptions used to estimate the fair value of stock options:

	Three Months Ended September 30,						Nine months Ended September 30,
	2019			2018			2019			2018
Risk-free interest rate		1.5	%		2.8	%		2.4	%		2.7	%
Expected volatility		72.7	%		72.8	%		72.6	%		71.1	%
Expected dividend yield		0	%		0	%		0	%		0	%
Expected life of options in years		5.9			6.3			6.2			6.3

The weighted-average grant date fair value of options granted during the nine months ended September 30, 2019 and 2018 was $3.01 and $2.37, respectively. As of September 30, 2019, there was unrecognized compensation cost of approximately $5.8 million related to unvested stock option awards, and the weighted-average period over which this cost is expected to be recognized is 2.7 years.

10. Income Taxes

During the three and nine months ended September 30, 2019, the Company recorded no income tax expense. The Company expects to be in an overall taxable loss position for 2019. No tax expense is expected in the next several years as the Company expects to generate taxable net operating losses and corresponding valuation allowances due to its investments in its lead product candidates and other pipeline products.

11. Net Income (Loss) Per Share of Common Stock

The following table summarizes the computation of basic and diluted net income (loss) per share attributable to common stockholders of the Company:

	Three Months Ended September 30,					Nine months Ended September 30,
(in thousands, except per share data)	2019		2018			2019			2018
Net income (loss)	$	3,082	$	(10,662	)	$	(8,208	)	$	(32,770	)
Weighted average shares used to compute basic and diluted net income (loss) per share		31,595		31,437			31,534			27,288
Dilutive effect of employee stock option plans		903		—			—			—
Dilutive weighted-average common shares outstanding		32,498		31,437			31,534			27,288
Basic net income (loss) per common share	$	0.10	$	(0.34	)	$	(0.26	)	$	(1.20	)
Diluted net income (loss) per common share	$	0.09	$	(0.34	)	$	(0.26	)	$	(1.20	)

Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period. Diluted net income (loss) per share is computed by dividing the net income (loss) by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method, if inclusion of these is dilutive. Because the Company reported a net loss for the three and nine months ended September 30, 2018, and nine months ended September 30, 2019, diluted net loss per common share is the same as basic net loss per common share for those periods.

The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding because of their anti-dilutive impact to earnings per share:

	September 30,
	2019		2018
	(in thousands)
Options to purchase common stock		4,795		4,119
Employee stock purchase plan		59		70
Total		4,854		4,189

12. Subsequent Events

In October 2019, the FDA approved the NDA for PF708 under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug. In connection with the FDA approval of PF708, the Company earned a $2.5 million milestone payment under the collaboration agreement with Alvogen, payable upon Alvogen’s receipt of notice of NDA approval. The Company recognized this $2.5 million as license revenue in the fourth quarter of 2019.

In October 2019, the Company received an $11 million cash payment for the September 2019 achievement of a development milestone for PF745 associated to the Jazz collaboration. The Company recognized this $11.0 million as license revenue in the third quarter of 2019.

In October 2019, the Company announced the successful completion of its PF708 comparative use human factors study and its submission of the final study report to the FDA. An estimate of the financial effect of this subsequent event cannot be determined as of the report release date.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

The following discussion and analysis should be read together with our consolidated financial statements and the notes to those statements included elsewhere in this Form 10-Q. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our management’s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally in the section entitled “Risk Factors” and this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Forward-looking statements include, but are not limited to:

•

the sufficiency of our cash and cash equivalents and cash generated from operations to meet our working capital and capital expenditure needs for the next 12 months;

•

the performance of our collaboration partner Alvogen, upon which we are dependent on to commercialize the FDA-approved PF708 product;

•

our reliance on Jazz, Alvogen, NT Pharma and any future collaboration partner’s performance over which we do not have control;

•

our and any potential future collaboration partner’s ability to enroll patients in our clinical studies at the pace that we project;

•

our expectation to expand our product pipeline;

•

our expectations regarding the initiation, timing, progress and the success of the design, primary and secondary end points, and duration of the clinical trials and planned clinical trials and studies for our current product candidates and reporting results from same;

•

whether the results of our and our collaboration partners’ trials and studies will be sufficient to support domestic or global regulatory filings and approvals for PF708, and whether we are able to obtain an “A” therapeutic equivalence designation for the FDA-approved PF708 product relative to the reference drug Forteo;

•

our and our collaboration partners’ ability to maintain regulatory approval of the FDA-approved PF708 product or seek and obtain regulatory approval for PF708 and our other product candidates, and if approved, maintain regulatory approval and the timing of such potential regulatory approvals;

•

Our expectations with respect to the commercialization of the FDA-approved PF708 product by Alvogen;

•

our reliance on third-parties to conduct clinical studies;

•

our reliance on third-party contract manufacturers and Alvogen to manufacture and supply the FDA-approved PF708 product, PF708 and our other product candidates for us;

•

the benefits of the use of the FDA-approved PF708 product, PF708, or any of our other product candidates;

•

the rate and degree of market acceptance of the FDA-approved PF708 product, PF708 or any of our other product candidates, if approved for sale;

•

regulatory developments in the United States and foreign countries;

•

our expectations regarding government and third-party payor coverage and reimbursement;

•

our and our collaboration partners’ ability to manufacture the FDA-approved PF708 product, PF708 and our other product candidates in conformity with regulatory requirements and to scale up manufacturing of the FDA-approved PF708 product, PF708 and our other product candidates to commercial scale;

•

our ability to successfully build a specialty sales force, or collaborate with third-parties including our existing collaboration partners, Alvogen and NT Pharma, to commercialize the FDA-approved PF708 product, PF708 and our other product candidates;

•

our and our collaboration partners’ ability to compete with companies currently producing the reference products, including Forteo;

•

our ability to compete with companies that may also seek and obtain approval for therapeutically equivalent versions of Forteo;

•

our ability to retain and recruit key personnel, including development of a sales and marketing function;

•

our ability to obtain and maintain intellectual property protection for the FDA-approved PF708 product, PF708, our Pfēnex Expression Technology® or any other product candidates;

•

our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;

•

our expectations regarding the market size, size of patient populations, and growth potential for the FDA-approved PF708 product, PF708 and our product candidates, if approved for commercial use;

•

our estimates of the expected patent expiration timelines for Forteo and other branded reference drugs and biologics;

•

our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act;

•

our ability to develop new products and product candidates;

•

our ability to successfully establish and successfully maintain appropriate collaborations and derive significant revenue from those collaborations;

•

our financial performance; and

•

developments and projections relating to our competitors and our industry.

Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part II, Item 1A, “Risk Factors,” elsewhere in this Form 10-Q filed with the Securities and Exchange Commission, or SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Form 10-Q, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.

Pfēnex^TM and Pfēnex Expression Technology^® are our primary registered trademarks. Other service marks, trademarks, and trade names referred to in this Form 10-Q are the property of their respective owners.

In this Form 10-Q, “we,” “us” and “our” refer to Pfenex Inc. and its subsidiaries.

Overview

We are a development and licensing biotechnology company focused on leveraging our Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, we have created an advanced pipeline of potential therapeutic equivalents, novel biologics, vaccine and vaccine components, and biosimilars. On October 4, 2019, the U.S. Food and Drug Administration (FDA) approved the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo ® (teriparatide injection) as the reference drug. Like Forteo, this FDA-approved

PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. We are requesting that the FDA designate the FDA-approved PF708 product as therapeutically equivalent (“A” rated) to Forteo, which would potentially permit the product to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states. Pursuant to our Development and License Agreement with Alvogen Malta Operations Ltd. (Alvogen), Alvogen is responsible for commercializing and manufacturing the FDA-approved PF708 product and for fulfilling all regulatory requirements associated with maintaining the PF708 NDA. Alvogen also has exclusive rights to commercialize and manufacture PF708 in the EU, certain countries in the Middle East and North Africa (MENA), and the rest of world (ROW) territories (the latter defined as all countries outside of the EU, U.S. and MENA, excluding Mainland China, Hong Kong, Singapore, Malaysia and Thailand). Alvogen submitted a centralized marketing authorization application for PF708 to the EMA using the biosimilar pathway with Forsteo® as the reference medicinal product, and the application has been accepted. Forteo® and Forsteo® are approved and marketed by Eli Lilly companies for the treatment of osteoporosis in certain patients with a high risk of fracture. Forteo® and Forsteo® achieved $1.6 billion in global product sales in 2018. Alvogen intends to launch the FDA-approved PF708 product in the U.S. upon an FDA decision on the therapeutic equivalence rating of the product. In addition, we are developing hematology/oncology products in collaboration with Jazz Pharmaceuticals Ireland Limited (Jazz) including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. Both PF743 and PF745 are being developed for the treatment of Acute Lymphoblastic Leukemia (ALL) and other hematological malignancies. Jazz recently reported completing a Phase I study for PF743 (JZP-458) and plans to initiate a Phase 2/3 study later in 2019. We also use our Pfēnex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccine candidates under development by Merck & Co., Inc. (Merck) and Serum Institute of India Private Ltd. (SIIPL). Both have licenses to the Pfēnex Expression Technology for the production of CRM197 for use in conjugate vaccine products.

We plan to expand our pipeline and revenue opportunities selectively and in stages. We are focused on achieving this growth through a combination of increasing our portfolio of partnered as well as wholly-owned peptides and complex proteins of which the first set of programs are underway. For example, we are in early development of PF810, a new wholly-owned recombinant peptide program. In addition, we are exploring opportunities to develop novel modalities through an assessment program designed to evaluate and pursue validated biologic pathways that are differentially druggable via a selected modality in specific diseases. We are currently exploring a range of modality platforms and targets that are potentially compatible with our Pfēnex Expression Technology.

Recent Developments

As described herein, on October 4, 2019, the FDA approved the NDA for PF708 under 505(b)(2) regulatory pathway, with Forteo as the reference drug. On October 14, 2019, we announced the successful completion of our PF708 comparative use human factors study and our submission of the final study report to the FDA. The study data demonstrate that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo for each critical user task evaluated in the study based on pre-specified statistical analysis of critical patient and caregiver tasks. We believe this submission completes the information package required by the FDA to evaluate the therapeutic equivalence of the PF708 product. We are seeking FDA designation of the recently-approved product as therapeutically equivalent to Forteo, which would permit PF708 to be automatically substituted for Forteo in many states.

Developed FDA-Approved Product, Our Product Candidates and Collaborations

The following summarizes certain information about the FDA-approved product that we developed, our product candidates, and collaborations:

Developed Product and Product Candidate	Branded Reference Drug	Program

FDA-Approved PF708 Product	Forteo	• Approved in the United States; licensed to Alvogen
PF708	Forteo	• Product candidate in EU, MENA, and Rest of World licensed to Alvogen (excluding areas licensed to NT Pharma)
		• Product candidate in Mainland China, Hong Kong, Singapore, Malaysia, Thailand licensed to NT Pharma
Multiple Hematology/Oncology Product Candidates	Various	• Licensed to Jazz

The FDA-approved product that we developed, product candidates, and collaborations include the following:

FDA-Approved PF708 Product

In October 2019, the FDA approved the NDA for PF708 under the 505(b)(2) regulatory pathway, with Forteo ® (teriparatide injection) as the reference drug. The FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. This FDA-approved PF708 product will be commercialized and manufactured in the U.S. by our collaboration partner, Alvogen. We are currently in the process of transferring the NDA to Alvogen pursuant to our collaboration agreement. Forteo (marketed by Eli Lilly and Company) achieved $1.6 billion in global product sales in 2018. Almost half of these product sales came from the United States alone. Alvogen intends to launch FDA-approved PF708 in the U.S. upon an FDA rating decision on the therapeutic equivalence evaluation of the product.

The FDA approval of the FDA-approved PF708 product was supported by data from Study PF708-301, which compared the effect of PF708 and Forteo in osteoporosis patients. The PF708-301 study enrolled a total of 181 patients, with 90 patients receiving PF708 and 91 patients receiving Forteo. 82 patients completed the study in the FDA-approved PF708 product treatment group, compared with 81 patients in the Forteo treatment group. The primary study endpoint was anti-drug antibody (ADA) incidence after 24 weeks of drug treatment. 2.2% (2/90) of patients who received PF708 and 2.2% (2/91) of patients who received Forteo had detectable antibodies to teriparatide, and one of the two patients who received PF708 developed neutralizing antibodies to teriparatide. The secondary study endpoints included mean percentage changes in lumbar-spine bone mineral density (BMD) and median percentage changes in bone turnover markers (BTM) after 24 weeks of drug treatment, as well as pharmacokinetic (PK) parameters for up to four hours after the first dose. Safety endpoints were incidences of adverse events (AE) and serious adverse events (SAE).

The PF708-301 study showed comparable overall profiles between PF708 and Forteo across multiple endpoints. These results from the PF708-301 study, along with bioequivalence findings from Study PF708-101 in healthy subjects, supported the PF708 NDA submitted in December 2018 pursuant to the 505(b)(2) pathway. On October 4, 2019 the NDA was approved by the FDA.

In addition to obtaining FDA approval of PF708, we have been continuing our efforts to obtain an “A” therapeutic equivalence designation for the product relative to its reference drug, Forteo. A determination of therapeutic equivalence (as shown by an “A” rating) may permit the FDA-approved PF708 product to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states. Consistent with our interactions with the FDA and the agency’s draft guidance document on comparative use human factors studies for demonstrating the therapeutic equivalence of drug-device combination products, we successfully completed the PF708 comparative use human factors (HF) study and submitted the final study report to the FDA in October 2019. The study data demonstrate that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo for each critical user task evaluated in the study based on a pre-specified statistical analysis of critical patient and caregiver tasks.

The comparative use HF study was a simulated use study intended to evaluate the effect of each product’s delivery device and user interface on critical task performance by untrained osteoporosis patients and caregivers. The study used a paired design of the FDA-approved PF708 and the Forteo products.

A total of 102 untrained participants, 52 osteoporosis patients and 50 caregivers, completed the study. For 67% (12 of 18) of critical tasks performed in the patient user group, and 83% (15 of 18) performed in the caregiver group, PF708 had fewer or equal user errors (UE) when compared to Forteo. Importantly, in each of the instances where PF708 had marginally higher user error rates, 33% (6/18) of critical tasks performed in the patient user group, and 17% (3/18) of critical tasks performed in the caregiver user group, the magnitude of the differences (≤ 2 UEs and ≤ 3 UEs, respectively) did not exceeded the predetermined maximum allowable difference in either user group. For these reasons, Pfenex believes the study data demonstrate that the user interface of the FDA-approved PF708 product is noninferior to that of Forteo based on pre-specified statistical analysis of critical patient and caregiver tasks. With submission of the final study report to FDA, Pfenex believes this completes the information package required by the FDA to evaluate the therapeutic equivalence of the PF708 product. For a discussion of certain significant risks relating to the FDA-approved PF708 product, please see the following Risk Factors: “The FDA-approved PF708 Product, PF708 and our other product candidates, if approved, face significant competition from the reference products and from therapeutic equivalent products of the reference products, and from other products. Our or our collaboration partners’ failure to effectively compete may prevent us from achieving significant market penetration and expansion.” and “If the FDA-approved PF708 product does not receive an “A” therapeutic equivalence designation from the FDA, our business may suffer.”

In June 2018, we and Alvogen entered into a Development and License Agreement (US Alvogen Agreement) pursuant to which Alvogen received the exclusive right to commercialize and manufacture PF708 in the United States. Alvogen intends to launch the FDA-approved PF708 product in the U.S. upon an FDA decision on the therapeutic equivalence evaluation of the product. In February 2019 we and Alvogen expanded our collaboration, granting Alvogen exclusive rights to commercialize and manufacture PF708 in the EU, certain countries in the MENA, and the ROW territories (the latter defined as all countries outside of the EU, US and MENA,

excluding Mainland China, Hong Kong, Singapore, Malaysia and Thailand). We believe this collaboration leverages Alvogen’s established international experience and expertise in regulatory, IP and supply chain activities, as well as its established network of specialty pharmaceutical companies to conduct sales and marketing activities in these regions. Alvogen submitted a centralized application to the European Medicines Agency (EMA) for PF708 on May 6, 2019, and the filing was accepted by the EMA on May 23, 2019. We believe that PF708 could be approved in the EU as early as the second half of 2020, pending marketing authorization by the European Commission under the EU centralized procedure and other factors. In October 2019, Alvogen’s partner SAJA, submitted a Marketing Authorization Application (MAA) for PF708 to the Kingdom of Saudi Arabia's Saudi Food and Drug Authority (SFDA). Subject to applicable regulatory approvals, PF708 will be commercialized in Europe and other jurisdictions by Alvogen’s current and/or future commercialization partners including Theramex in Europe, SAJA, a Tamer Group company in MENA, JAMP Pharma in Canada, Kamada Ltd. in Israel, and Pharmbio Korea, Inc. in South Korea. Alvogen is responsible for overseeing any clinical development, regulatory, litigation, commercial manufacturing or commercialization activities of its partners in these jurisdictions. We are eligible to receive additional upfront and milestone payments of $1.5 million for the EU and MENA and additional potential milestone payments for ROW. For EU, MENA and ROW, we may also be eligible to receive up to 60% of Alvogen’s gross profit derived from product sales, if approved, depending on geography and cost of goods sold. In connection with the October 2019 FDA approval of PF708, we earned a $2.5 million milestone payment under our collaboration with Alvogen payable upon Alvogen’s receipt of notice of NDA approval.

In April 2018, we and China NT Pharma Group Company Ltd. (NT Pharma) entered into a Development and License Agreement (NT Pharma Agreement), pursuant to which we granted an exclusive license to NT Pharma to commercialize PF708 in Mainland China, Hong Kong, Singapore, Malaysia and Thailand and a non-exclusive license to conduct development activities in such territories with respect to PF708. In accordance with the agreement, we received a payment of $2.5 million upon signing the NT Pharma Agreement and may be eligible to receive additional payments of up to $22.5 million based on the achievement of certain development, regulatory, and sales-related milestones. We may also be eligible to receive double-digit royalties on net sales of PF708. NT Pharma is responsible for any further development required to achieve regulatory approval as well as commercialization activities in the applicable territories.

In accordance with regulatory requirements we provided notice of Paragraph IV certification (Notice Letter) to Eli Lilly and Company (Lilly) on February 19, 2019 that PF708 does not infringe any valid claim of the ’334 patent. Under the Hatch-Waxman Act, Lilly had 45 days from the receipt of the Notice Letter to file a patent infringement lawsuit against us that would cause a 30-month litigation stay of approval for PF708. On April 11, 2019 we announced the expiration of the 45-day period for Lilly to file a lawsuit under the Hatch-Waxman Act and stay the approval of PF708 for 30 months. Lilly did not file a lawsuit within this time period, and there was no 30-month litigation stay that delayed approval of the FDA-approved PF708 product.

In May 2019, we entered into an agreement with Alvogen for us to provide PF708 drug substance batches and pen components in exchange for $2.3 million. This product sold to Alvogen was initially manufactured by our CMO for manufacturing process validation purposes as part of the PF708 NDA submission to the FDA for approval. We do not expect to have similar transactions with our collaboration partners in the future. The $2.3 million was recorded as product revenue in the consolidated statements of operations during the three and nine months ended September 30, 2019.

Jazz Collaboration – multiple early stage hematology/oncology product candidates with Jazz. In July 2016, we entered into a license and option agreement with Jazz, pursuant to which we and Jazz are developing hematology/oncology products, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase, and Jazz will have the exclusive right to manufacture and commercialize such products throughout the world. In addition, pursuant to the agreement, we have granted Jazz certain other rights to negotiate the exclusive right to develop, manufacture and commercialize throughout the world other hematology/oncology products that are currently or in the future may be developed by us. In the third quarter of 2017, we achieved a process development milestone associated with this collaboration. In December 2017, we and Jazz signed an amended and restated agreement under which we will be eligible to receive an additional $43.5 million in amendment fee and development milestone payments as compared to the 2016 agreement, increasing the total value of upfront, option and amendment fee payments and potential payments for the achievement of development, regulatory and sales-related milestones associated with the collaboration to an aggregate of $224.5 million. We will also continue to be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement. In December 2017, as part of the amended and restated agreement, we received a total payment of $18.5 million, consisting of an upfront payment of $5.0 million and a payment of $13.5 million for development achievement. In the second quarter of 2018, we achieved two development milestones and received $0.8 million for successful achievement of process development milestones for PF745. In August 2019, Jazz reported that they have completed a Phase I study for PF743 (JZP-458) and plan to initiate a Phase 2/3 study in fourth quarter 2019. In September 2019, we achieved a development milestone and received $11 million in connection with process development activities for PF745.

CRM197 – We have both licenses and supply agreements in place for CRM197, which is a non-toxic mutant of diphtheria toxin. It is a well-characterized protein and functions as a carrier for polysaccharides and haptens, making them immunogenic. We have developed unique CRM197 production strains based on our Pfēnex Expression Technology platform. As a result of our

development efforts, we previously entered into commercial licenses for production strains capable of producing CRM197 with both Merck & Co., Inc. (Merck) and Serum Institute of India Private Ltd. (SIIPL). Merck and SIIPL are using the CRM197 produced via the licensed production strain in multiple clinical stage products. Those products currently include Merck’s 15-valent pneumococcal conjugate vaccine, PCV-15 (V114) currently in several ongoing Phase 3 clinical studies and SIIPL’s 10-valent pneumococcal conjugate vaccine Pneumosil® currently in WHO Prequalification and a pentavalent meningococcal conjugate vaccine currently in a Phase 3 clinical study. The CRM197 production strains utilized by both Merck and SIIPL are unique and exclusively licensed to each party. These commercial license agreements with Merck and SIIPL contemplate potential maintenance and milestone fees as well as royalties on net sales. Additionally, as part of the SIIPL commercial license agreement, SIIPL supplies both reagent grade and cGMP CRM197 to Pfenex, who supplies the product to vaccine development-focused pharmaceutical partners.

Arcellx Development, Evaluation and License Agreement – We previously entered into a development, evaluation and license agreement with Arcellx which provides access to the Pfēnex Expression Technology platform to advance Arcellx’s proprietary sparX proteins that activate, silence and reprogram Antigen- Receptor Complex T cell-based therapies. Under the terms of the agreement, we are eligible to receive development funding in addition to development, regulatory and commercial milestones ranging from $2.6 million to $18 million for each product incorporating a sparX protein expressed using the Pfēnex Expression Technology, as well as royalties on worldwide sales of any such products. We currently have two sparX proteins in development with Arcellx. As of September 30, 2019, we have earned $1.8 million in development funding from Arcellx.

Additional Biosimilar and Novel Vaccine Pipeline Products – Our pipeline includes biosimilar candidates to certain reference products, including biosimilar candidates to Lucentis (PF582) and Neulasta (PF529) and two novel anthrax vaccine candidates, Px563L and RPA563, which are funded by the Biomedical Advanced Research and Development Authority (BARDA). In November of 2017, we paused development on both PF582 and PF529. We do not intend to advance PF582 or PF529 without development and commercial collaboration partners. In March 2019 we received a notice from BARDA advising us of BARDA’s decision not to exercise development options for cGMP manufacturing, preclinical studies and Phase 1/2b study readiness in connection with our Px563L and RPA563 novel anthrax vaccine program. Following the receipt of the notice from BARDA and pursuant to discussions with BARDA, we deprioritized this program in our portfolio.

Due to our significant research and development expenditures, we have generated significant operating losses since inception. To date, we have not received meaningful revenue from the commercial sale of the FDA-approved product that we have developed or any of our product candidates.

The FDA-approved PF708 product, our other product candidates and collaborations are enabled by our patented protein production platform, Pfēnex Expression Technology, which we believe confers several important competitive advantages compared to traditional techniques for protein production. The platform has demonstrated a high success rate for the production of complex proteins with higher titers of high quality protein, as well as speed and cost advantages. The development of proteins requires several competencies which represent both challenges and barriers to entry. Due to their inherent complexity, proteins require the use of living organisms to efficiently produce them at a large scale. Traditional techniques for protein production employ a trial and error approach to production organism, or strain, selection and process optimization, which is inherently inefficient and typically produces suboptimal results. This historically inefficient process provides barriers to creating or replicating complex proteins, adds significant time to market and results in the high cost of goods typical of biologic therapeutics. Together, these limitations pose significant hurdles for companies interested in entering the market with novel biologics, biosimilars and therapeutic equivalents. Our platform utilizes a proprietary high throughput robotically-enabled parallel approach, which allows the construction and testing of thousands of unique protein production strains in parallel, thereby allowing us to produce and characterize complex proteins while reducing the time and cost of development and long-term production.

Our revenue for the three months ended September 30, 2019 and 2018 was $15.2 million and $3.6 million, respectively, and $28.4 million and $11.5 million for the nine months ended September 30, 2019 and 2018, respectively. Our historical revenue has been primarily derived from monetizing our Pfēnex Expression Technology platform through collaboration agreements, service agreements, government contracts and reagent protein product sales, which provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees.

As of September 30, 2019, we had an accumulated deficit of $209.5 million, of which $89.8 million was attributable to recognizing the accretion in the redemption value of our convertible preferred stock. We recognized net income of $3.1 million for the three months ended September 30, 2019 versus $10.7 million net loss for the three months ended September 30, 2018. We recognized net loss of $8.2 million and $32.8 million for the nine months ended September 30, 2019 and 2018, respectively. As we continue to develop and invest more resources into the development and commercialization of our product candidates, our net operating losses will continue over the next several years. Adequate funding may not be available to us on commercially reasonable terms, or at all. Since our inception we have funded our operations primarily through the sale and issuance of common stock in our public offerings, revenue from our collaboration agreements, government contracts, service agreements, and reagent protein product sales, our prior

credit facility and the private placement of equity securities. We have devoted substantially all of our capital resources to the research and development of our product candidates and working capital requirements.

Critical Accounting Policies, Significant Judgments and Use of Estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue and expenses during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions. The accompanying unaudited consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and related footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2018. Except as otherwise disclosed, there have been no material changes in our critical accounting policies and estimates in the preparation of our financial statements during the three and nine months ended September 30, 2019 compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 11, 2019.

Results of Operations

Comparison of the three and nine months ended September 30, 2019 and 2018

The following table summarizes our net loss during the periods indicated:

	Three Months Ended September 30,								Nine months Ended September 30,
(in thousands, except percentages)	2019		2018			Change			2019			2018			Change
Revenue	$	15,248	$	3,570			327	%	$	28,421		$	11,506			147	%
Cost of revenue		1,143		1,479			(23	)%		3,837			3,923			(2	)%
Gross profit		14,105		2,091			575	%		24,584			7,583			224	%
Operating expense
Research and development		6,931		9,045			(23	)%		19,691			28,590			(31	)%
Selling, general and administrative		4,147		3,823			8	%		13,296			11,920			12	%
Total operating expense		11,078		12,868			(14	)%		32,987			40,510			(19	)%
Income (loss) from operations		3,027		(10,777	)		(128	)%		(8,403	)		(32,927	)		(74	)%
Other income, net		55		115			(52	)%		195			157			24	%
Net income (loss)	$	3,082	$	(10,662	)		(129	)%	$	(8,208	)	$	(32,770	)		(75	)%

Revenue

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands, except percentages)

2019

2018

Change

2019

2018

Change

Revenue

15,248

3,570

327

28,421

11,506

147

Revenue increased by $11.6 million, or 327%, to $15.2 million in the three-month period ended September 30, 2019, compared to $3.6 million in the same period in 2018. The increase in revenue was primarily due to an $11 million development milestone reached during the quarter related to the Jazz collaboration agreement.

Revenue increased by $16.9 million, or 147%, to $28.4 million in the nine-month period ended September 30, 2019, compared to $11.5 million in the same period in 2018. The increase in revenue was primarily due to an $11 million development milestone reached related to the Jazz collaboration agreement, upfront and milestone payments received from Alvogen related to development of PF708, higher service revenue and increased sales of our CRM197 product, partially offset by decreased activity related to our BARDA program.

Cost of Revenue

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands, except percentages)

2019

2018

Change

2019

2018

Change

Cost of revenue

1,143

1,479

(23

3,837

3,923

Cost of revenue decreased by approximately $0.4 million, or (23)%, to $1.1 million in the three month period ended September 30, 2019, compared to $1.5 million in the same period in 2018. The decrease was primarily due to the decreased activity related to our BARDA program.

Cost of revenue decreased by approximately $0.1 million, or (2)%, to $3.8 million in the nine months ended September 30, 2019, compared to $3.9 million in the same period in 2018. The decrease was primarily due to the decreased activity related to our BARDA program.

Research and Development

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands, except percentages)

2019

2018

Change

2019

2018

Change

Research and development

6,931

9,045

(23

19,691

28,590

(31

Research and development expenses decreased by approximately $2.1 million, or (23)%, to $6.9 million in the three month period ended September 30, 2019, compared to $9.0 million in same period in 2018. The decrease was primarily due to the reduction of labor and subcontractor costs as the majority of the work performed to support the PF708 NDA filing was completed in late 2018.

Research and development expenses decreased by approximately $8.9 million, or (31)%, to $19.7 million in the nine months ended September 30, 2019, compared to $28.6 million in the same period in 2018. The decrease was primarily due to expenses incurred in the first half of 2018 for our Phase 3 clinical trial and regulatory activities related to PF708.

We expect research and development expenses to vary in the near future depending on the phase of the programs we are advancing. The timing and amount of expenses incurred for our product candidates will depend largely upon the outcomes of current or future clinical studies for our product candidates, as well as the related regulatory requirements, manufacturing costs and any costs associated with the advancement of our preclinical programs.

Selling, General and Administrative

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands, except percentages)

2019

2018

Change

2019

2018

Change

Selling, general and administrative

4,147

3,823

13,296

11,920

Selling, general and administrative expenses increased by approximately $0.3 million, or 8%, to $4.1 million in the three month period ended September 30, 2019, compared to $3.8 million in the same period in 2018. The increases were primarily due to an increase in expenses related to IP legal, consulting, and the expansion of business development efforts.

Selling, general and administrative expenses increased by approximately $1.4 million, or 12%, to $13.3 million in the nine months ended September 30, 2019, compared to $11.9 million in the same period in 2018. The increases were primarily due to an increase in expenses related to IP legal, consulting, and the expansion of business development efforts.

Liquidity and Capital Resources

To date, we have funded our operations primarily through the sale and issuance of common stock in our public offerings, revenue from our collaboration agreements, government contracts, service agreements, and reagent protein product sales, our prior credit facility and the private placement of equity securities. At September 30, 2019, we had $32.5 million in cash and cash equivalents and $0.2 million in restricted cash as bank collateral for our corporate credit card program compared to $56.2 million in cash and cash equivalents and $0.2 million in restricted cash as of December 31, 2018.

In July 2016, we entered into a development and license agreement with Jazz Pharmaceuticals for the development and commercialization of multiple early stage hematology/oncology product candidates, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase, and in the third quarter of 2017, achieved a process development milestone. The agreement also includes an option for Jazz to negotiate a license for a recombinant pegaspargase product candidate with us. Under the terms of the agreement, we received an upfront and option payment totaling $15.0 million in July 2016 and may be eligible to receive additional payments based on the achievement of certain research and development, regulatory, and sales-related milestones.

In December 2017, we and Jazz entered into an amended and restated agreement, bringing the total value of payments and potential payments associated with the collaboration to $224.5 million. In addition, we may be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement. Under the amended and restated agreement, in the second quarter of 2018, we achieved two process development milestones for PF745. In September 2019, we achieved a development milestone and recognized $11.0 million in revenue for successful achievement of a process development milestone for PF745, and we received cash payment for this milestone in October 2019.

In October 2019, the FDA approved the NDA for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo® (teriparatide injection) as the reference drug. Our collaboration partner, Alvogen, intends to launch the FDA-approved PF708 product in the U.S. upon an FDA decision on the therapeutic equivalence evaluation of the product. In consideration for the licenses and other rights granted to Alvogen under the agreement, we received an upfront payment of $2.5 million, and to date have achieved two development milestones for $2.5 million each, one of which was the milestone achievement for FDA approval of PF708 in October 2019, and may be eligible to receive an additional $20 million in support and regulatory milestone payments. We are also eligible to receive a 50% gross profit split on sales if the product is rated as Therapeutically Equivalent (AP) to Forteo and up to 40% if rated differently.

In March 2018, we entered into an equity sales agreement (Sales Agreement) with William Blair & Company, L.L.C. (William Blair) to sell shares of our common stock having aggregate sales proceeds of up to $20.0 million, from time to time, through an “At the market” equity offering program under which William Blair will act as sales agent. Under the Sales Agreement, we set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that William Blair will be entitled to compensation for its services that will equal 3.0% of the gross sales price per share of all shares sold through William Blair under the Sales Agreement. The Sales Agreement shall automatically terminate upon the issuance and sale of placement shares equaling sales proceeds of $20.0 million and may be terminated earlier by either us or William Blair upon five days’ notice. We have no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. Through September 30, 2019, we have not sold any shares under the Sales Agreement.

On May 25, 2018, we closed an underwritten public offering of 7,820,000 shares of our common stock at a price of $5.50 per share, which included the full exercise by the underwriters of their option to purchase an additional 1,020,000 shares of our common stock. Net proceeds from this offering were approximately $39.5 million.

We believe that our existing cash and cash equivalents and our cash inflow from operations will be sufficient to meet our anticipated cash needs for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. We currently have no credit facility or committed sources of capital although we may receive milestone and other contingent payments under our current license and collaboration agreements. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, our dependence on Alvogen to commercialize PF708, whether we obtain an “A” therapeutic equivalence designation for the FDA-approved PF708 product, and the extent to which we may enter into additional agreements with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials and studies. Our future capital requirements will depend on many factors, including:

•

the timing and extent of spending on our research and development efforts;

•

our ability to enter into and maintain collaboration, licensing, commercialization and other arrangements and the terms and timing of such arrangements;

•

our ability to retain Alvogen as a collaboration partner for the FDA-approved PF708 product and PF708 on commercially acceptable terms;

•

whether we and Alvogen obtain, in a timely manner or at all, an “A” therapeutic equivalence designation for the FDA-approved PF708 product that may allow such product to be automatically substituted for Forteo depending on applicable laws and policies within each of the 50 states;

•

the cost of manufacturing and commercialization activities, if any;

•

the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

•

the receipt of any collaboration or milestone payments;

•

the scope, rate of progress, results and FDA acceptance of the results, and cost of our clinical trials, preclinical testing and other related activities for our product candidates;

•

the emergence of competing technologies or other adverse market developments;

•

the time and costs involved in seeking and obtaining regulatory and marketing approvals in multiple jurisdictions for our product candidates that successfully complete clinical trials;

•

the introduction of new product candidates and the number and characteristics of product candidates that we pursue;

•

the timing, receipt and amount of sales, profit sharing or royalties, if any, from the FDA-approved PF708 product, PF708, and any other potential products;

•

the degree and rate of market acceptance and coverage and reimbursement by payors of the FDA-approved PF708 product, PF708 and any of our other product candidates launched by us or our collaboration partners;

•

the potential expansion of our sales and marketing activities; and

•

the potential acquisition and in-licensing of other technologies, products or assets.

If we were to experience any delays or encounter issues with any of the above, including with respect to obtaining an “A” therapeutic equivalence designation for the FDA-approved PF708 product, Alvogen’s commercial launch of the FDA-approved PF708 product in the U.S., clinical holds, failed studies, inconclusive or hard-to-interpret results, safety or efficacy issues, or other regulatory challenges that require longer follow-up of existing studies, additional major studies, or additional supportive studies in order to pursue marketing approval, it could further increase the costs associated with the above and delay or suspend revenues.

We will need to raise additional capital to fund our operations in the near future. Funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our clinical trials, research and development programs or commercialization efforts. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

Cash Flows

The following table sets forth the primary sources and uses of cash, cash equivalents and restricted cash for each of the periods presented below:

	Nine months Ended September 30,
(in thousands)	2019			2018
Net cash (used in) provided by:
Operating activities	$	(22,902	)	$	(28,288	)
Investing activities		(1,076	)		(1,020	)
Financing activities		276			39,469
Net (decrease) increase in cash, cash equivalents and restricted cash	$	(23,702	)	$	10,161

Net cash used in operating activities

Net cash used in operating activities was $22.9 million during the nine months ended September 30, 2019 compared to $28.3 million during the same period in 2018. The decrease in net cash used in operating activities was primarily due to increased revenue in the nine months ended September 30, 2019, associated with our achievement of milestones under our agreements with Jazz and Alvogen. This decrease was partially offset by an increase in trade receivables related to our achievement of the milestone under the Jazz agreement, an increase in deferred revenue, as well as a decrease to accrued liabilities.

Net cash used in investing activities

Net cash used in investing activities was $1.1 million during the nine months ended September 30, 2019 compared to $1.0 million used in the same period in 2018. We used the funds to purchase property and equipment in both nine month periods.

Net cash provided by financing activities

Cash provided by financing activities was $0.3 million during the nine months ended September 30, 2019 compared to cash provided from financing activities of $39.5 million during the same period in 2018. On May 25, 2018, we closed an underwritten public offering of 7,820,000 shares of our common stock at a price of $5.50 per share, which included the full exercise by the underwriters of their option to purchase an additional 1,020,000 shares of our common stock. Net proceeds from the offering were approximately $39.5 million. In both periods, cash was used for repayment of capital lease obligations, offset by proceeds from cash provided by the issuance of common stock in connection with our Employee Stock Purchase Plan.

Off-Balance Sheet Arrangements

In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future but have not yet been made. As of September 30, 2019, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations.

Contractual Obligations and Commitments

There have been no material changes during the nine months ended September 30, 2019 to our contractual obligations disclosed in our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2018.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Numerous updates were issued in 2016 that provide clarification on a number of specific issues as well as requiring additional disclosures. The financial information included in our 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in our 2019 Form 10-K but effective as of January 1, 2019 in that filing. However, we will continue to account for revenue recognition under ASC Topic 605 for interim periods in 2019 and will not be required to amend our Form 10-Q filings filed throughout 2019 to reflect the January 1, 2019 adoption date. The guidance allows for the use of one of two retrospective application methods: the full retrospective method or the modified retrospective method. We plan to adopt the standard in fiscal year 2019 using the modified retrospective method. We do not expect the new standard to have a material impact on the recognition of revenue from our services and our reagent protein product sales. We are currently evaluating the impact of the new standard on historical revenue recorded for our collaboration agreements.

operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification dictates whether lease expense is to be recognized based on an effective interest method or on a straight-line basis over the term of the lease. Additional qualitative and quantitative disclosures will be required to give financial statement users information on the amount, timing and judgments related to a reporting entity’s cash flows arising from leases. The financial information included in our 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in our 2019 Form 10-K but effective as of January 1, 2019 in that filing. However, we will continue to account for leases under ASC Topic 840 for interim periods in 2019 and will not be required to amend our Form 10-Q filings filed throughout 2019 to reflect the January 1, 2019 adoption date. We are currently evaluating the impact of the adoption of this accounting standard update on our consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718), which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The financial information included in our 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in our 2019 Form 10-K but effective as of January 1, 2019 in that filing. The adoption of this guidance is not expected to have a material impact on the consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. ASU 2018-15 is effective for us beginning in the first quarter of fiscal year 2020, with early adoption permitted. We are currently evaluating this guidance to determine the impact on our financial statements and related disclosures.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. ASU No. 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in ASU No. 2018-18 are required to be applied retrospectively to the date of initial application of ASC 606. We are currently evaluating the impact of ASU No. 2018-08 on our consolidated financial statements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and foreign currency exchange rates. As of September 30, 2019, we did not hold or issue financial instruments for trading purposes.

Interest rate fluctuation risk

The primary objective of our investment activities is to preserve our capital to fund our operations. We also seek to maximize income from our cash and cash equivalents without assuming significant risk. To achieve our objectives, we invest our cash and cash equivalents in money market funds, treasury obligations, short term certificates of deposit and high-grade corporate securities, directly or through managed funds, with maturities of nine months or less. As of September 30, 2019, we had cash and cash equivalents of $32.5 million consisting of cash of $10.2 million and investments of $22.3 million in highly liquid U.S. money market funds. A portion of our investments may be subject to interest rate risk and could fall in value if market interest rates increase. However, because our investments are primarily short-term in duration, we believe that our exposure to interest rate risk is not significant and a 100 basis point movement in market interest rates would not have a significant impact on the total value of our portfolio. We actively monitor changes in interest rates.

Foreign currency exchange risk

We contract with clinical research organizations, investigational sites and suppliers in foreign countries. We are therefore subject to fluctuations in foreign currency rates in connection with these agreements. We have not entered into any material foreign currency hedging contracts although we may do so in the future. To date we have not incurred any material effects from foreign currency changes on these contracts. The effect of a 10% adverse change in exchange rates on foreign currency denominated cash and payables as of September 30, 2019 would not have been material. However, fluctuations in currency exchange rates could harm our business in the future.

Inflation risk

Inflation may affect us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our business, financial condition or results of operations for any period presented herein.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s (SEC) rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2019 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Management recognizes that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

On May 6, 2019, Pfenex filed two petitions for inter partes review of U.S. Patent No. 9,422,345 (“the ‘345 patent”; entitled “Expression System”), which is owned by GlaxoSmithKline Biologicals S.A., with the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office. The ‘345 patent relates to polynucleotides that express diphtheria toxin mutants, including the diphtheria toxin mutant CRM197. These two petitions, IPR2019-01027 and IPR2019-01028, seek, inter alia, a determination that certain claims in the ‘345 patent are invalid. Institution decisions by the PTAB for IPR2019-01027 and IPR2019-01028 are expected within the 2019 calendar year, and final written decisions on the validity of the challenged claims of the ‘345 patent, if these two petitions are instituted by the PTAB, by the end of 2020. On August 9, 2019, Pfenex filed a third petition for inter partes review of the ‘345 patent with the PTAB of the U.S. Patent and Trademark Office. The third petition, IPR2019-01478, seeks, inter alia, a determination that certain claims in the ‘345 patent are invalid. An institution decision by the PTAB for IPR2019-01478 is expected within the first quarter of 2020, and a final written decision on determining the validity of the challenged claims of the ‘345 patent, if the third petition is instituted by the PTAB, by the end of the first quarter of 2021.

ITEM 1A.

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q, before making an investment decision. The risks and uncertainties described below may not be the only ones we face. If any of the risks actually occur, our business, financial condition, operating results, cash flows and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.

Risks Relating to our Financial Condition and Need for Additional Capital

We have a limited operating history and expect to generate significant losses for the foreseeable future. If we or our collaboration partners are not successful in completing the development of our product candidates or in commercializing the FDA-approved PF708 product, PF708 or our other product candidates and generating significant revenue, we will not be profitable.

With the exception of two years, we have incurred annual net operating losses since inception, and to date have generated only limited revenue from government contracts, service agreements, collaboration agreements, and reagent protein product sales. We have recognized net losses of $8.2 million and $32.8 million for the nine months ended September 30, 2019 and 2018, respectively, and $39.6 million for the year ended December 31, 2018. As of September 30, 2019, we had an accumulated deficit of $209.5 million and net working capital of $40.4 million. To date, we have funded our operations primarily through the sale and issuance of common stock in our public offerings, revenue from our collaboration agreements, government contracts, service agreements, and reagent protein product sales, our prior credit facility and the private placement of equity securities. As of September 30, 2019, we had capital resources consisting of cash and cash equivalents of $32.5 million. As we continue to develop and invest more resources into the development and commercialization of our product candidates, our net operating losses will continue over the next several years. For Pfenex to become profitable, Alvogen must successfully commercialize and manufacture the FDA-approved PF708 product and we must successfully develop and obtain regulatory approval for additional product candidates, and effectively manufacture and commercialize the additional product candidates we develop. In June 2018 and February 2019, we entered into agreements with Alvogen in which we granted Alvogen exclusive rights to commercialize PF708 in the United States, MENA, and rest of world. In October 2019, we received FDA approval for PF708 and Alvogen is responsible for marketing the FDA-approved PF708 product in the United States. The loss for any reason of Alvogen as a key partner could have a significant and adverse impact on our business. If we are unable to retain Alvogen as a partner on commercially acceptable terms, PF708 may not be commercialized as planned and there could be delays in or suspension of the U.S. commercial launch of the FDA-approved PF708 product. In May 2019, Alvogen, our collaboration partner, submitted a centralized application to the EMA for PF708 and the application was accepted for review. In October 2019, Alvogen’s partner SAJA submitted a Marketing Authorization Application (MAA) for PF708 to the Kingdom of Saudi Arabia's Saudi Food and Drug Authority (SFDA).

With respect to the FDA-approved PF708 product, our future revenue will depend upon the performance of our collaboration partner, Alvogen, whether we obtain, in a timely manner or at all, an “A” therapeutic equivalence designation for the FDA-approved PF708 product that may allow such product to be automatically substituted for Forteo depending on applicable laws and policies within each of the 50 states, the size of any markets in which PF708 or such other product candidate may receive approval, and our and our collaboration partners’ ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for the FDA-approved PF708 product, PF708 and our other product candidates in those markets. We, Alvogen, and our other collaboration partners may never succeed in these activities and therefore may never generate revenue that is significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.

We will require substantial additional funds to seek and obtain regulatory approval and commercialize our current product candidates and, if additional capital is not available, we may need to limit, scale back or cease our operations.

Since our inception, a significant portion of our resources have been dedicated to the preclinical and clinical development of the FDA-approved PF708 product, PF708, and our other product candidates. We believe that we will continue to expend substantial resources for the foreseeable future for the preclinical and clinical development of our current product pipeline, and the development of any other indications and product candidates we may choose to pursue, either alone or with a strategic collaboration partner. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical studies, and manufacturing and supply as well as marketing and selling any products that receive marketing authorization. Because the outcome of any clinical trial is highly uncertain and we are substantially dependent on third parties, including Alvogen, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of the FDA-approved PF708 product, PF708, and our other product candidates and preclinical products under development. We may also need to obtain substantial additional sources of funding to develop our other product candidates and our preclinical products under development as currently contemplated. If such additional funding is not available on favorable terms or at all, we may need to delay or reduce the scope of our product candidate development programs, or grant rights in the United States, as well as outside the United States, to our product candidates to one or more partners.

We believe that our available cash and cash equivalents, including the proceeds from any revenue from our government contracts, service agreements, collaboration agreements, and reagent protein product sales will be sufficient to meet our anticipated cash needs for at least the next twelve months. However, changing circumstances and risks and uncertainties associated with our product development efforts may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected. Our future capital requirements may vary depending on the following:

•

the timing and extent of spending on our research and development efforts;

•

our ability to enter into and maintain collaboration, licensing, commercialization and other arrangements and the terms and timing of such arrangements;

•

our ability to retain Alvogen as a collaboration partner for the FDA-approved PF708 product and PF708 on commercially acceptable terms;

•

the cost of manufacturing and commercialization activities, if any;

•

the receipt of any collaboration or milestone payments;

•

the scope, rate of progress, results and FDA acceptance of the results, and cost of our clinical trials, preclinical testing and other related activities for our product candidates;

•

the emergence of competing technologies or other adverse market developments;

•

the time and costs involved in seeking and obtaining regulatory and marketing approvals in multiple jurisdictions for our product candidates that successfully complete clinical trials;

•

the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

•

the introduction of new product candidates and the number and characteristics of product candidates that we pursue;

•

the timing, receipt and amount of sales, profit sharing or royalties, if any, from the FDA-approved PF708 product, PF708, and any other potential products;

•

the potential expansion of our sales and marketing activities; and

•

the potential acquisition and in-licensing of other technologies, products or assets.

We may need to raise additional capital to fund our operations in the near future. If we seek additional funding in the future, additional funds may not be available to us on acceptable terms or at all. We may seek to raise additional funds through equity, equity-linked or debt financings. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to holders of our equity securities and could contain covenants that restrict our operations. We have a sales agreement in place with William Blair to sell up to $20.0 million worth of shares of our common stock, from time to time, through an “at the market” equity offering program under which William Blair will act as sales agent. As of September 30, 2019, $20.0 million worth of shares of our common stock remained available for sale under the “at the market” equity offering program. Any additional equity financing may be dilutive to our stockholders. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail the advancement of one or more of our product candidates. We also could be required to seek funds through arrangements with collaboration partners or others that may require us to relinquish rights to some of our technologies or product candidates which we would otherwise pursue on our own.

Our quarterly operating results may fluctuate significantly.

Our operating results are subject to quarterly fluctuations. Our operating results are and will be affected by numerous factors, including:

•

variations in the level of expenses related to our development and any future commercialization programs;

•

sales by Alvogen of the FDA-approved PF708 product;

•

addition or termination of clinical trials;

•

any intellectual property infringement lawsuit in which we may become involved;

•

regulatory developments affecting any of our products; and

•

our execution of any service, collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements.

If our quarterly operating results fall below the expectations of investors or securities analysts, the market price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the market price of our stock to fluctuate substantially.

Risks Relating to our Business and our Industry

Our business operations are dependent upon our senior management team and the ability of our other employees to execute on our business strategy. If we fail to attract, integrate, and keep senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize any product candidates we develop.

Our success depends in part on our continued ability to attract, integrate, retain, and motivate highly qualified management, clinical and scientific personnel, including our ability to develop an effective working relationship among senior management. Our president and chief executive officer, Eef Schimmelpennink, joined us in August 2017; our senior vice president, chief financial officer, Susan Knudson, joined us in February 2018; our senior vice president, chief operating officer, Dr. Shawn Scranton, joined us in October 2018 and our senior vice president, chief scientific officer, Dr. Martin Brenner, joined us in March 2019.

As new employees gain experience in their roles, we could experience inefficiencies or a lack of business continuity due to loss of historical knowledge and a lack of familiarity of new employees with business processes, operating requirements, policies and procedures, and we may experience additional costs as new employees gain necessary experience. It is important to our success that these key employees quickly adapt to and excel in their new roles. If they are unable to do so, our business and financial results could be materially adversely affected. In addition, the loss of the services of any member of our senior management or our scientific or technical support staff might significantly delay or prevent the development of our products or achievement of other business objectives by diverting management’s attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business.

We believe that our future success is highly dependent upon the contributions of our senior management, particularly our Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Chief Operating Officer, and Chief Scientific Officer, as well as our senior scientists and other members of our senior management team. Employment agreements with our Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Chief Operating Officer, and Chief Scientific Officer, as well as our offer letters with our senior scientists, all provide for “at-will” employment. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of any product candidates we develop.

Competition for qualified personnel in the biotechnology and pharmaceuticals industry is intense due to the limited number of individuals who possess the skills and experience required. To help attract, retain, and motivate qualified employees, we use share-based incentive awards such as employee stock options. Other companies may provide more generous compensation and benefits, more diverse opportunities and better chances for career advancement than we do. Some of these advantages may be more appealing to high-quality candidates and employees than those we have to offer. In addition, any decline in our stock price could create additional challenges related to our ability to compete effectively with respect to equity compensation. We may need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all, which may cause our business and operating results to suffer.

If an improved version of a reference product, such as Forteo, is developed, or if the market for a reference product significantly declines, sales or potential sales of the FDA-approved PF708 product or PF708 may suffer.

Reference product (“originator”) sponsor companies may develop improved versions as part of a life cycle extension strategy and may obtain regulatory approval of the improved version under a supplemental biologics license application (BLA) or NDA. If an originator sponsor company, such as Eli Lilly, succeeds in obtaining an approval of an improved product, such as for Forteo, it may capture a significant share of the collective market and significantly reduce the market for the reference product, and thereby reduce the size of the market for the FDA-approved PF708 product or PF708, if approved in other territories. The improved product also may be protected by additional patent rights.

Competition in the pharmaceutical market is intense. Reference products face competition on numerous fronts as technological advances are made that may offer patients a more convenient form of administration or increased efficacy, or as new products are introduced. As new products are approved that compete with the reference product for PF708, such as Forteo, sales may be significantly and adversely impacted and may render the originator obsolete. If the market for Forteo is impacted, we and Alvogen in turn may lose significant market share or market potential for the FDA-approved PF708 product and PF708. As a result, the value of the FDA-approved PF708 product, PF708 and our product pipeline could be negatively impacted and our business, prospects and financial condition could suffer.

The FDA-approved PF708 product, PF708 and our other product candidates, if approved, face significant competition from the reference products and from therapeutic equivalent products of the reference products, and from other products. Our or our collaboration partners’ failure to effectively compete may prevent us from achieving significant market penetration and expansion.

We and Alvogen face highly competitive pharmaceutical markets. With the FDA approval for PF708, Alvogen is responsible for commercializing and manufacturing the FDA-approved PF708 product in the U.S. Successful competitors in the pharmaceutical market have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to consumers and medical professionals. Numerous companies, universities, and other research institutions are engaged in developing, patenting, manufacturing and marketing of products competitive with the FDA-approved PF708 product, PF708 and other product candidates we are developing. For example, in April 2017, the FDA approved Radius Health’s TYMLOS^®(abaloparatide), and in April 2019, the FDA approved Evenity (romosozumab) a once monthly monoclonal antibody product developed by Amgen and UCB, each of which compete with the FDA-approved PF708 product. Teva Pharmaceuticals USA, Inc. has filed an ANDA referencing Forteo that, if approved, could compete with the FDA-approved PF708 product. Apotex Corp. also has submitted an ANDA for a generic version of Forteo, and other generic drug manufacturers may have filed and/or in the future may file ANDAs referencing Forteo that, if approved, could compete with the FDA-approved PF708 product. Any such competition could also adversely affect the market size and opportunity for the FDA-approved PF708 product and PF708. Many of these potential competitors, such as Amgen Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Limited, and Radius Health are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources. Recent and potential future merger and acquisition activity in the biotechnology and pharmaceutical industries is likely to result in even more resources being concentrated among a smaller number of our competitors. These companies also maintain greater brand recognition and more experience and expertise in undertaking preclinical testing and clinical trials of product candidates and obtaining the FDA and other regulatory approvals of products. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds that could make the FDA-approved PF708 product, PF708 and our other product candidates obsolete.

In addition, the FDA has approved PF708 pursuant to the 505(b)(2) regulatory pathway in the U.S. with Forteo as the reference product. Only if the FDA-approved PF708 product obtains an “A” therapeutic equivalence designation may the FDA-approved PF708 product be permitted to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states. In the case of Teva’s and Apotex’s competitive products, upon any approval of such competitor’s ANDA by the FDA, such competitor’s product would be permitted to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states, without the need to obtain an “A” therapeutic equivalence designation.

In addition, the FDA-approved PF708 product, and if approved, PF708 and our other product candidates, face competition from companies that develop and commercialize products that compete directly with our products. See “Risks Related to Government Regulation—If the FDA approves other therapeutic equivalent or generic products with Forteo as the reference drug and these drug products are successfully commercialized, the FDA-approved PF708 product may face additional competition and our business could suffer.”

If any competitor products are approved that compete with the FDA-approved PF708 product, PF708 or our other product candidates as described herein, our product revenue could suffer and it would have a material adverse effect on our financial condition and results of operations.

Use of the FDA-approved PF708 product, PF708 or our other product candidates could be associated with side effects or adverse events.

Use of the FDA-approved PF708 product, PF708 or our other product candidates could be associated with side effects or adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of the FDA-approved PF708 product, PF708 or our other product candidates may be observed at any time, including in clinical trials or when a product is commercialized, and any such side effects or adverse events may negatively affect our and our collaboration partners’ ability to obtain and maintain regulatory approval or market the FDA-approved PF708 product, PF708 or our product candidates. Side effects such as toxicity or other safety issues associated with the use of the FDA-approved PF708 product, PF708 or our product candidates could require us, Alvogen, or our other collaboration partners to perform additional studies or halt development or sale of the FDA-approved PF708 product, PF708 or these other product candidates or expose us, Alvogen, or our other collaboration partners to product liability lawsuits which would harm our business. We, Alvogen, or our other collaboration partners may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of the FDA-approved PF708 product, PF708 or our other product candidates which were not planned or anticipated. We, Alvogen, or our other collaboration partners may also be required to change product labeling, including increasing the prominence and content of warnings and contraindications for our products. The FDA could require us or our collaboration partners to develop a Risk Evaluation and Mitigation Strategy (REMS) for such product or, if a REMS is already in place, to incorporate additional requirements under the REMS, and foreign regulatory authorities may require similar risk management strategies. There can be no assurance that we or our collaboration partners will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.

In addition, if we, Alvogen, and our other collaboration partners are successful in commercializing the FDA-approved PF708 product, or if approved, PF708 outside the U.S., or any other product candidates, the FDA, European Medicines Agency (EMA), competent authorities of the Member States of the European Economic Area (EEA), and other foreign regulatory agency regulations require that the application holder timely report certain information about adverse medical events. We, Alvogen, or our other collaboration partners may fail to report adverse events we become aware of within the prescribed timeframe. We, Alvogen, or our other collaboration partners may also fail to appreciate that we or our collaboration partners have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or delayed in time from the use of our products. If we or our collaboration partners fail to comply with our reporting obligations, the FDA, the EMA, competent authorities of the Member States of the EEA, or other foreign regulatory agencies could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of our products.

With the FDA approval of the PF708 product, we are substantially dependent on the commercial success of the FDA-approved PF708 product to be marketed by Alvogen in the U.S. In addition, we currently rely on a limited number of third parties for a substantial portion of our revenue. The loss of or a change in Alvogen or any of these third parties, including its creditworthiness, could materially reduce our revenue and adversely impact our financial position.

Alvogen’s ability to successfully commercialize the FDA-approved PF708 product, the first FDA-approved product that we developed, is critical to the execution of our business strategy. For a discussion of risks relating to the degree of market acceptance and commercial success of the PF708 product, please see the risk factors entitled: “The FDA-approved PF708 product, PF708 and our other product candidates, if approved, face significant competition from the reference products and from therapeutic equivalent

products of the reference products, and from other products. Our or our collaboration partners’ failure to effectively compete may prevent us from achieving significant market penetration and expansion;” ”Although the FDA-approved PF708 product has obtained regulatory approval from the FDA, PF708 may not be approved by other regulatory authorities and even if PF708 or our other product candidates obtain additional regulatory approvals, they may never achieve market acceptance or commercial success.;” and “If the FDA-approved PF708 product does not receive an “A” therapeutic equivalence designation from the FDA, our business may suffer.” Alvogen may experience significant fluctuations in sales of the FDA-approved PF708 product from period to period and, ultimately, we may never generate sufficient revenue from our agreement with Alvogen to reach or maintain profitability or sustain anticipated levels of operation. Any inability on the part of Alvogen to successfully commercialize the FDA-approved PF708 product in the U.S. and to successfully commercialize PF708 in any significant international markets where PF708 may be subsequently approved, or any significant delay, could have a material effect on our financial condition and results of operations. We have also entered into an agreement with China NT Pharma Group Company Ltd. (NT Pharma) to develop and commercialize PF708 in certain territories. The prospects for the FDA-approved PF708 product and PF708 depend on the expertise, development and commercial skills, and financial strength of Alvogen and NT Pharma.

In addition to our reliance on the commercial success of the FDA-approved PF708 product and PF708, two third parties accounted for more than 10% of our 2018 and 2017 revenue and one third party accounted for more than 10% of our 2016 revenue. Jazz and BARDA each accounted for more than 10% of our revenue in 2018 and 2017, and Pfizer accounted for more than 10% of our 2016 revenue.

In addition, in August 2016, we entered into a termination agreement with Pfizer pursuant to which our development and license agreement was terminated and all rights to PF582 returned to us. The termination accelerated recognition of $45.8 million of revenue that had been previously deferred, and we will not recognize any additional future revenue under this agreement. Pfizer will no longer be responsible for manufacturing, clinical studies and commercialization of PF582. We will not receive additional revenue from Pfizer.

The loss of any key collaboration partner, especially Alvogen and/or Jazz, or any significant adverse change in the size or terms of a contract with a key third party could significantly reduce our revenue over the short term. Moreover, having our revenue concentrated among a limited number of entities creates a concentration of financial risk for us, and in the event that any significant third party is unable to fulfill its payment obligations to us, our operating results and cash position would suffer. See “Risks Relating to our Reliance on Third Parties—We are substantially dependent on the expertise of Alvogen, Jazz, and NT Pharma to develop and commercialize the FDA-approved PF708 product, PF708 and certain other product candidates. If we fail to maintain our current strategic relationship with Alvogen, Jazz, NT Pharma, or with any future collaboration partner, our business, commercialization prospects and financial condition may be materially adversely affected.”

We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.

We continue to evaluate our business strategy and, as a result, may modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial or other reasons. For example, in 2017 we decided to pause development activities on PF582 and PF529 and focus development efforts elsewhere within the product portfolio while we continue to engage potential strategic partners for PF582 and PF529 to advance the programs and maximize value. As a result of changes in our strategy, we have and may in the future change or refocus our existing product development, commercialization and manufacturing strategies. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Our decisions to allocate our research and development, management and financial resources toward particular product candidates may not lead to the development of viable commercial products and may divert resources from better opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect and could cause us to miss valuable opportunities.

We currently have limited marketing capabilities and no sales organization.

We currently have limited sales and marketing capabilities. We have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team.

To commercialize and manufacture the FDA-approved PF708 product and PF708, we have entered into collaboration agreements with Alvogen and NT Pharma and the prospects for the FDA-approved PF708 product and PF708 depend on the expertise, development and commercial skills, and financial strength of Alvogen and NT Pharma. Under the Alvogen agreements, Alvogen has the exclusive right to commercialize and manufacture PF708 in the United States, European Union, Middle East, North Africa, and the rest of the world not covered by the NT Pharma territory. The loss for any reason of Alvogen as a key partner could have a significant and adverse impact on our business. If we are unable to retain Alvogen as a partner on commercially acceptable terms, we may not be able to commercialize the FDA-approved PF708 product and PF708, if approved, as planned and we could experience delays in or suspension of the U.S. commercial launch of the FDA-approved PF708 product. Under the NT Pharma agreement, we granted an exclusive license to NT Pharma to commercialize PF708 in certain Asian countries and a non-exclusive license to conduct development activities in such territories with respect to PF708. For our other product candidates, if approved, we will need to identify potential sales, marketing and distribution partners or establish our own internal sales force. In the future, we may choose to collaborate with other third parties that have direct sales forces and established distribution systems, either to augment our own sales force or in lieu of our own sales force. If we are unable to maintain and/or enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize the FDA-approved PF708 product or our other product candidates. If we are not successful in commercializing the FDA-approved PF708 product, or PF708 or our other product candidates, if approved, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.

We enter into various contracts in the normal course of our business that periodically incorporate provisions whereby we indemnify the other party to the contract. In the event we would have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial position and results of operations.

In the normal course of business, we periodically enter into academic, commercial and consulting agreements that contain indemnification provisions. With respect to our academic agreements, we may be required to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees’ exercise of rights under the agreement. With respect to commercial agreements entered into with our protein production customers, we typically provide indemnification for claims from third parties arising out of any potential intellectual property infringement associated with our Pfēnex Expression Technology^® in the course of performing our services. With respect to our commercial agreements, the bulk of which are with contract manufacturers, we indemnify our vendors from third-party product liability claims which result from the production, use or consumption of the product, as well as for certain alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we indemnify them from claims arising from the good faith performance of their services. In all of the above cases, we do not indemnify the parties for claims resulting from the negligence or willful misconduct of the indemnified party.

In certain circumstances, we maintain insurance coverage which we believe may limit our obligations under certain of these indemnification provisions. However, we do not carry insurance for all risks that our business may encounter, including our obligations under certain indemnification provisions. To the extent we do not have insurance to cover certain indemnification obligations, we are denied insurance coverage, or our obligation under an indemnification provision exceeds applicable insurance coverage, any significant, uninsured liability may require us to pay substantial amounts, which would adversely affect our working capital and results of operations.

We may have difficulty expanding our operations successfully.

As we advance our product candidates through the development process, we will need to expand our development, regulatory, manufacturing, quality, sales and marketing capabilities or contract with other organizations to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various collaboration partners, suppliers and other organizations, including with respect to the commercialization of the FDA-approved PF708 product and PF708.

As of September 30, 2019, we had 83 full-time employees, including a total of 23 employees who hold Ph.D. or other doctoral degrees. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Therefore, we will need to continue to expand our managerial, operational, finance and other resources to manage our operations and clinical trials, continue our development activities and potentially commercialize our current product candidates, if approved. In order to effectively execute our growth strategy, we will be required to:

•

manage our clinical trials effectively;

•

identify, recruit, retain, incentivize and integrate additional employees;

•

establish and maintain collaborations with third parties for the development and commercialization of the FDA-approved PF708 product, PF708 and our product candidates, or otherwise build and maintain a sales, marketing and distribution infrastructure to commercialize PF708 or any other products for which we may obtain marketing approval;

•

manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and

•

continue to improve our operational, financial and management controls, reporting systems and procedures.

Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. In addition, this expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives, or disrupt our operations, which could materially impact our business, revenue, and operating results.

The U.S. government holds certain intellectual property rights related to our Anthrax vaccines, Px563L and RPA563.

Although we have intellectual property related to expression of recombinant protective antigen in P. fluorescens, the U.S. government holds certain patents related to the recombinant protective antigen in Px563L and RPA563, as well as certain license rights to intellectual property related to other Px563L components used to produce the final vaccine, which, if exercised, could materially impact our business, revenue and operating results. We have rights to utilize this intellectual property held by the U.S. government by virtue of the Authorization and Consent clauses of our contracts with the U.S. government.

Our contracts with the U.S. government, and our subcontracts with U.S. government contractors, require ongoing funding decisions by the U.S. government; reduced or discontinued funding of these contracts could cause our financial condition and operating results to suffer materially.

Development of our anthrax vaccines, Px563L and RPA563, is funded by BARDA. The funding for government programs is subject to Congressional appropriations, often made on a fiscal year basis, even for programs designed to continue for several years. These appropriations can be subject to political considerations and stringent budgetary constraints. For example, on March 29, 2019, we received notice from BARDA informing us of BARDA’s decision to not exercise development options for cGMP manufacturing and potential Phase 1/2b study readiness for Px563L and RPA563. Following the receipts of the notice from BARDA and pursuant to ongoing discussions with BARDA, we deprioritized this program in our portfolio. Additionally, our government-funded development contracts give the U.S. government the right, exercisable in its sole discretion, to extend this contract for successive options following a base period of performance. The value of the services to be performed during these options may constitute the majority of the total value of the underlying contract. If levels of government expenditures and authorizations for biodefense decrease or shift to programs in areas where we do not offer products or are not developing product candidates, or if the U.S. government otherwise declines to exercise its options under its contracts with us, our business, revenue and operating results would suffer.

Our current contract with BARDA is a cost-plus fixed fee contract and potential future contracts with the U.S. government may also be structured this way. Under our cost-plus fixed fee contracts, we are allowed to recover our approved costs plus a fixed fee. The total price on a cost-plus fixed fee contract is based primarily on allowable costs incurred, but generally is subject to contract funding limitations. U.S. government regulations require us to notify our customer of any cost overruns or underruns on a cost-plus fixed fee contract. If we incur costs in excess of the funding limitation specified in the contract, we may not be able to recover those cost overruns.

Moreover, changes in U.S. government contracting policies could directly affect our financial performance. Factors that could materially adversely affect our U.S. government contracting business include:

•

budgetary constraints affecting U.S. government spending generally, or specific departments or agencies in particular;

•

changes in U.S. government fiscal policies or available funding;

•

changes in U.S. government defense and homeland security priorities;

•

changes in U.S. government programs or requirements;

•

adoption of new laws or regulations;

•

technological developments;

•

U.S. government shutdowns, threatened shutdowns or budget delays;

•

competition and consolidation in our industry; and

•

general economic conditions.

These or other factors could cause U.S. government departments or agencies to reduce their development funding or future purchases under contracts, to exercise their right to terminate contracts or fail to exercise their options to extend our contracts, any of which could have a material adverse effect on our business, financial condition, operating results and ability to meet our financial obligations.

Unfavorable provisions in government contracts, some of which are customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our financial condition and operating results.

Government contracts contain provisions that give the U.S. government substantial rights and remedies, many of which are not typically found in commercial contracts, including provisions that allow the U.S. government to:

•

terminate existing contracts, in whole or in part, for any reason or no reason;

•

unilaterally reduce or modify the government’s obligations under such contracts or subcontracts, without the contractor’s consent, including by imposing equitable price adjustments;

•

audit contract-related costs and fees, including allocated indirect costs;

•

claim rights, including intellectual property rights, in products and data developed under such agreements;

•

under certain circumstances involving public health and safety, license inventions made under such agreements to third parties;

•

suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;

•

impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such contracts;

•

suspend or debar the contractor from doing future business with the government;

•

decline to exercise an option to continue a contract;

•

exercise an option to purchase only the minimum amount, if any, specified in a contract;

•

decline to exercise an option to purchase the maximum amount, if any, specified in a contract;

•

claim rights to facilities or to products, including intellectual property, developed under the contract;

•

require repayment of contract funds spent on construction of facilities in the event of contract default;

•

take actions that result in a longer development timeline than expected;

•

change the course of a development program in a manner that differs from the contract’s original terms or from our desired development plan, including decisions regarding our partners in the program;

•

pursue civil or criminal remedies under the False Claims Act (FCA) and False Statements Act; and

•

control or prohibit the export of products.

Generally, government contracts, including our contract with BARDA, contain provisions permitting unilateral termination or modification, in whole or in part, at the U.S. government’s convenience. Under general principles of government contracting law, if the U.S. government terminates a contract for convenience, the government contractor may recover only its incurred or committed costs, settlement expenses and profit on work completed prior to the termination. If the U.S. government terminates a contract for default, the government contractor is entitled to recover costs incurred and associated profits on accepted items only and may be liable for excess costs incurred by the government in procuring undelivered items from another source. In addition, government contracts normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:

•

specialized accounting systems unique to government contracts;

•

mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;

•

public disclosures of certain contract information, which may enable competitors to gain insights into our research program;

•

mandatory internal control systems and policies; and

•

mandatory socioeconomic compliance requirements, including labor standards, non-discrimination and affirmative action programs and environmental compliance requirements.

If we fail to maintain compliance with these requirements, we may be subject to potential contract or FCA liability and to termination of our contracts.

Furthermore, we are required to enter into agreements and subcontracts with third parties, including suppliers, consultants and other third-party contractors in order to satisfy our contractual obligations pursuant to our agreements with the United States government. Negotiating and entering into such arrangements can be time-consuming and we may not be able to reach agreement with such third parties. Any such agreement must also be compliant with the terms of our government contract. Any delay or inability to enter into such arrangements or entering into such arrangements in a manner that is non-compliant with the terms of our contract, may result in violations of our contract.

We may not have the right to prohibit the U.S. government from using certain technologies developed by us, and we may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally takes the position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts.

Most U.S. government contracts grant the U.S. government the right to use on a royalty free basis, for or on behalf of the U.S. government, any technologies developed and data first produced by the contractor under the government contract. If we were to develop technology under a contract with such a provision, we might not be able to prohibit third parties, including our competitors, from using that technology in providing products and services to the U.S. government.

Our business is subject to audit by the U.S. government and a negative audit could adversely affect our business.

U.S. government agencies such as the Department of Health and Human Services (HHS) and the Defense Contract Audit Agency (DCAA) routinely audit and investigate government contractors and recipients of federal grants and contracts. These agencies review a contractor’s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.

The HHS and the DCAA also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s accounting, purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded. If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:

•

termination of contracts;

•

forfeiture of profits;

•

suspension of payments;

•

fines; and

•

suspension or prohibition from conducting business with the U.S. government.

In addition, we could suffer serious reputational harm if allegations of impropriety were made against us, which could cause our stock price to decrease.

The United States government’s determination to award a future contract may be challenged by an interested party, such as another bidder, at the United States Government Accountability Office (GAO) or in federal court. If such a challenge is successful, any future contract we may be awarded may be terminated.

The laws and regulations governing the procurement of goods and services by the U.S. government provide procedures by which other bidders and interested parties may challenge the award of a government contract. If we are awarded a government contract, such challenges or protests could be filed even if there are not any valid legal grounds on which to base the protest. If any such protests are filed, the government agency may decide to suspend our performance under the contract while such protests are being considered by the GAO or the applicable federal court, thus potentially delaying delivery of payment. In addition, we could be forced to expend considerable funds to defend any potential award. If a protest is successful, the government may be ordered to terminate the contract and resolicit proposals. The government agencies with which we have contracts could even be directed to award a potential contract to one of the other bidders.

Laws and regulations affecting government contracts make it more costly and difficult for us to successfully conduct our business.

We must comply with numerous laws and regulations relating to the formation, administration and performance of government contracts, which can make it more difficult for us to retain our rights under our government contracts, including our contract with BARDA. These laws and regulations affect how we conduct business with government agencies. Among the most significant government contracting regulations that affect our business are:

•

the Federal Acquisition Regulations (FAR) and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;

•

the Truth in Negotiations Act, which requires certification and disclosure of cost or pricing data in connection with contract negotiations;

•

business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include other requirements such as the Anti-Kickback Statute and Foreign Corrupt Practices Act;

•

export and import control laws and regulations; and

•

laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.

Any material changes in applicable laws and regulations could restrict our ability to maintain our existing BARDA contract and obtain new contracts, which could limit our ability to conduct our business and materially adversely affect our results of operations.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of products we develop.

We face a risk of product liability as a result of the clinical testing of our product candidates and may face an even greater risk in connection with the commercialization of the FDA-approved PF708 product in addition to any other of our products that may be approved. For example, we may incur liability if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Regardless of the merits or eventual outcome, liability claims may result in:

•

decreased demand for the FDA-approved PF708 product, PF708 or any other product candidates or products we develop;

•

injury to our reputation and significant negative media attention;

•

withdrawal of clinical trial participants or cancellation of clinical trials;

•

costs to defend the related litigation;

•

a diversion of management’s time and our resources;

•

substantial monetary awards to trial participants or patients;

•

regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;

•

loss of revenue; and

•

the inability to commercialize any products we develop.

Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could impact the commercialization of PF708 and any other products we develop. We currently carry product liability insurance in the amount of $10.0 million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. Since we have received FDA approval for the PF708 product in the United States and if we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such products; however, we may be unable to obtain this liability insurance on commercially reasonable terms.

Our employees, independent contractors, principal investigators, CROs, CMOs, consultants and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk that our employees, independent contractors, principal investigators, third-party clinical research organizations (CROs) and contract manufacturing organizations (CMOs), consultants and collaboration partners may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) regulations of the FDA and comparable foreign authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; (2) manufacturing standards; (3) federal and state healthcare fraud and abuse laws and regulations; or (4) laws that require the reporting of true and accurate financial information and data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Ethics and Conduct, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Our cash and cash equivalents and short-term investments could be adversely affected if the financial institutions in which we hold our cash and cash equivalents and short-term investments fail.

We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation (FDIC) insurance limit. While we monitor the cash balances in our accounts and adjust the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which we deposit fails or is subject to other adverse conditions in the financial or credit markets. To date, we have experienced no loss or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that access to our invested cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets.

We may be subject to information technology failures, including data protection breaches and cyber-attacks, that could disrupt our operations, damage our reputation and adversely affect our business, operations, and financial results.

We rely on our information technology systems for the effective operation of our business and for the secure maintenance and storage of confidential data relating to our business and third-party businesses. Although we have implemented security controls to protect our information technology systems, experienced programmers or hackers may be able to penetrate our security controls, and develop and deploy viruses, worms and other malicious software programs that compromise our confidential information or that of third parties and cause a disruption or failure of our information technology systems. Any such compromise of our information technology systems could result in the unauthorized publication of our confidential business or proprietary information, result in the unauthorized release of customer, supplier or employee data, result in a violation of privacy or other laws, expose us to a risk of litigation, or damage our reputation. The cost and operational consequences of implementing further data protection measures either as a response to specific breaches or as a result of evolving risks, could be significant. In addition, our inability to use or access our information systems at critical points in time could adversely affect the timely and efficient operation of our business. Any delayed sales, significant costs or lost customers resulting from these technology failures could adversely affect our business, operations and financial results.

Third parties with which we conduct business have access to certain portions of our sensitive data. In the event that these third parties do not properly safeguard our data that they hold, security breaches could result and negatively impact our business, operations and financial results.

Our business involves the use of hazardous materials and we, our collaboration partners, and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.

Our research and development and manufacturing activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use and disposal of hazardous materials owned by us, including small quantities of acetonitrile, methanol, ethanol, ethidium bromide and compressed gases, and other hazardous compounds. We and our collaboration partners, manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products.

Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations.

We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, and the handling of biohazardous materials. Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. For claims not covered by workers’ compensation insurance, we also maintain an employer’s liability insurance policy in the amount of $1.0 million per occurrence and in the aggregate. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.

Environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Any inability to comply with environmental laws and regulations may adversely affect our business and operating results.

Changes in accounting principles, or interpretations thereof, could have a significant impact on our financial position and results of operations.

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, referred to as GAAP. These principles are subject to interpretation by the Securities and Exchange Commission (SEC) and various bodies formed to interpret and create appropriate accounting principles. A change in these principles can have a significant effect on our reported results and may even retroactively affect previously reported transactions. Additionally, the adoption of new or revised accounting principles may require that we make significant changes to our systems, processes and controls.

It is not clear if or when these potential changes in accounting principles may become effective, whether we have the proper systems and controls in place to accommodate such changes and the impact that any such changes may have on our financial position and results of operations.

Although the FDA-approved PF708 product has obtained regulatory approval from the FDA, PF708 may not be approved by other regulatory authorities and even if PF708 or our other product candidates obtain additional regulatory approvals, they may never achieve market acceptance or commercial success.

Although the FDA-approved PF708 product has obtained regulatory approval from the FDA, and even if we obtain other regulatory approvals, the FDA-approved PF708 product or any of our other product candidates, if approved, may not achieve market acceptance among physicians and patients and may not be commercially successful. The degree and rate of market acceptance of the FDA-approved PF708 product, PF708, or any of our other product candidates for which we receive approval depends on a number of factors, including:

•

the performance of our collaboration partners, including Alvogen, Jazz, and NT Pharma;

•

the safety and efficacy of the product as demonstrated in clinical trials;

•

the clinical indications for which the product is approved;

•

acceptance by physicians, major operators of clinics and patients of the product as a safe and effective treatment;

•

whether we obtain an “A” therapeutic equivalence designation for the FDA-approved PF708 product, which may allow the product to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states;

•

whether we or Alvogen are able to obtain timely and adequate coverage and reimbursement for our products by key payors, such as Medicare Part D for the FDA-approved PF708 product in the United States;

•

proper training and administration of our products by physicians, medical staff, and patients;

•

the potential and perceived advantages of our products over alternative treatments;

•

the cost of treatment in relation to alternative treatments and willingness to pay for the FDA-approved PF708 product, PF708 and our other product candidates, if approved, on the part of physicians and patients;

•

relative convenience and ease of administration;

•

the prevalence and severity of adverse events; and

•

the effectiveness of our sales and marketing efforts.

Any failure by the FDA-approved PF708 product or product candidates that obtain regulatory approval to achieve market acceptance or commercial success would materially adversely affect our results of operations and delay, prevent or limit our ability to generate revenue and continue our business.

Risks Relating to our Reliance on Third Parties

We are substantially dependent on the expertise of Alvogen, Jazz, and NT Pharma to develop and commercialize the FDA-approved PF708 product, and PF708 and certain other product candidates, if approved. If we fail to maintain our current strategic relationship with Alvogen, Jazz, NT Pharma, or with any future collaboration partner, our business, commercialization prospects and financial condition may be materially adversely affected.

Because we have limited or no capabilities for commercial, manufacturing, sales, marketing and distribution, we have entered into alliances and may need to enter into additional alliances with other companies to develop and commercialize our products that we have developed and our product candidates. For example, to commercialize the FDA-approved PF708 product and PF708 if approved in other territories, we have entered into collaboration agreements with Alvogen and NT Pharma and the prospects for the FDA-approved PF708 product and PF708 if approved outside the U.S., depends in part on the expertise, commercial skills, and financial strength of Alvogen and NT Pharma. Under the Alvogen agreement, Alvogen has the exclusive right to commercialize and manufacture the FDA-approved PF708 product in the United States, and PF708 in the European Union, Middle East, North Africa, and the rest of the world not covered by the NT Pharma agreement. We may be unable to establish or maintain this relationship with Alvogen on a commercially reasonable basis, if at all. In addition, Alvogen may have similar or more established relationships with our competitors. Moreover, the loss for any reason of Alvogen as a key partner could have a significant and adverse impact on our business. If we are unable to retain Alvogen as a partner on commercially acceptable terms, the commercialization of PF708 may not occur as planned and there could be delays in or suspension of the commercial launch of the FDA-approved PF708 product in the U.S. Under the NT Pharma agreement, we granted an exclusive license to NT Pharma to commercialize PF708 in certain Asian countries, if approved, and a non-exclusive license to conduct development activities in such territories with respect to PF708. In addition, we entered into an agreement with Jazz, pursuant to which we have transferred the development, manufacturing and commercialization of certain product candidates.

In July 2016, we entered into a license and option agreement with Jazz, pursuant to which we and Jazz are collaboratively developing hematology/oncology products, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase, and Jazz has the exclusive right to manufacture and commercialize such products throughout the world. In December 2017, we amended the agreement. We may be eligible to receive additional payments under the amended agreement of up to $177.5 million based on achievement of certain research and development, regulatory and sales-related milestones, bringing the total value of payments and potential payments associated with the collaboration to $224.5 million. In addition, we may be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement.

The prospects for the FDA-approved PF708 product, and PF708 and the other product candidates developed under these collaborations depend on the expertise, development and commercial skills, and financial strength of Alvogen, Jazz, and NT Pharma. Our collaborations with Alvogen, Jazz, NT Pharma or any future collaboration partner may not be successful, and we may not realize the expected benefits from such collaborations, due to a number of important factors, including but not limited to the following:

•

Alvogen, Jazz, NT Pharma, or any future collaboration partner may terminate their agreements with us prior to completing development or commercialization of the FDA-approved PF708 product, PF708 or the other product candidates under the collaboration, in whole or in part, adversely impacting the potential approval and our revenue from licensed products;

•

the timing and amount of any payments we may receive under these agreements will depend on, among other things, the efforts, allocation of resources, and successful commercialization of the FDA-approved PF708 product and PF708 by Alvogen or the relevant product candidates by Jazz, NT Pharma, or any future collaboration partner, as applicable, under our agreements;

•

the timing and amounts of expense reimbursement that we may receive are uncertain; or

•

Alvogen, Jazz, NT Pharma, or any future collaboration partner may change the focus of their development or commercialization efforts or pursue or emphasize higher priority programs.

A failure of Alvogen, Jazz, NT Pharma or any future collaboration partner to successfully develop our product candidates which are covered by the collaboration, or to commercialize the PF708 product, PF708 or such other product candidates, or the termination of our agreements with Alvogen, Jazz, NT Pharma, or any future collaboration partner, as applicable, may have a material adverse effect on our business, results of operations and financial condition.

We are dependent on Alvogen for the commercial manufacture and supply of the FDA-approved PF708 product. The manufacture of the FDA-approved PF708 product is complex and Alvogen may encounter difficulties in production, particularly with respect to scaling up Alvogen’s manufacturing capabilities of the FDA-approved PF708 product.

The process of manufacturing the FDA-approved PF708 product is complex, highly-regulated and subject to multiple risks. The manufacture of the FDA-approved PF708 product, PF708, and our product candidates involve complex processes and is subject to the risks more fully described in the risk factor entitled “We rely on our collaboration partners, and other third parties, and in some cases a single third party, to manufacture commercial, nonclinical and clinical supplies of our product candidates, supply key materials to manufacture our other product candidates, and to store critical components of our other product candidates for us. Our business could be harmed if those third parties fail to provide us with sufficient quantities of our other product candidates or fail to do so at acceptable quality levels or prices.”

We have been assisting Alvogen with the transfer of our manufacturing processes for the FDA-approved PF708 product. The transfer of process to Alvogen, or to CMOs selected by Alvogen, and the actual manufacture of the FDA-approved PF708 product by Alvogen or its selected CMOs, is subject to risk and may not ultimately be successful or may take longer to succeed than expected, which could delay or impair commercialization activities in the U.S., which would have an adverse effect on our business. Such transfer activities also require a significant amount of attention from our personnel, which may disrupt our other development activities, which in turn may have an adverse effect on our business.

Reliance on Alvogen and third-party manufacturers entails risks to which we would not be subject if we manufactured the FDA-approved PF708 product ourselves, including reliance on Alvogen or the third-party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by Alvogen or the third-party because of factors beyond our control, including a failure to manufacture the FDA-approved PF708 product in accordance with specifications, and the possibility of termination or nonrenewal of the agreement by Alvogen, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA requires that the FDA-approved PF708 product be manufactured according to cGMP. Any failure by Alvogen to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of the FDA-approved PF708 product or PF708 in a timely manner, could lead to delay in, or failure to obtain, regulatory approval of PF708 in territories outside the U.S. In addition, failure to comply with cGMP could be the basis for the FDA to issue a warning letter, withdraw approvals previously granted to us or our collaboration partners, or take other regulatory or legal action, including recall or seizure of the FDA-approved PF708 product, PF708 or other product candidate, total or partial suspension of production, suspension of on-going clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction, or imposing civil and criminal penalties.

Because we have received FDA approval for PF708, Alvogen is obligated to use diligent efforts to continue to develop, manufacture and commercialize the FDA-approved PF708 product at Alvogen’s cost and expense. We and Alvogen have not yet identified alternate suppliers for the FDA-approved PF708 product, nor have we identified alternate suppliers for any other product candidate, in the event the current CMOs we utilize are unable to scale to commercial production, pass required preapproval inspections, or if we otherwise experience any problems with them. Although we believe alternative third-party suppliers with the necessary manufacturing and regulatory expertise and facilities exist, it would be expensive and take a significant amount of time to arrange for, and qualify, alternative suppliers. Furthermore, if Alvogen is required to identify, qualify and contract with new manufacturing suppliers of the FDA-approved PF708 product or PF708, Alvogen would need to demonstrate to the satisfaction of the FDA in a bridging study that any new supply of the FDA-approved PF708 product is substantially the same as the previous supply of FDA-approved PF708 product. A bridging study may require further clinical testing, including testing in patients. We cannot assure you that we can arrange for alternative third-party manufacturing sources for the FDA-approved PF708 product on commercially reasonable terms or in a timely manner, or that such manufacturers or collaboration partners will be capable of manufacturing the FDA-approved PF708 product in compliance with cGMP and to FDA’s satisfaction.

Any significant disruption in our supplier relationships could harm our business. Any significant delay in the supply of a product candidate or its key materials for an ongoing clinical study could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If Alvogen, our manufacturers or we are unable to purchase these key materials for the PF708 product, the commercial launch of the FDA-approved PF708 product could be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of the FDA-approved PF708 product.

We rely on our collaboration partners, and other third parties, and in some cases a single third party, to manufacture commercial, nonclinical and clinical supplies our product candidates, supply key materials to manufacture our other product candidates, and to store critical components of our other product candidates for us. Our business could be harmed if those third parties fail to provide us with sufficient quantities of our other product candidates or fail to do so at acceptable quality levels or prices.

We do not currently have the infrastructure or capability internally to manufacture supplies of our product candidates for use in clinical studies, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on Alvogen, our collaboration partners, and other third-party manufacturers, including with respect to PF708, to manufacture PF708 or our product candidates for preclinical and clinical studies, and commercial supply. In addition, following FDA approval of PF708, Alvogen will also supply NT Pharma with PF708 if requested by NT Pharma. Successfully transferring complicated manufacturing techniques to manufacturing organizations and scaling up these techniques for commercial quantities will be time consuming and we may not be able to achieve such transfer. We are currently transferring manufacturing techniques related to PF708 to Alvogen. Moreover, the market for contract manufacturing services for protein therapeutics is highly cyclical, with periods of relatively abundant capacity alternating with periods in which there is little available capacity. If our need for contract manufacturing services increases during a period of industry-wide production capacity shortage, we may not be able to produce our product candidates on a timely basis or on commercially viable terms. Although we generally do not begin a clinical study unless we believe we have a sufficient supply of a product or product candidate to complete such study, any significant delay or discontinuation in the supply of a product or product candidate for an ongoing clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing, and potential regulatory approval of our current product candidates, which could harm our business and results of operations.

Reliance on Alvogen, our collaboration partners, and other third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, Alvogen, our collaboration partners, and other third-party manufacturers may not be able to comply with cGMP, or similar regulatory requirements outside the United States. Our failure, or the failure of Alvogen, our collaboration partners, or other third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, untitled or warning letters, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, and criminal prosecutions, any of which could significantly and adversely affect supplies of PF708 or any other product candidates or products that we may develop. Any failure or refusal to supply the components for PF708 or our other product candidates that are being developed could delay, prevent or impair clinical development or commercialization efforts. If our manufacturers were to breach or terminate their manufacturing arrangements with us, the development or commercialization of the affected products or product candidates could be delayed, which could have an adverse effect on our business. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.

In order to produce the quantities of the FDA-approved PF708 product necessary to meet anticipated market demand, Alvogen or any manufacturer that we and our collaboration partners engage may need to increase manufacturing capacity. If we, Alvogen, our collaboration partners, or our manufacturers are unable to produce the FDA-approved PF708 product, PF708 for commercial sales or for clinical studies, or any of our product candidates in sufficient quantities to meet the requirements for the launch of these products or to meet future demand, our revenue and gross margins could be adversely affected. Although we currently believe that we, Alvogen, our collaboration partners, and our manufacturers will not have any material supply issues, we cannot be certain that we will be able to obtain long-term supply arrangements for PF708 or any of our other product candidates or materials used to produce such product candidate on acceptable terms, if at all. If we, Alvogen, or our collaboration partners are unable to arrange for manufacturing, either through a third party or Alvogen, or to do so on commercially reasonable terms, we may not be able to market the FDA-approved PF708 product or complete development of or market any of our other product candidates.

Any significant disruption in our supplier relationships could harm our business. We source key materials from third parties, either directly through agreements with suppliers or indirectly through our manufacturers who have agreements with suppliers. There are a small number of suppliers for certain capital equipment and key materials that are used to manufacture our product candidates. Such suppliers may not sell these key materials to our manufacturers at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the acquisition of these key materials by our manufacturers. Any significant delay in the supply of a product candidate or its key materials for an ongoing clinical study could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidate. If Alvogen, our manufacturers, collaboration partners, or we are unable to purchase these key materials for PF708 our other product candidates after regulatory approval, the commercial launch of our product candidates, if approved, could be delayed or there could be a shortage in supply, which would impair our ability to generate revenues from their sale.

We also rely on third parties to store master and working cell banks for PF708 and our other product candidates. We have master and working cell banks and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks, which could materially and adversely affect our business, financial condition and results of operations.

Our existing product development and/or commercialization arrangements, and any that we may enter into in the future, may not be successful, which could adversely affect our ability to generate revenues from the FDA-approved PF708 product and develop and commercialize PF708 and our other product candidates.

We are a party to collaboration arrangements with other pharmaceutical companies for the development and/or commercialization of the FDA-approved PF708 product, PF708 and our current and future product candidates. In such alliances, we would expect our collaboration partners to provide substantial capabilities in clinical development, manufacturing, regulatory affairs, sales and marketing, both in the United States and internationally. For example, to commercialize the FDA-approved PF708 product and PF708, we have entered into collaboration agreements with Alvogen and NT Pharma and the prospects for the FDA-approved PF708 product and PF708 depend in part on the expertise, development and commercial skills, and financial strength of Alvogen and NT Pharma. Under the Alvogen agreement, Alvogen has the exclusive right to commercialize and manufacture PF708 in the United States, European Union, Middle East, North Africa, and the rest of the world not covered by the NT Pharma agreement. Under the NT Pharma agreement, we granted an exclusive license to NT Pharma to commercialize PF708 in certain Asian countries and a non-exclusive license to conduct development activities in such territories with respect to PF708.

To the extent that we decide to enter into additional collaboration agreements, we will face significant competition in seeking appropriate collaboration partners. Any failure to meet our clinical milestones with respect to an unpartnered product candidate would make finding a collaboration partner more difficult. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement, and we cannot guarantee that we can successfully maintain such relationships or that the terms of such arrangements will be favorable to us. If we fail to maintain, establish and implement collaboration or other alternative arrangements, the value of our business and operating results will be adversely affected.

We may not be successful in our efforts to establish, implement and maintain collaborations or other alternative arrangements if we choose to enter into such arrangements. The terms of any collaboration or other arrangements that we may establish may not be favorable to us. The management of collaborations may take significant time and resources that distract our management from other matters. Our ability to successfully collaborate with any current or future collaboration partners may be impaired by multiple factors including:

•

a collaboration partner may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;

•

a collaboration partner may cease development in therapeutic areas which are the subject of alliances with us;

•

a collaboration partner may change the success criteria for a particular program or product candidate thereby delaying or ceasing development of such program or candidate;

•

a significant delay in initiation of certain development activities by a collaboration partner will also delay payments tied to such activities, thereby impacting our ability to fund our own activities;

•

a collaboration partner could develop a product that competes, either directly or indirectly, with our current or future products, if any;

•

a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;

•

a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;

•

a collaboration partner may exercise its rights under the agreement to terminate our collaboration;

•

a dispute may arise between us and a collaboration partner concerning the commercialization of the FDA-approved PF708 product or PF708 or the research, development, or commercialization of another product candidate resulting in a delay in milestones, royalty payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources;

•

the results of our clinical trials may not match our collaboration partners’ expectations, even if statistically significant;

•

a collaboration partner may not adequately protect or enforce the intellectual property rights associated with a product or product candidate; and

•

a collaboration partner may use our proprietary information or intellectual property in such a way as to invite litigation from a third party.

Any such activities by our current or future collaboration partners could adversely affect us financially and could harm our business reputation.

In addition to product development and commercialization capabilities, we may depend on our alliances with other companies to provide substantial additional funding for development and commercialization of the FDA-approved PF708 product, and PF708 and other product candidates, if approved. We may not be able to obtain funding on favorable terms from these alliances, and if we are not successful in doing so, we may not have sufficient funds to develop a particular product candidate internally, or to bring product candidates to market. Failure to bring our product candidates to market will prevent us from generating sales revenue, and this may substantially harm our business. Furthermore, any delay in entering into these alliances could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. As a result, our business and operating results may be adversely affected.

We rely on CROs to conduct and oversee our planned clinical trials for our product candidates and other clinical trials for product candidates we are developing or may develop in the future. If our CROs do not successfully carry out their contractual duties, meet expected deadlines, or otherwise conduct the trials as required or comply with regulatory requirements, or if our relationship with our CRO terminates, we and our collaboration partners may not be able to seek or obtain regulatory approval for or commercialize our product candidates when expected or at all, and our business could be substantially harmed.

We will continue to rely upon medical institutions, clinical investigators and contract laboratories to conduct our trials in accordance with our clinical protocols and in accordance with applicable legal and regulatory requirements. These third parties play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical trials. These third parties are not our employees, and except for remedies available to us under our agreements with such third parties, there is no guarantee that any such third party will devote adequate time and resources to our clinical trial. If our CRO or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, or if they otherwise perform in a substandard manner, our clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete development of, seek or obtain regulatory approval for, or successfully commercialize our product candidates. We plan to rely heavily on these third parties for the execution of clinical trials for products we are developing or may develop in the future and will control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on our CRO does not relieve us of our regulatory responsibilities.

We, our CRO and our collaboration partners are required to comply with Good Clinical Practice (GCP), which are regulations and guidelines enforced by regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we, our CRO or our collaboration partners fail to comply with applicable GCP regulations, the clinical data generated in clinical trials may be deemed unreliable and submission of marketing applications may be delayed or the regulatory authorities may require us to perform additional clinical trials before accepting our applications for review or approving marketing applications. We cannot assure that, upon inspection, a regulatory authority will determine that any of our clinical trials comply or complied with applicable GCP regulations. In addition, clinical trials must be conducted with product produced under current Good Manufacturing Practices (cGMP) regulations, which are enforced by regulatory authorities. Any failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if our CRO violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.

Comparative clinical trials require a substantial number of patients that can form the basis for generating statistically significant results. Delays in site initiation or unexpectedly low patient enrollment rates may delay the results of the clinical trial. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. Further, if our relationship with our CRO is terminated, we may be unable to enter into arrangements with an alternative CRO on commercially reasonable terms, or at all. Switching or adding CROs can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship with our CROs, there can be no assurance that we will not encounter such challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, prospects, financial condition or results of operations.

We rely on third-party suppliers, and in some instances a single third-party supplier, for the manufacture and supply of certain materials in our protein production services, and these suppliers could cease to manufacture the materials, go out of business or otherwise not perform as anticipated.

We rely on third-party suppliers for our protein production services and in some instances a single third-party supplier, for the manufacture and supply of certain materials. We currently rely, and expect to continue to rely, on a single-source supplier for the manufacture and supply of CRM197. To meet these demands, our supplier is in the process of increasing production capacity, and we also have established a repository in the United States that is capable of storing a safety stock of CRM197 and the CRM197 cell bank. Furthermore, we have taken steps to identify alternate sources of supply sufficient to support future needs; however, there may be delays in switching to these alternative suppliers if our contract with primary sources are terminated without notice. Regardless of the foregoing alternative measures, we cannot guarantee that we will have an adequate supply of CRM197. If we are unable to secure adequate quantities of CRM197 from our primary supplier, from potential secondary suppliers or from our safety stock, we may be required to identify additional suppliers. If we are required to engage additional suppliers, we may not be able to enter into an alternative supply arrangement on commercially reasonable terms, or at all. Even if we are able to identify additional suppliers and enter into agreements on commercially reasonable terms, we may incur delays associated with identifying and qualifying additional suppliers and negotiating the terms of any supply contracts. These delays could adversely impact our business and negatively affect profitability of our protein production services.

We have entered into collaborations with third parties in connection with the development of PF708 and certain of our other product candidates. Even if we believe that the development of our technology, PF708 and other product candidates is promising, our partners may choose not to proceed with such development.

Our existing agreements with our collaboration partners, Alvogen, Jazz, and NT Pharma, and any future collaboration agreements we may enter into, are generally subject to termination by the counterparty on short notice upon the occurrence of certain circumstances. Accordingly, even if we believe that the development of product candidates is worth pursuing, our partners may choose not to continue with such development. If any of our collaborations are terminated, such as the termination of our collaboration with Pfizer in August 2016, we may be required to devote additional resources to the development of our product candidates or seek a new collaboration partner on short notice, and the terms of any additional collaboration or other arrangements that we establish may not be favorable to us.

We are also at risk that our current and any potential collaborations or other arrangements may not be successful. Factors that may affect the success of our collaborations include the following:

•

our collaboration partners may incur financial and cash flow difficulties that force them to limit or reduce their participation in our joint projects;

•

our collaboration partners may be pursuing alternative technologies or developing alternative products that are competitive to our technology and products, either on their own or in partnership with others;

•

our collaboration partners may terminate their collaboration with us, which could make it difficult for us to attract new partners or adversely affect perception of us in the business and financial communities; and

•

our collaboration partners may pursue higher priority programs or change the focus of their development programs, which could affect their commitment to us.

If we cannot maintain successful collaborations, our business, financial condition and operating results may be adversely affected.

If we are unable to maintain our commercial supply agreements with key customers purchasing CRM197, sales revenue could decline.

We primarily sell CRM197 directly to biopharmaceutical companies and currently have several supply agreements in place for supply of CRM197. To establish and maintain relationships with customers, we believe we need to maintain adequate supplies of CRM197, remain price competitive, comply with regulatory regulations and provide high quality products. If we are unable to establish and maintain arrangements for the sale of CRM197, our revenue and profits would decline.

Risks Relating to Our Intellectual Property

Our collaboration partners and other third parties may assert ownership or commercial rights to inventions we develop from our use of the materials which they provide to us, or otherwise arising from our collaboration.

We collaborate with other companies and institutions with respect to research and development matters. Also, we rely on numerous third parties to provide us with materials that we use to develop our technology. If we cannot successfully negotiate sufficient ownership, licensing and/or commercial rights to any inventions that result from our use of any third-party collaborator’s materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator’s materials, or data developed in a collaborator’s study, our ability to capitalize on the market potential of these inventions or developments may be limited or precluded altogether.

If our efforts to protect our intellectual property related to our platform technology, PF708 and our current or future product candidates are not adequate, we may not be able to compete effectively in our market.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to PF708 and our current product candidates and our development programs. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. In particular, our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our platform, PF708 and product candidates. However, we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in our market.

The patentability of inventions, and the validity, enforceability and scope of patents in the biotechnology and pharmaceutical industry involve complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or license may fail to result in issued patents in the United States or foreign countries. There is a substantial amount of prior art in the biotechnology and pharmaceutical fields, including scientific publications, patents and patent applications. Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. We may be unaware of certain prior art relating to our patent applications and patents, which could prevent a patent from issuing from a pending patent application or result in an issued patent being invalidated. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable.

Patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant and, in addition, may be challenged before national courts at any time. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we hold, license or pursue with respect to our product candidates is threatened, it could threaten our ability to commercialize PF708 or our product candidates. In addition, recent changes to the patent laws of the United States provide additional procedures for third parties to challenge the validity of issued patents based on patent applications filed after March 15, 2013. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to PF708, our current or future product candidates is challenged, then it could threaten our ability to commercialize PF708, our current or future product candidates and could threaten our ability to prevent competitive products from being marketed. Further, if we encounter delays in our clinical trials, the period of time during which we could market our current or future product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates, or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March 16, 2013, or patents issuing from such applications, an interference proceeding can be provoked by a third party or instituted by the United States Patent and Trademark Office (USPTO), to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March 16, 2013, the United States transitioned to a “first-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to “first-to-file” from “first-to-invent” is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act (Leahy-Smith Act) signed into law on September 16, 2011. Among some of the other significant changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. It is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.

Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors could provoke them to bring counterclaims against us, and some of our competitors have substantially greater intellectual property portfolios than we have.

Although the PF708 product has been approved by the FDA and even if PF708 is approved in the EU, we or our collaboration partner may be delayed in selling the FDA-approved PF708 product or PF708 due to direct or indirect legal challenges.

Although the PF708 product has received marketing approval in the U.S. and even if PF708 receives marketing approval in the EU, we may also be subject to direct legal challenges from Eli Lilly and Company, the manufacturer of Forteo, and we could be delayed or prevented from launching PF708 as a result of court orders, regulatory stays, or the time necessary to resolve such challenges. For instance, we are aware of at least two instances of a third party being subject to litigation initiated by Eli Lilly and Company on a product purporting to be a generic version of Eli Lilly’s Forteo (teriparatide [rDNA origin] injection) product. In accordance with regulatory requirements we provided notice of Paragraph IV certification (Notice Letter) to Eli Lilly and Company (Lilly) on February 19, 2019 that PF708 does not infringe any valid claim of the ‘334 patent. Under the Hatch-Waxman Act, Lilly had 45 days from the receipt of the Notice Letter to file a patent infringement lawsuit against Pfenex that would cause a 30-month litigation stay of approval for PF708. On April 11, 2019 we announced the expiration of the 45-day period for Lilly to file a lawsuit under the Hatch-Waxman Act and stay the approval of PF708 for 30 months. Lilly did not file a lawsuit within this time period, and there was no 30-month litigation stay delaying FDA approval of PF708.

If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.

In addition to the protection afforded by patents, we also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain or enforce and any other elements of our product development processes that involve proprietary know-how, information or technology that is not covered by patents.

As part of our efforts to protect our trade secrets and other confidential information, we require our employees, consultants, collaborators and advisors to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements, however, may

not provide us with adequate protection against improper use or disclosure of confidential information, and these agreements may be breached. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. We also note in this respect that trade secret protection in foreign countries may not provide protection to the same extent as federal and state laws in the United States. A breach of confidentiality could significantly affect our competitive position. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, collaborators or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by others in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. Also, third parties, including our competitors, may independently develop substantially equivalent proprietary information and technologies or otherwise lawfully gain access to our trade secrets and other confidential information. In such a case, we would have no right to prevent such third parties from using such proprietary information or technologies to compete with us, which could harm our competitive position.

If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.

Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patents owned or controlled by other parties. Our competitors have developed large portfolios of patents and patent applications in fields relating to our business and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving that a patent is invalid is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Also, in proceedings before courts in Europe, the burden of proving invalidity of the patent usually rests on the party alleging invalidity. Third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit

As a result of patent infringement claims, or to avoid potential claims, we may choose or be required to seek licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.

There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future products. For example, on May 6, 2019, Pfenex filed two petitions for inter partes review of U.S. Patent No. 9,422,345 (“the ‘345 patent”, entitled “Expression System”), which is owned by GlaxoSmithKline Biologicals S.A., with the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office. The ‘345 patent relates to polynucleotides that express diphtheria toxins, including the diphtheria toxin mutant CRM197. These two petitions, IPR2019-01027 and IPR2019-01028, seek, inter alia, a determination that certain claims in the ‘345 patent are invalid. Institution decisions by the PTAB for IPR2019-01027 and IPR2019-01028 are expected within the 2019 calendar year, and final written decisions on the validity of the challenged claims of the ‘345 patent, if these two petitions are instituted by the PTAB, by the end of 2020. On August 9, 2019, Pfenex filed a third petition for inter partes review of the ‘345 patent with the PTAB of the U.S. Patent and Trademark Office. The third petition, IPR2019-01478, seeks, inter alia, a determination that certain claims in the ‘345 patent are invalid. An institution decision by the PTAB for IPR2019-01478 is expected within the first quarter of 2020, and a final written decision on the validity of the challenged claims of the ‘345 patent, if the third petition is instituted by the PTAB, by the end of the first quarter of 2021. We cannot predict the ultimate outcome of our invalidity claims related to the ‘345 patent. If the claims of the ‘345 patent are upheld as valid and we are unable to enter into licenses on commercially acceptable terms, we could be prevented from commercializing a product or be forced to cease some aspects of our business operations. Third parties may submit applications for patent term extensions in the United States and/or supplementary protection certificates in the EU member States seeking to extend certain patent protection which, if approved, may interfere with or delay the launch of one or more of our biosimilar or vaccine products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations. We may become involved in lawsuits to protect or enforce our inventions, patents or other intellectual property or the patents of our licensors, which could be expensive and time consuming.

Competitors may infringe our intellectual property, including our patents or the patents of our licensors. In addition, one or more of our third-party collaborators may have submitted, or may in the future submit, a patent application to the USPTO without naming a lawful inventor that developed the subject matter in whole or in part while under an obligation to execute an assignment of rights to us. As a result, we may be required to file infringement or inventorship claims to stop third-party infringement, unauthorized use, or to correct inventorship. This can be expensive, particularly for a company of our size, and time-consuming. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied.

An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing.

Interference, derivation or other proceedings brought at the USPTO or any foreign patent authority may be necessary to determine the priority or patentability of inventions with respect to our patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us may fail. An unfavorable outcome in any such proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing party or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management. We may not be able, alone or with our licensors or collaborators, to prevent misappropriation of our trade secrets, confidential information or proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.

We may not be able to globally protect our intellectual property rights.

Filing, prosecuting and defending patents on products and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases, may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our technologies and this circumstance would have a material adverse effect on our business.

We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets of former or other employers.

Many of our employees and consultants, including our senior management, have been employed or retained by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees or consultants have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s or consultant’s former or other employer. We are not aware of any material threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

Risks Related to Government Regulation

The approval processes of the FDA, EMA, and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we and our collaborators are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, marketing, distribution, post-approval monitoring and reporting, and export and import of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States, by the EMA and Competent Authorities of the Member States of the EEA, and by other regulatory authorities in other countries, and regulations differ from country to country. Neither we nor any collaboration partner is permitted to market any product candidate in the United States until approval from the FDA is received, or in the EEA until we receive European Commission authorization or approval from one or more Competent Authorities of the Member States of the EEA, as applicable. The time required to obtain approval from regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials, and depends upon numerous factors, including the substantial discretion of such regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions, which may cause delays in the filing of an application and/or the approval or the decision not to approve an application. In May 2019, Alvogen, our collaboration partner, submitted a centralized application to the EMA for PF708, and the application was accepted for review. In October 2019, Alvogen submitted a Marketing Authorization Application (MAA) to the Kingdom of Saudi Arabia's Saudi Food and Drug Authority (SFDA). We received approval from the FDA for the PF708 product in October 2019. Other than the PF708 product NDA and the applications submitted to the EMA and SFDA for PF708, we and our collaboration partners have not submitted any marketing applications to regulatory authorities and, other than receipt of regulatory approval from the FDA for the PF708 product, neither we nor our collaboration partners have obtained regulatory approval for any other product candidate and it is possible that none of our other existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

Applications for our product candidates could fail to receive regulatory approval or their regulatory approval could be delayed for many reasons, including but not limited to the following:

•

the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a Biologics License Application (BLA) under the section 351(a) pathway of the PHSA; an NDA under the section 505(b)(2) of the Food, Drug, and Cosmetic Act; a BLA for a biosimilar product application under the section 351(k) pathway of the PHSA, a marketing authorization under Article 6 of Regulations (EC) No. 726/2004 and/or Article 8(3), 10(1), 10(3) or 10a of Directive 2001/83/EC in the EEA, a biosimilar marketing authorization under Article 6 of Regulation (EC) No. 726/2004 and/or Article 10(4) of Directive 2001/83/EC in the EEA, or other submission or to obtain regulatory approval in the United States, the EEA, or elsewhere;

•

regulatory authorities may disagree with the design (including the duration) or implementation of our clinical trials and may, at any time, determine that the regulatory pathway that we have committed to for any product candidate is inappropriate;

•

the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;

•

regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

•

we may be unable to demonstrate to the satisfaction of regulatory authorities that a product candidate’s risk-benefit ratio for its proposed indication is acceptable;

•

regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies; and

•

the approval policies or regulations of regulatory authorities may significantly change in a manner that renders our clinical data insufficient for approval.

This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to seek or obtain regulatory approval to market any other product candidates, which would significantly harm our business, results of operations and prospects. Moreover, any delays in the commencement or completion of clinical testing could significantly impact our product development costs and could result in the need for additional financing.

In addition, even if we or our collaboration partners were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than requested, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

If we fail to obtain approval for our most advanced product candidates or if the FDA-approved PF708 product, PF708 or our most advanced product candidates are not commercially successful, we may have to curtail our product development programs and our business would be materially harmed.

We have invested a significant portion of our time, financial resources and efforts in the development of PF708 and our other product candidates. The clinical and commercial success of our product candidates and the commercial success of the FDA-approved PF708 product will depend on a number of factors, including our and our collaboration partners’ ability to assure the following:

•

timely and successful completion of all necessary clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the accurate and satisfactory performance of third-party contractors;

•

our ability to find suitable collaboration partners to develop our current product candidates or our ability to obtain substantial additional sources of funding to develop our current product candidates;

•

timely receipt of necessary marketing approvals from the FDA, the European Commission, and similar foreign regulatory authorities;

•

maintaining an acceptable safety and adverse event profile of the FDA-approved PF708 product, PF708 and any other product candidates following approval;

•

achieving and maintaining compliance with all regulatory requirements applicable to our product candidates, including PF708, and the FDA approved PF708 product, or any other approved products;

•

making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities;

•

commercial sales of the FDA-approved PF708 product, PF708 and our other product candidates, if and when approved, whether alone or in collaboration with others;

•

whether we or our collaboration partners are able to obtain timely and adequate coverage and reimbursement for our newly approved products by key payors, such as Medicare Part D for the FDA-approved PF708 product in the United States;

•

obtaining and maintaining patent and trade secret protection and regulatory exclusivity, where available, for our current product candidates;

•

the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;

•

acceptance of the FDA-approved PF708 product, or our products candidates, if approved, by patients, the medical community and third-party payors; and

•

the ability to raise additional capital on acceptable terms to achieve our goals.

If we and our collaboration partners are unable to seek and obtain regulatory approval or adequate coverage and reimbursement for the FDA-approved PF708 product or of our product candidates in a timely manner or at all, we may never realize revenue from these products and we may have to curtail our other product development programs. As a result, our business, financial condition and results of operations would be materially harmed.

Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Furthermore, we rely on our collaboration partners, CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials for our product candidates. While we have agreements governing the committed activities of our collaboration partners and CROs, we have limited influence over their actual performance. A failure of one or more clinical trials can occur at any time during the trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates that have shown promising results in early studies may still suffer significant setbacks in subsequent clinical studies. There is a high failure rate for drugs and biologics proceeding through clinical studies, and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier clinical trials, and we cannot be certain that we will not face similar setbacks. Even if the clinical trials for our product candidates are completed, nonclinical and clinical data are often susceptible to varying interpretations and analyses, and the results may not be sufficient to obtain regulatory approval for our product candidates.

We have in the past and may in the future experience delays in ongoing clinical trials for our product candidates, and we do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. The commencement or completion of clinical trials can be delayed or aborted for a variety of reasons, including delay or failure to:

•

generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation of human clinical studies;

•

raise sufficient capital to fund a trial;

•

obtain regulatory approval, or feedback on trial design, necessary to commence a trial;

•

identify, recruit and train suitable clinical investigators;

•

reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

•

obtain institutional review board (IRB) approval or Ethics Committee (EC) positive opinion, as applicable at each site;

•

identify, recruit, and enroll suitable patients to participate in a trial;

•

have patients complete a trial or return for post-treatment follow-up;

•

ensure clinical sites observe trial protocol or continue to participate in a trial;

•

address any patient safety concerns that arise during the course of a trial;

•

address any conflicts with new or existing laws or regulations;

•

add a sufficient number of clinical trial sites;

•

manufacture sufficient quantities of product candidate for use in clinical trials; and

•

avoid delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies, or the inability to do any of the foregoing.

Patient enrollment is a significant factor in the completion of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or the ECs of the institutions in which such trials are being conducted, by the data safety monitoring board, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

If we or our collaboration partners experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenue from any of these product candidates will be delayed. In addition, any delays in completing clinical trials for our product candidates will increase our costs, slow down our product candidate development and approval process and jeopardize our or our collaboration partners’ ability to commence product sales and generate revenue. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

The development, manufacture and commercialization of therapeutic equivalent and vaccine products pose unique risks, and our failure to successfully introduce therapeutic equivalent and vaccine products could have a negative impact on our business and future operating results.

We are actively working to develop multiple therapeutic equivalent products and vaccines. The cost to develop each proposed therapeutic equivalent drug, and vaccine product candidate could vary significantly and is highly dependent on the specific compound and the amount and type of clinical work that will be necessary for regulatory approval. There can be no assurance that our clinical work will be successful, or that regulatory authorities will not require additional clinical development beyond that which we have planned. Additionally, we may enter into alliances and collaborations to fund biosimilar and therapeutic equivalent product research and development activities, and our ability to realize the benefits of such arrangements may depend on the success of any such biosimilar or therapeutic equivalent product program. Due to events beyond our control or the risks identified herein, we may be unable to fund all or some of our internal biosimilar, therapeutic equivalent, and vaccine product research and development initiatives, which would have an adverse impact on our strategy and growth initiatives.

If the FDA approves other therapeutic equivalent or generic products with Forteo as the reference drug and these drug products are successfully commercialized, the FDA-approved PF708 product may face additional competition and our business could suffer.

Other companies may seek FDA approval to manufacture and market therapeutic equivalent or generic product versions of Forteo. In October 2017, the FDA issued a draft guidance document that identified standards by which chemically manufactured, or synthetic, versions of Forteo may be approved under the 505(j), or Abbreviated New Drug Application (ANDA), regulatory pathway, which would not require the conduct of a comparative clinical trial in patients for approval of the product. Teva Pharmaceuticals USA, Inc. has filed an ANDA referencing Forteo that, if approved, could compete with the FDA-approved PF708 product. Apotex Corp. also has submitted an ANDA for a generic version of Forteo and other generic drug manufacturers may have filed and/or in the future may file ANDAs referencing Forteo. Products approved under the ANDA pathway are considered generic drugs, and generally are approved as therapeutic equivalents to the reference product, and therefore may be automatically substituted for the reference listed drug, depending on health care statutes and policies within each of the 50 states. The potential automatic substitution of these generic products may adversely affect our collaboration partner’s ability to generate revenue with the FDA-approved PF708 product. If other therapeutic equivalent or generic product versions of Forteo are approved and successfully commercialized, Alvogen may never achieve significant market share for the FDA-approved PF708 product, our revenue would be reduced and, as a result, our business, prospects and financial condition could suffer.

If the FDA-approved PF708 product does not receive an “A” therapeutic equivalence designation from the FDA, our business may suffer.

In addition to obtaining FDA approval of our PF708 NDA, we and Alvogen have been seeking an “A” therapeutic equivalence designation for the FDA-approved PF708 product relative to the reference drug Forteo, which may permit the FDA-approved PF708 product to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states. Consistent with our interactions with the FDA and its draft guidance document on demonstrating the therapeutic equivalence of drug-device combination products, we have completed a comparative human factors study comparing the FDA-approved PF708 product and Forteo. This human factors study was designed to further support a finding that the PF708 product is therapeutically equivalent to Forteo. On October 14, 2019, we announced the successful completion of our PF708 comparative use human factors study and our submission of the final study report to the FDA. The study data demonstrate that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo® for each critical user task evaluated in the study based on a pre-specified statistical analysis of critical patient and caregiver tasks. We submitted the study results to the FDA in October 2019 for the FDA’s consideration of a therapeutic equivalence designation for the FDA-approved PF708 product. While we believe this submission completes the information package required by the FDA to evaluate the therapeutic equivalence of the FDA-approved PF708 product, we cannot assure you that FDA will grant an “A” therapeutic equivalence designation to the FDA-approved PF708 product relative to Forteo, or that the FDA will make a timely decision regarding therapeutic equivalence. In addition, if we do not receive an “A” therapeutic equivalence designation, this may significantly impact Alvogen’s ability to maximize revenues in the marketplace and could have a material adverse effect on our royalty revenues.

Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the Agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Failure to obtain regulatory approval in each regulatory jurisdiction would prevent us and our collaboration partners from marketing our products to a larger patient population and reduce our commercial opportunities.

In order to market our products in the EU, the United States and other jurisdictions, we or our collaboration partners must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. For example, in the EU, the EMA is responsible for the assessment of centralized marketing authorization applications for human medicines. This procedure results in a single marketing authorization granted by the European Commission that is valid in all EU Member States, as well as in EEA States Iceland, Liechtenstein and Norway. The time required to obtain approval abroad may differ from that required to obtain FDA approval. When a marketing authorization application is submitted to the EMA, a related scientific evaluation is conducted by the EMA’s Committee for Medicinal Products for Human Use (CHMP), and a scientific opinion is prepared concerning the suitability of the product for authorization. This scientific opinion is sent to the European Commission which, before arriving at a final decision on a marketing authorization application, must consult the Standing Committee on Medicinal Products for Human Use. The Standing Committee is composed of representatives of the EU member states and chaired by a non-voting European Commission representative. The European Parliament also has a related “droit de regard.” The European Parliament’s role is to ensure that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization. In accordance with the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days. This excludes clock stops during which additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP.

The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval as well as additional or different risks and we or our collaboration partners may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. We or our collaboration partners

may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products within the United States or in any market outside the United States. Failure to obtain these approvals would materially and adversely affect our business, financial condition and results of operations.

The FDA-approved PF708 product, PF708, and any of our other product candidates, if approved, will be subject to ongoing regulatory review.

The FDA-approved PF708 product, PF708 and any of our other product candidates, if approved, and any products we develop will be subject to ongoing regulatory review with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. Manufacturers and manufacturers’ facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP. As such, we, our collaboration partners, and our contract manufacturers will be subject to continual and unannounced review and inspections by the regulatory authorities governing the markets in which we wish to sell our products. Accordingly, we, our collaboration partners and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.

The PF708 product NDA and any regulatory approvals that we and our collaboration partners may receive for PF708 or any of our other product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or on other conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 trials, and surveillance to monitor the safety and efficacy or the safety, purity, and potency of the product candidate. We and our collaboration partners will be required to promptly report any serious and unexpected adverse events and certain quality or production problems with our products to regulatory authorities, as well as submit other periodic reports. Any new legislation addressing drug or biologic product safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. We and our collaboration partners will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drug and biologic products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved labeling. As such, we will not be allowed to promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA, 351(k) application or marketing authorization application must submit new or supplemental applications and obtain prior approval for certain changes to the approved product, product labeling, or manufacturing process. We or our collaboration partners could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in penalties or other adverse consequences, up to and including potential withdrawal of marketing approval.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of a product, or if we or our collaboration partners fail to comply with applicable regulatory requirements, such regulatory agency may impose restrictions on that product or us or our collaboration partners, including requiring withdrawal of the product from the market. If we or our collaboration partners fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may subject us to administrative or judicially imposed sanctions or other actions, including, among other things:

•

adverse publicity, fines or untitled or warning letters;

•

mandated modifications to promotional materials or requirements to provide corrective information to healthcare practitioners;

•

a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;

•

civil or criminal penalties;

•

injunctions;

•

suspending or withdrawing regulatory approval;

•

suspending any of our ongoing clinical studies;

•

refusing to approve pending applications or supplements to approved applications submitted by us;

•

imposing restrictions on our operations, including suspending or closing our contract manufacturers’ facilities; or

•

seizing or detaining products or requiring a product recall.

Any government investigation of alleged violations of law could require us or our collaboration partners to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our or our collaboration partners’ ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.

We or our collaboration partners will also be subject to various health care fraud and abuse laws, including anti-kickback, false claims and fraud laws, and physician payment transparency laws, and any violations by us of such laws could result in fines or other penalties.

We received FDA approval for the FDA-approved PF708 product in October 2019. Because Alvogen is commercializing the FDA-approved PF708 product, Alvogen will be subject to healthcare regulation and enforcement by the U.S. federal government and the states related to the FDA-approved PF708 product. If we or our collaboration partners commercialize PF708 or our other product candidates, we or they will be subject to analogous healthcare regulation and enforcement in the applicable jurisdictions in which we or they commercialize our product candidates. These laws include anti-kickback, fraud and abuse, false claims, and physician sunshine laws and regulations. In the United States, for example, the federal Anti-Kickback Statute (AKS) prohibits, among other things, knowing and willful solicitation, offer, receipt, or payment of remuneration, directly or indirectly, by persons and entities in exchange for or to induce either the referral of patients for, or the purchase, order, arrangement or recommendation of any good or service that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Violations of the AKS may also result civil and criminal penalties, including criminal fines and imprisonment, or exclusion from federal healthcare programs. Liability under the AKS may be established without proving actual knowledge of the statute or specific intent to violate it, and a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. The federal civil False Claims Act (FCA) imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment of government funds. Actions under the FCA may be brought by as qui tam actions by private individuals in the name of the government. Violations of the FCA can result in significant mandatory monetary penalties per false claim or statement, treble damages and exclusion from federal health care programs. The federal Physician Payments Sunshine Act requires, among other parties, certain manufacturers of drugs for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to CMS information related to payments and other transfers of value made to physicians, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.

The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may violate one or more of the requirements. If our or our collaborators’ operations are found to be in violation of any of such laws or any other governmental regulations that apply, we or our collaborators may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of operations, and exclusion from participation in federal and state healthcare programs, any of which could adversely affect our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us or our collaboration partners for violation of these laws, even if successfully defended against, could cause us or our collaboration partners to incur significant legal expenses and divert management’s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.

Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure investors that our or our collaborators’ internal control policies and procedures will prevent violations of these laws, or allegations of such violations, which could result in fines, penalties or prosecution and/or otherwise have a negative impact on our business, results of operations and reputation.

We also may be subject to healthcare privacy and data privacy laws and regulations, and violations of these laws could result in government enforcement actions and create liability for us, private litigation and/or adverse publicity that could negatively affect our business.

We may be subject to laws and regulations covering data privacy and the protection of health-related and other personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of personal information. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant

penalties), private litigation and/or adverse publicity that could negatively affect our business. In addition, healthcare providers who prescribe our products and research institutions we collaborate with are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we potentially could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.

EU member states, Switzerland and other countries have also adopted data protection laws and regulations that impose significant compliance obligations. In the EU, the collection and use of personal health data is governed by the provisions of the General Data Protection Regulation (GDPR). The GDPR entered into application on 25 May 2018, repealing the Data Protection Directive and increasing our responsibility and liability in relation to the processing of personal data of EU subjects. The GDPR, together with the national legislation of the individual EU member states governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting.

These obligations and restrictions concern, in particular, the consent of the individuals to whom the personal data relates, the information provided to the individuals, the transfer of personal data outside the EU, security breach notifications, security and confidentiality of the personal data, as well as substantial potential fines for breaches of the data protection obligations. Data protection authorities from the different EU member states may interpret the GDPR and national laws differently and impose additional requirements, which add to the complexity of processing personal data of EU subjects.

With respect to the transfer of personal data out of the EU, the GDPR provides that the transfer of personal data to countries that the European Commission does not consider to provide an adequate level of data protection, including the United States, is permitted only on specific legal bases.

Our failure to comply with these laws, or changes in the way in which these laws are implemented, could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.

Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us or our collaboration partners to obtain regulatory approval of our product candidates and to produce, market, and distribute our products after approval is obtained, if any.

From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacturing, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or lengthen FDA review times for our product candidates. We cannot determine how changes in regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future. Such changes could require substantial time and impose significant costs and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm our business, financial condition, and results of operations.

If efforts by manufacturers of reference products to delay or limit the use of therapeutic equivalent products are successful, sales of therapeutic equivalent products may suffer.

Many manufacturers of reference products have increasingly used legislative, regulatory and other means in attempts to delay regulatory approval of and competition from therapeutic equivalent products. If these or other efforts to delay or block competition are successful, we or our collaboration partners may be unable to sell our therapeutic equivalent product candidates, which could have a material adverse effect on our sales and profitability.

Our and our collaboration partners’ sales are dependent on the availability and level of coverage and reimbursement from third-party payors who continue to implement cost-cutting measures and more stringent reimbursement standards.

In the United States and internationally, our and our collaboration partners’ ability to generate revenue on sales of our products are dependent, in significant part, on the availability and level of coverage and reimbursement from third-party payors, such as state and federal governments and private insurance plans. Insurers have implemented cost-cutting measures and other initiatives to enforce more stringent reimbursement standards and likely will continue to do so in the future. These measures include the establishment of more restrictive formularies and increases in the out-of-pocket obligations of patients for such products. In addition, particularly in the U.S. and increasingly in other countries, we will be required to provide discounts and pay rebates to state and federal governments and agencies in connection with purchases of our products that are reimbursed by such entities.

As Alvogen commercializes the FDA-approved PF708 product, a significant portion of the product’s revenue may be obtained through government payors, such as Medicare and Medicaid. For example, we expect that a substantial proportion of the U.S. market for the FDA-approved PF708 product could be subject to coverage and reimbursement under the federal healthcare program Medicare Part D. Any delay or failure by Alvogen to obtain adequate coverage for the FDA-approved PF708 product or to qualify for or receive adequate reimbursement under these programs could impact Alvogen’s ability to maximize revenues in the marketplace and could have a material adverse effect on revenues from such products.

In March 2010, the ACA was enacted with a goal of reducing the cost of healthcare, improving quality, and expanding access to care. The ACA has substantially changed the way healthcare is financed by both government and private insurers and has significantly affected the pharmaceutical industry. The ACA, among other things, implemented new price reporting requirements for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, added new entity types eligible for participation in the Public Health Service’s 340B drug pricing program, established annual fees and taxes on manufacturers of certain prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices.

In addition, legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. For example, beginning April 1, 2013, Medicare payments for all items and services, including drugs and biologics, were reduced by 2% per fiscal year under the sequestration required by the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012. Subsequent legislation extended the 2% reduction to 2027, which went into effect on April 1, 2013 and will stay in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the American Tax Payer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals. We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal, state and foreign governments will pay for healthcare products and services, which could result in reduced demand for the FDA-approved PF708 product or our product candidates, if approved, or additional pricing pressures. Some of the provisions of the ACA have yet to be fully implemented, and certain provisions have been subject to judicial and Congressional challenges. In addition, there have been efforts by the Trump Administration to repeal or replace certain aspects of the ACA and to alter the implementation of the ACA and related laws. For example, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the Tax Act, included a provision repealing the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, commonly referred to as the “individual mandate”. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is invalid in its entirety as a result of the tax penalty associated with the “individual mandate” being repealed by Congress as part of the Tax Act. This ruling is under appeal and stayed pending appeal. It is unclear how this decision, subsequent appeals, and other efforts to repeal or replace, or invalidate, the Affordable Care Act, or portions thereof, will impact the Affordable Care Act and its implementation, and our business.

With the approval of the FDA-approved PF708 product, we anticipate that Alvogen will need to participate in the Medicaid Drug Rebate program. Participation is required for federal funds to be available for our covered outpatient drugs under Medicaid and, if applicable, Medicare Part B. Under the Medicaid Drug Rebate Program, we or our collaboration partners would be required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid and, if applicable, Part B of the Medicare program.

Federal law requires that any company that participates in the Medicaid Drug Rebate Program also participate in the Public Health Service’s 340B drug pricing program in order for federal funds to be available for the manufacturer’s drugs under Medicaid and Medicare Part B. The 340B drug pricing program requires participating manufacturers to agree to charge statutorily-defined covered entities no more than the 340B “ceiling price” for the manufacturer’s covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients.

In addition, in order to be eligible to have its products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, a manufacturer also must participate in the U.S. Department of Veterans Affairs, or VA, Federal Supply Schedule, or FSS, pricing program. Under this program, the manufacturer is obligated to make its innovator and single source products available for procurement on an FSS contract and charge a price to four federal agencies, VA, U.S. Department of Defense, or DoD, Public Health Service and U.S. Coast Guard, that is no higher than the statutory Federal Ceiling Price. Moreover, pursuant to regulations issued by the DoD Defense Health Agency to implement Section 703 of the National Defense Authorization Act for Fiscal Year 2008, manufacturers are required to provide rebates on utilization of their innovator and single source products that are dispensed to TRICARE beneficiaries by TRICARE network retail pharmacies. The requirements under the Medicaid Drug Rebate, 340B, FSS, and TRICARE programs could reduce the revenue we or our collaboration

partners may generate from any products that are commercialized in the future and could adversely affect our business and operating results.

If we or our collaboration partners successfully commercialize the FDA-approved PF708 product, PF708 or any of our product candidates and if we or our collaboration partners participate in the Medicaid drug rebate program or other governmental pricing programs, failure to comply with reporting and payment obligations under these programs could result in additional reimbursement requirements, penalties, sanctions, and fines which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

The Medicaid Drug Rebate Program and other governmental pricing programs require participating manufacturers to report pricing data to various government agencies. Pricing calculations vary among products and programs and include average manufacturer price and best price for the Medicaid Drug Rebate Program, average sales price for certain categories of drugs that are paid under Part B of the Medicare program, and non-federal average manufacturer price for the VA FSS pricing program. If we or our collaborators successfully commercialize the FDA-approved PF708 product, PF708 or any of our other product candidates and participate in such governmental pricing programs, we or our collaboration partners will be liable for errors associated with submission of pricing data. That liability could be significant. For example, knowing submission of false average manufacturer price, average sales price, best price, or non-federal average manufacturer price information to the government, or failure to timely submit such information, could result in liability for significant civil monetary penalties. The foregoing also could be grounds for other sanctions, such as termination from the Medicaid Drug Rebate Program.

Foreign governments tend to impose strict price controls, which may adversely affect our revenue, if any.

In some foreign countries, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. Our existing or future collaboration partners, if any, may elect to reduce the price of our products in order to increase the likelihood of obtaining reimbursement approvals which could adversely affect our revenues and profits. To obtain reimbursement or pricing approval in some countries, we or our collaboration partners may also be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.

If in the future we and our collaboration partners are not able to demonstrate biosimilarity of our biosimilar product candidates to the satisfaction of regulatory authorities, those partners will not obtain regulatory approval for commercial sale of our biosimilar product candidates and our future results of operations would be adversely affected.

Our future results of operations depend on our future collaboration partners’ ability to obtain regulatory approval for and commercialize our proposed biosimilar products. To obtain regulatory approval for the commercial sale of these product candidates, those partners will be required to demonstrate to the satisfaction of regulatory authorities that, among other things, our proposed biosimilar products are highly similar to biological products already licensed by the FDA pursuant to BLAs, notwithstanding minor differences in clinically inactive components, and that they have no clinically meaningful differences as compared to the marketed biological products in terms of the safety, purity and potency of the products. In the EEA, the similar nature of a biosimilar and a reference product is demonstrated by comprehensive comparability studies covering quality, biological activity, safety and efficacy.

To make a final determination of biosimilarity or interchangeability, regulatory authorities may require additional confirmatory information beyond what our collaboration partners plan to initially submit in applications for approval, such as more in-depth analytical characterization, animal testing, or further clinical studies. Provision of sufficient information for approval may prove difficult and expensive. We cannot predict whether any of our biosimilar product candidates will meet regulatory authority requirements for approval as a biosimilar or interchangeable product. To date, the FDA has not approved a biosimilar product as being interchangeable to the reference drug.

We and our collaboration partners intend to market our products outside of the United States, and we will be subject to the risks of doing business outside of the United States.

Because we and our collaboration partners intend to market PF708 and our product candidates, if approved, outside of the United States, our business is subject to risks associated with doing business outside of the United States. Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including:

•

changes in a specific country’s or region’s political and cultural climate or economic condition;

•

unexpected changes in foreign laws and regulatory requirements;

•

difficulty of effective enforcement of contractual provisions in local jurisdictions;

•

inadequate intellectual property protection in foreign countries;

•

trade-protection measures, import or export licensing requirements such as Export Administration Regulations promulgated by the U.S. Department of Commerce and fines, penalties or suspension or revocation of export privileges;

•

efforts to develop an international sales, marketing and distribution organization may increase our expenses, divert our management’s attention from the acquisition or development of product candidates or cause us to forgo profitable licensing opportunities in these geographies;

•

the effects of applicable foreign tax structures and potentially adverse tax consequences; and

•

significant adverse changes in foreign currency exchange rates.

Moreover, our partners and third-party contractors located outside the U.S. may have inadequate compliance programs or may fail to respect the laws and guidance of the territories in which they operate. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition and results of operations.

Risks Relating to Owning Our Common Stock

The market price of our stock may fluctuate significantly, and investors may have difficulty selling their shares.

Our stock is currently traded on NYSE American, but we can provide no assurance that we will be able to maintain an active trading market on NYSE American or any other exchange in the future. The trading volume of our stock tends to be low relative to our total outstanding shares, and we have several stockholders who hold substantial blocks of our stock. As of September 30, 2019, we had 31,622,914 shares of common stock outstanding, and stockholders holding at least 5% of our stock, individually or with affiliated persons or entities, collectively beneficially owned or controlled approximately 53% of such shares. Sales of large numbers of shares by any of our large stockholders could adversely affect our trading price, particularly given our relatively small historic trading volumes. If stockholders holding shares of our common stock sell, indicate an intention to sell, or if it is perceived that they will sell, substantial amounts of their common stock in the public market, the trading price of our common stock could decline.

Since shares of our common stock were sold in our initial public offering in July 2014 at a price of $6.00 per share, our stock price has ranged from $2.07 to $24.41 through September 30, 2019. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this quarterly report on Form 10-Q, factors that may cause volatility in our share price include:

•

actual or anticipated quarterly variation in our results of operations or the results of our competitors;

•

announcements by us or our competitors of new commercial products, significant contracts, commercial relationships or capital commitments;

•

issuance of new or changed securities analysts’ reports or recommendations for our stock;

•

developments or disputes concerning our intellectual property or other proprietary rights;

•

changes to our organization and management;

•

commencement of, or our involvement in, litigation;

•

market conditions in the relevant market;

•

reimbursement or legislative changes in the relevant market;

•

failure to complete significant sales;

•

regulatory developments that may impact the FDA-approved PF708 product, PF708 and our product candidates;

•

any future sales of our common stock or other securities;

•

any major change to the composition of our board of directors or management; and

•

general economic conditions and slow or negative growth of our markets.

The stock market in general and market prices for the securities of biopharmaceutical companies like ours in particular, have from time to time experienced volatility that often has been unrelated to the operating performance of the underlying companies.

These broad market and industry fluctuations may adversely affect the market price of our common stock, regardless of our operating performance.

We may be subject to securities litigation, which is expensive and could divert management attention.

The market price of our common stock has been and will likely continue to be volatile, and in the past companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

If securities or industry analysts publish unfavorable research about our business or cease to cover our business, our stock price and/or trading volume could decline.

The trading market for our common stock may rely, in part, on the research and reports that equity research analysts publish about us and our business. We do not have any control of the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts cease coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.

If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, the market price of our common stock may decline.

We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. Any such future issuance, including any issuances pursuant to our “at the market” equity offering program under our sales agreement with William Blair, could result in substantial dilution to our existing stockholders and could cause our stock price to decline. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, the market price of our common stock may decline.

Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could reduce the price that our common stock might otherwise attain and may dilute your voting power and your ownership interest in us.

Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. We also register the offer and sale of all shares of common stock that we may issue under our equity compensation plans.

We are an “emerging growth company” and a “smaller reporting company” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies could make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (JOBS Act) enacted in April 2012. We will cease to be an emerging growth company on December 31, 2019. As long as we remain an “emerging growth company,” we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not “emerging growth companies.” These exemptions include:

•

not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;

•

not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;

•

reduced disclosure obligations regarding executive compensation; and

•

exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

We have taken advantage of reduced reporting burdens in our reports filed with the Securities and Exchange Commission (SEC). In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. We have elected to avail ourselves of this exemption and, as a result, our financial statements may not be comparable to the financial statements of reporting companies who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. Notwithstanding the above, we are also currently a “smaller reporting company.” Specifically, similar to “emerging growth companies,” “smaller reporting companies” are able to provide simplified executive compensation disclosures in their filings and have certain other decreased disclosure obligations in their SEC filings. We cannot predict whether investors will find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the market price of our common stock may be reduced or more volatile.

If we fail to maintain effective internal control over financial reporting in the future, the accuracy and timing of our financial reporting may be adversely affected.

As a public company, and particularly after we cease to be an “emerging growth company” on December 31, 2019, we incur and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. As a public company, we are subject to reporting and other obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act, including the requirements of SOX Section 404, which require annual management assessments of the effectiveness of our internal control over financial reporting. In particular, Section 404 requires us to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on, and our independent registered public accounting firm potentially to attest to, the effectiveness of our internal control over financial reporting. As an “emerging growth company,” we avail ourselves of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404. However, we may no longer avail ourselves of this exemption when we cease to be an “emerging growth company” on December 31, 2019. Had our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional control deficiencies amounting to significant deficiencies or material weaknesses may have been identified. When our independent registered public accounting firm is required to undertake an assessment of our internal control over financial reporting, the cost of our compliance with Section 404 will correspondingly increase. Our compliance with applicable provisions of Section 404 will require that we incur substantial accounting expense and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements. If we fail to implement the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory agencies such as the SEC. In addition, failure to comply with Section 404 or the report by us of a significant deficiency or material weakness may cause investors to lose confidence in our financial statements, and the trading price of our common stock may decline. If we fail to identify or remedy any significant deficiency or material weakness, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities laws and NYSE American listing requirements regarding the timely filing of periodic reports, investors may lose confidence in our financial reporting, our access to the capital markets may be restricted, and the trading price of our common stock may decline.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

We expect to generate a tax net operating loss for 2019. The 2018 net operating loss carryforwards are available to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have not analyzed whether we already experienced an ownership change in the past for purposes of Sections 382 and 383 of the Code. We may have experienced an ownership change in connection with sale of securities pursuant to a predecessor registration statement or otherwise and we may experience ownership changes in the future as a result of shifts in our stock ownership, including as a result of the sale of securities. As a result, if or when we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.

We are incurring increased costs as a result of operating as a public company and our management is required to devote substantial time to new compliance initiatives and corporate governance practices including maintaining an effective system of internal control over financial reporting.

As a public company, and increasingly after we are no longer an “emerging growth company” and/or “smaller reporting company,” we are incurring significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC, and the NYSE American impose numerous requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Also, the Securities Exchange Act of 1934 (Exchange Act), as amended, requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. Our management and other personnel devote a substantial amount of time to comply with these laws and regulations. These requirements have increased and will continue to increase our legal, accounting, and financial compliance costs and have made and will continue to make some activities more time consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or our board committees or as executive officers. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and changing governance practices.

The Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and the effectiveness of our disclosure controls and procedures quarterly. In particular, Section 404(a) of the Sarbanes-Oxley Act requires us to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting. Section 404(b) of Sarbanes-Oxley Act (Section 404(b)) also requires our independent registered public accounting firm to attest to the effectiveness of our internal control over financial reporting. As an “emerging growth company,” we are availing ourselves of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404(b). However, we may no longer avail ourselves of this exemption when we are no longer an “emerging growth company.” When our independent registered public accounting firm is required to undertake an assessment of our internal control over financial reporting, the cost of our compliance with Section 404(b) will correspondingly increase. Our compliance with applicable provisions of Section 404 requires us and will continue to require us to incur substantial accounting expense and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements.

Furthermore, investor perceptions of our company may suffer if deficiencies are found, and this could cause a decline in the market price of our stock. Irrespective of any required compliance with Section 404, any failure of our internal control over financial reporting could have a material adverse effect on our stated operating results and harm our reputation. If we are unable to implement these requirements effectively or efficiently, it could harm our operations, financial reporting, or financial results and could result in an adverse opinion on our internal controls from our independent registered public accounting firm.

Our directors, executive officers and principal stockholders will continue to have substantial control over us and could limit investors’ ability to influence the outcome of key transactions, including transactions that would cause a change of control.

As of September 30, 2019, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock and their respective affiliates beneficially owned or controlled approximately 55% of the outstanding shares of our common stock. Accordingly, these executive officers, directors and stockholders and their respective affiliates, acting as a group, have substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transactions. These stockholders may therefore delay or prevent a change of control of us, even if such a change of control would benefit our other stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:

•

We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.

•

We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.

•

We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

•

We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.

•

The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.

•

We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.

To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.

Provisions in our certificate of incorporation and bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:

•

authorize our board of directors to issue, without further action by the stockholders, up to 10,000,000 shares of undesignated preferred stock;

•

require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;

•

specify that special meetings of our stockholders can be called only by our board of directors, the chairman of the board of directors, or the chief executive officer;

•

establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;

•

establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year terms;

•

provide that our directors may be removed only for cause;

•

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;

•

specify that no stockholder is permitted to cumulate votes at any election of directors; and

•

require a super-majority of votes to amend certain of the above-mentioned provisions.

These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.

We have broad discretion in the use of the net proceeds from our public offerings, including our “at the market” offering, and may not use them effectively.

We have broad discretion as to how to spend and invest the proceeds from our public offerings, including our “at-the-market” offering with William Blair, and we may spend or invest these proceeds in a way with which our stockholders disagree. Accordingly, investors will need to rely on our judgment with respect to the use of these proceeds and these uses may not yield a favorable return to our stockholders. In addition, until the net proceeds are used, they may be placed in investments that do not produce significant income or that may lose value.

With the exception of the issuance of shares of common stock to our preferred stockholders in connection with the payment of all accrued and unpaid dividends in connection with our initial public offering, we do not anticipate paying any cash dividends in the foreseeable future.

At the closing of our initial public offering, our board of directors issued shares of common stock to pay all accrued but unpaid dividends on our convertible preferred stock. With the exception of this dividend, we do not anticipate paying cash dividends on any classes of our capital stock in the foreseeable future. We currently intend to retain our future earnings for the foreseeable future to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain on an investment in our common stock for the foreseeable future.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(a) Recent Sale of Unregistered Securities

None.

(b) Issuer Purchases of Equity Securities

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

The documents listed in the Exhibit Index of this Quarterly Report on Form 10-Q are incorporated by reference or are filed with this Quarterly Report on Form 10-Q, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).

EXHIBIT INDEX

Exhibit		Incorporated by Reference Herein
Number	Description	Form	File No.	Exhibit	Filing Date

31.1#	Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2#	Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**	Certifications of Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	XBRL Instance Document.

101.SCH	XBRL Taxonomy Extension Schema Document.

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB	XBRL Taxonomy Extension Label Linkbase Document.

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

#	Filed herewith.

The information in this exhibit is furnished and deemed not filed with the Securities and Exchange Commission for purposes of section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of Pfenex Inc. under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	PFENEX INC.

Dated: November 7, 2019	By:	/s/ Evert B. Schimmelpennink
		Evert B. Schimmelpennink
		Chief Executive Officer, President and Secretary
		(Principal Executive Officer)

Dated: November 7, 2019	By:	/s/ Susan A. Knudson
		Susan A. Knudson
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 pfnx-ex311_8.htm EX-31.1 pfnx-ex311_8.htm

Exhibit 31.1

CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Evert B. Schimmelpennink, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Pfenex Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2019		/s/ Evert B. Schimmelpennink
		Evert B. Schimmelpennink
		Chief Executive Officer, President and Secretary
		(Principal Executive Officer)

EX-31.2 3 pfnx-ex312_7.htm EX-31.2 pfnx-ex312_7.htm

Exhibit 31.2

CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Susan A. Knudson, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Pfenex Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2019		/s/ Susan A. Knudson
		Susan A. Knudson
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-32.1 4 pfnx-ex321_6.htm EX-32.1 pfnx-ex321_6.htm

Exhibit 32.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Evert B. Schimmelpennink, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, that the Quarterly Report of Pfenex Inc. on Form 10-Q for the quarterly period ended September 30, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Pfenex Inc.

Date: November 7, 2019	By:	/s/ Evert B. Schimmelpennink
	Evert B. Schimmelpennink
	Chief Executive Officer, President and Secretary
	(Principal Executive Officer)

I, Susan A. Knudson, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, that the Quarterly Report of Pfenex Inc. on Form 10-Q for the quarterly period ended September 30, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Pfenex Inc.

Date: November 7, 2019	By:	/s/ Susan A. Knudson
	Susan A. Knudson
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 5 pfnx-20190930.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares pfnx:Financial_Institution pfnx:Customer xbrli:pure pfnx:Milestone 0001478121 2019-01-01 2019-09-30 0001478121 2019-11-01 0001478121 2019-09-30 0001478121 2018-12-31 0001478121 us-gaap:LicenseAndServiceMember 2019-07-01 2019-09-30 0001478121 us-gaap:LicenseAndServiceMember 2018-07-01 2018-09-30 0001478121 us-gaap:LicenseAndServiceMember 2019-01-01 2019-09-30 0001478121 us-gaap:LicenseAndServiceMember 2018-01-01 2018-09-30 0001478121 us-gaap:TechnologyServiceMember 2019-07-01 2019-09-30 0001478121 us-gaap:TechnologyServiceMember 2018-07-01 2018-09-30 0001478121 us-gaap:TechnologyServiceMember 2019-01-01 2019-09-30 0001478121 us-gaap:TechnologyServiceMember 2018-01-01 2018-09-30 0001478121 us-gaap:ProductMember 2019-07-01 2019-09-30 0001478121 us-gaap:ProductMember 2018-07-01 2018-09-30 0001478121 us-gaap:ProductMember 2019-01-01 2019-09-30 0001478121 us-gaap:ProductMember 2018-01-01 2018-09-30 0001478121 2019-07-01 2019-09-30 0001478121 2018-07-01 2018-09-30 0001478121 2018-01-01 2018-09-30 0001478121 2017-12-31 0001478121 2018-09-30 0001478121 us-gaap:CommonStockMember 2017-12-31 0001478121 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001478121 us-gaap:RetainedEarningsMember 2017-12-31 0001478121 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001478121 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001478121 2018-01-01 2018-03-31 0001478121 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001478121 us-gaap:CommonStockMember 2018-03-31 0001478121 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001478121 us-gaap:RetainedEarningsMember 2018-03-31 0001478121 2018-03-31 0001478121 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001478121 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001478121 2018-04-01 2018-06-30 0001478121 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001478121 us-gaap:CommonStockMember 2018-06-30 0001478121 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001478121 us-gaap:RetainedEarningsMember 2018-06-30 0001478121 2018-06-30 0001478121 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001478121 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001478121 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001478121 us-gaap:CommonStockMember 2018-09-30 0001478121 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001478121 us-gaap:RetainedEarningsMember 2018-09-30 0001478121 us-gaap:CommonStockMember 2018-12-31 0001478121 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001478121 us-gaap:RetainedEarningsMember 2018-12-31 0001478121 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001478121 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001478121 2019-01-01 2019-03-31 0001478121 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001478121 us-gaap:CommonStockMember 2019-03-31 0001478121 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001478121 us-gaap:RetainedEarningsMember 2019-03-31 0001478121 2019-03-31 0001478121 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001478121 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001478121 2019-04-01 2019-06-30 0001478121 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001478121 us-gaap:CommonStockMember 2019-06-30 0001478121 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001478121 us-gaap:RetainedEarningsMember 2019-06-30 0001478121 2019-06-30 0001478121 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001478121 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001478121 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001478121 us-gaap:CommonStockMember 2019-09-30 0001478121 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001478121 us-gaap:RetainedEarningsMember 2019-09-30 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember 2017-12-01 2017-12-31 0001478121 pfnx:DevelopmentEvaluationAndLicenseAgreementMember pfnx:ArcellxMember srt:MinimumMember 2019-01-01 2019-09-30 0001478121 pfnx:DevelopmentEvaluationAndLicenseAgreementMember pfnx:ArcellxMember srt:MaximumMember 2019-01-01 2019-09-30 0001478121 pfnx:DevelopmentEvaluationAndLicenseAgreementMember pfnx:ArcellxMember 2019-01-01 2019-09-30 0001478121 pfnx:WilliamBlairCompanyLLCMember srt:MaximumMember 2018-03-01 2018-03-31 0001478121 pfnx:FollowOnPublicOfferingMember 2018-05-01 2018-05-31 0001478121 pfnx:FollowOnPublicOfferingMember 2018-05-31 0001478121 2017-01-31 0001478121 us-gaap:CreditAvailabilityConcentrationRiskMember 2019-09-30 0001478121 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2019-01-01 2019-09-30 0001478121 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2018-01-01 2018-12-31 0001478121 us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001478121 us-gaap:SalesRevenueNetMember 2018-07-01 2018-09-30 0001478121 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001478121 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2018-07-01 2018-09-30 0001478121 us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001478121 us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001478121 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001478121 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember country:US 2019-07-01 2019-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember country:US 2018-07-01 2018-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember country:US 2019-01-01 2019-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember country:US 2018-01-01 2018-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember 2018-07-01 2018-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0001478121 us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-09-30 0001478121 country:MT srt:MinimumMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001478121 country:MT srt:MinimumMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001478121 country:IE srt:MinimumMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001478121 country:IE srt:MinimumMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2018-07-01 2018-09-30 0001478121 country:IE srt:MinimumMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001478121 country:IE srt:MinimumMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001478121 us-gaap:FairValueInputsLevel1Member 2019-09-30 0001478121 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001478121 us-gaap:FairValueInputsLevel2Member 2019-09-30 0001478121 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001478121 us-gaap:FairValueInputsLevel3Member 2019-09-30 0001478121 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001478121 pfnx:ReagentProteinProductMember 2019-09-30 0001478121 pfnx:ReagentProteinProductMember 2018-12-31 0001478121 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001478121 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001478121 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001478121 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001478121 pfnx:FurnitureAndEquipmentMember 2019-09-30 0001478121 pfnx:FurnitureAndEquipmentMember 2018-12-31 0001478121 us-gaap:ComputerEquipmentMember 2019-09-30 0001478121 us-gaap:ComputerEquipmentMember 2018-12-31 0001478121 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-09-30 0001478121 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001478121 pfnx:ResearchAndLaboratoryEquipmentMember 2019-09-30 0001478121 pfnx:ResearchAndLaboratoryEquipmentMember 2018-12-31 0001478121 us-gaap:LeaseholdImprovementsMember 2019-09-30 0001478121 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001478121 us-gaap:ConstructionInProgressMember 2019-09-30 0001478121 us-gaap:ConstructionInProgressMember 2018-12-31 0001478121 us-gaap:OtherMachineryAndEquipmentMember 2019-09-30 0001478121 us-gaap:OtherMachineryAndEquipmentMember 2018-12-31 0001478121 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0001478121 us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0001478121 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0001478121 us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0001478121 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001478121 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001478121 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001478121 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001478121 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001478121 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001478121 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001478121 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001478121 us-gaap:CustomerRelationshipsMember 2019-09-30 0001478121 us-gaap:CustomerRelationshipsMember 2018-12-31 0001478121 us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0001478121 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001478121 us-gaap:TradeNamesMember 2019-09-30 0001478121 us-gaap:TradeNamesMember 2018-12-31 0001478121 pfnx:LiasionAgreeementWithAlvogenMember pfnx:AlvogenMaltaOperationsLtdMember 2019-05-01 2019-05-31 0001478121 pfnx:LiasionAgreeementWithAlvogenMember pfnx:AlvogenMaltaOperationsLtdMember 2019-01-01 2019-09-30 0001478121 pfnx:LiasionAgreeementWithAlvogenMember pfnx:AlvogenMaltaOperationsLtdMember 2019-09-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember 2018-06-01 2018-06-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember pfnx:SupportAndRegulatoryMilestoneMember 2018-06-01 2018-06-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember 2018-06-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember 2019-01-01 2019-09-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember 2019-02-01 2019-02-28 0001478121 pfnx:AlvogenMaltaOperationsLtdMember pfnx:NewDrugApplicationMember 2018-06-01 2018-06-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember pfnx:NewDrugApplicationMember 2018-06-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember pfnx:NewDrugApplicationMember 2019-01-01 2019-09-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember 2018-07-01 2018-09-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember us-gaap:UnbilledRevenuesMember 2019-09-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember us-gaap:BilledRevenuesMember 2019-09-30 0001478121 us-gaap:ProductMember pfnx:AlvogenMaltaOperationsLtdMember 2019-05-01 2019-05-31 0001478121 us-gaap:ProductMember pfnx:AlvogenMaltaOperationsLtdMember 2019-07-01 2019-09-30 0001478121 us-gaap:ProductMember pfnx:AlvogenMaltaOperationsLtdMember 2019-01-01 2019-09-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember us-gaap:SubsequentEventMember pfnx:NewDrugApplicationMember 2019-10-01 2019-10-31 0001478121 pfnx:NTPharmaAgreementMember 2018-04-01 2018-04-30 0001478121 pfnx:NTPharmaAgreementMember pfnx:ResearchAndDevelopmentRegulatoryAndSalesRelatedMilestoneMember 2018-04-01 2018-04-30 0001478121 pfnx:NTPharmaAgreementMember pfnx:NewDrugApplicationMember 2018-04-01 2018-04-30 0001478121 pfnx:NTPharmaAgreementMember pfnx:NewDrugApplicationMember 2018-04-30 0001478121 pfnx:ResearchAndDevelopmentMilestonesMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2018-01-01 2018-12-31 0001478121 pfnx:ResearchAndDevelopmentMilestonesMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-09-01 2019-09-30 0001478121 pfnx:ResearchAndDevelopmentMilestonesMember pfnx:JazzPharmaceuticalsIrelandLimitedMember us-gaap:SubsequentEventMember 2019-10-01 2019-10-31 0001478121 pfnx:ResearchAndDevelopmentRegulatoryAndSalesRelatedMilestoneMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2017-12-01 2017-12-31 0001478121 pfnx:ResearchAndDevelopmentMilestonesMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-01-01 2019-09-30 0001478121 pfnx:RegulatoryMilestonesMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-01-01 2019-09-30 0001478121 pfnx:SalesMilestonesMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-01-01 2019-09-30 0001478121 pfnx:NonSalesRelatedMilestoneMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-01-01 2019-09-30 0001478121 pfnx:SubstantiveNonSalesRelatedMilestoneMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-01-01 2019-09-30 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-01-01 2019-09-30 0001478121 pfnx:PegaspargaseProductMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2017-12-01 2017-12-31 0001478121 pfnx:HematologyProductMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2017-12-01 2017-12-31 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember pfnx:ResearchAndDevelopmentMilestonesMember 2017-12-01 2017-12-31 0001478121 pfnx:HematologyProductMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-09-30 0001478121 srt:MinimumMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-01-01 2019-09-30 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember srt:MaximumMember 2019-01-01 2019-09-30 0001478121 srt:MinimumMember pfnx:JazzPharmaceuticalsIrelandLimitedMember 2017-04-01 2017-06-30 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember srt:MaximumMember 2017-04-01 2017-06-30 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember 2019-07-01 2019-09-30 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember 2018-07-01 2018-09-30 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember 2018-01-01 2018-09-30 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember 2018-01-01 2018-12-31 0001478121 pfnx:FundingAgreementMember pfnx:UsDepartmentOfHealthAndHumanServicesMember 2015-08-01 2015-08-31 0001478121 pfnx:FundingAgreementMember pfnx:UsDepartmentOfHealthAndHumanServicesMember 2019-01-01 2019-09-30 0001478121 pfnx:FundingAgreementMember pfnx:UsDepartmentOfHealthAndHumanServicesMember 2018-05-31 0001478121 pfnx:FundingAgreementMember pfnx:UsDepartmentOfHealthAndHumanServicesMember pfnx:BasePeriodPerformanceContractsMember 2015-08-01 2015-08-31 0001478121 pfnx:FundingAgreementMember pfnx:UsDepartmentOfHealthAndHumanServicesMember pfnx:BasePeriodPerformanceContractsMember 2017-01-01 2017-01-31 0001478121 pfnx:FundingAgreementMember pfnx:UsDepartmentOfHealthAndHumanServicesMember pfnx:OptionPeriodContractsMember 2015-08-01 2015-08-31 0001478121 pfnx:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2019-07-01 2019-09-30 0001478121 pfnx:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2018-07-01 2018-09-30 0001478121 pfnx:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2019-01-01 2019-09-30 0001478121 pfnx:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2018-01-01 2018-09-30 0001478121 pfnx:OfficeAndLaboratoryEquipmentMember 2019-01-01 2019-09-30 0001478121 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001478121 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001478121 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001478121 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001478121 pfnx:EmployeesStockPurchasePlanMember 2019-07-01 2019-09-30 0001478121 pfnx:EmployeesStockPurchasePlanMember 2018-07-01 2018-09-30 0001478121 pfnx:EmployeesStockPurchasePlanMember 2019-01-01 2019-09-30 0001478121 pfnx:EmployeesStockPurchasePlanMember 2018-01-01 2018-09-30 0001478121 pfnx:OptionsToPurchaseCommonStockMember 2019-01-01 2019-09-30 0001478121 pfnx:OptionsToPurchaseCommonStockMember 2018-01-01 2018-09-30 0001478121 pfnx:AlvogenMaltaOperationsLtdMember us-gaap:SubsequentEventMember 2019-10-01 2019-10-31 0001478121 pfnx:AlvogenMaltaOperationsLtdMember us-gaap:LicenseAndServiceMember srt:ScenarioForecastMember 2019-10-01 2019-12-31 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember us-gaap:SubsequentEventMember 2019-10-01 2019-10-31 0001478121 pfnx:JazzPharmaceuticalsIrelandLimitedMember us-gaap:LicenseAndServiceMember 2019-07-01 2019-09-30 10-Q false 2019-09-30 2019 Q3 Pfenex Inc. 0001478121 --12-31 Accelerated Filer true false true 31675903 Yes Yes false 001-36540 DE 27-1356759 10790 Roselle Street San Diego CA 92121 858 352-4400 true false Common Stock, par value $0.001 per share PFNX NYSEAMER

32518000

56220000

200000

16215000 5171000

53000

207000

2357000

1851000

51343000

63649000

8374000

7671000

170000

133000

3859000

4248000

5577000

69323000

81278000

2233000

2005000

8352000

9812000

105000

5317000

269000

316000

10959000

17450000

2500000

29000

191000

13488000

20141000

32000

265311000

262405000

-209508000

-201300000

55835000

61137000

69323000

81278000

0.001

10000000

0.001

200000000

31622914

31467580

31622914

31467580

11562000

1874000

20430000

6869000

733000

1339000

3155000

3821000

2953000

357000

4836000

816000

15248000

3570000

28421000

11506000

1143000

1479000

3837000

3923000

14105000

2091000

24584000

7583000

6931000

9045000

19691000

28590000

4147000

3823000

13296000

11920000

11078000

12868000

32987000

40510000

3027000

-10777000

-8403000

-32927000

55000

115000

195000

157000

3082000

-10662000

-8208000

-32770000

0.10

-0.34

-0.26

-1.20

0.09

-0.34

-0.26

-1.20

31595000

31437000

31534000

27288000

32498000

31437000

31534000

27288000

-8208000

-32770000

968000

849000

389000

400000

2381000

2551000

-8000

11044000

439000

596000

268000

100000

-560000

-1887000

2031000

-5212000

-522000

207000

432000

-22902000

-28288000

1076000

1010000

10000

-1076000

-1020000

39522000

249000

212000

525000

197000

38000

276000

39469000

-23702000

10161000

56420000

57864000

32718000

68025000

747000

92000

154000

0 56000

18000

36000

1000

48000

23548000

24000

219446000

-161707000

57763000

17000

57000

19000

55000

909000

-11027000

23584000

24000

220467000

-172734000

47757000

7820000

8000

39514000

39522000

17000

14000

849000

-11081000

31421000

32000

260844000

-183815000

77061000

20000

65000

20000

60000

794000

1000

-10662000

31461000

32000

261764000

-194477000

67319000

31468000

32000

262405000

-201300000

15000

60000

17000

53000

880000

-3661000

31500000

32000

263398000

-204961000

58469000

58000

142000

830000

-7629000

31558000

32000

264370000

-212590000

51812000

47000

214000

18000

56000

671000

3082000

31623000

32000

265311000

-209508000

1. Organization and Summary of Significant Accounting Policies Business Activities and Organization Pfenex Inc. (the Company or Pfenex) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of potential therapeutic equivalents, vaccines, biologics, and biosimilars. On October 4, 2019, the U.S. Food and Drug Administration (FDA) approved the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo® (teriparatide injection) as the reference drug. Like Forteo, this FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. Marketing authorization applications are pending in other jurisdictions. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals Ireland Limited (Jazz) including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. Both PF743 and PF745 are being developed for the treatment of Acute Lymphoblastic Leukemia (ALL) and other hematological malignancies. The Company also uses its Pfēnex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccine candidates under development by Merck & Co, Inc. (Merck) and Serum Institute of India Private Ltd. (SIIPL). Both have licenses to the Pfēnex Expression Technology for the production of CRM197 for use in conjugate vaccine products.  The Company is focused developing its portfolio of partnered as well as wholly-owned peptides and complex proteins.  Currently, the Company is exploring opportunities to develop novel modalities through an assessment program designed to evaluate and pursue validated biologic pathways that are differentially druggable via a selected modality in specific diseases. In addition, the Company is exploring a range of modality platforms and targets that are potentially compatible with its Pfēnex Expression Technology. FDA-Approved PF708 Product On October 4, 2019, the FDA approved the NDA for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo  (teriparatide injection) as the reference drug.  The FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture.  The Company is currently in the process of transferring the NDA to Alvogen pursuant to the Alvogen Agreement, described below, between the companies.  In addition, the Company has been continuing its efforts to obtain an “A” therapeutic equivalence designation for the product relative to its reference drug, Forteo. A determination of therapeutic equivalence may permit the FDA-approved PF708 product to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states.  Consistent with the Company’s interactions with the FDA and the agency’s draft guidance document on demonstrating the therapeutic equivalence of drug-device combination products, the Company has completed a comparative human factors study comparing the FDA-approved PF708 product and Forteo.  This human factors study was designed to further support a finding that the FDA-approved PF708 product is therapeutically equivalent to Forteo. On October 14, 2019, the Company announced the successful completion of its PF708 comparative use human factors study and its submission of the final study report to the FDA.  The study data demonstrate that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo for each critical user task evaluated in the study based on pre-specified statistical analysis of critical patient and caregiver tasks.    The Company believes this submission completes the information package required by the FDA to evaluate the therapeutic equivalence of the PF708 product.  The Company’s collaboration partner, Alvogen, intends to launch the FDA-approved PF708 product in the U.S. upon an FDA decision on the therapeutic equivalence evaluation of the product.   In April 2018, the Company and China NT Pharma Group Company Ltd. (NT Pharma) entered into a Development and License Agreement (NT Pharma Agreement), pursuant to which the Company granted an exclusive license to NT Pharma to commercialize PF708 in Mainland China, Hong Kong, Singapore, Malaysia and Thailand and a non-exclusive license to conduct development activities in such territories with respect to PF708. The Company will be responsible for commercial manufacturing and providing product for commercial sale to NT Pharma. The Company will facilitate this obligation via its commercial partner Alvogen. NT Pharma is responsible for all regulatory submissions, development costs and costs associated with regulatory approvals in such territories. In June 2018, the Company and Alvogen Malta Operations Ltd. (Alvogen) entered into a Development and License Agreement (Alvogen Agreement) pursuant to which Alvogen has the exclusive right to commercialize and manufacture PF708 in the United States. The Company expects Alvogen to launch FDA-approved PF708 in the U.S. upon an FDA rating decision on the therapeutic equivalence evaluation of the product. Following the FDA approval of the NDA for PF708, the FDA-approved PF708 product will be commercialized and manufactured in the U.S. by Alvogen. The Company is currently in the process of transferring the NDA to Alvogen pursuant to its collaboration agreement.   In February 2019, the Company and Alvogen entered into additional agreements, extending Alvogen’s rights to commercialize and manufacture PF708 to include the European Union (EU), certain countries in the Middle East and North Africa (MENA) and to the rest of world (ROW) territories (excluding certain Asian countries granted to NT Pharma). Alvogen is responsible for local activities and for overseeing any clinical development, regulatory, litigation, commercial manufacturing and commercialization activities in these jurisdictions. Collaboration Partner: Jazz Pharmaceuticals Ireland Limited In July 2016, the Company and Jazz announced an agreement under which the Company granted Jazz worldwide rights to develop and commercialize multiple early stage hematology/oncology product candidates, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. In December 2017, the parties amended the Jazz agreement, bringing the total value of payments and potential payments associated with the collaboration to $224.5 million. In addition, the Company may be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement. Pfēnex Expression Technology Licenses: CRM197 The Company has both licenses and supply agreements in place for CRM197, which is a non-toxic mutant of diphtheria toxin.  It is a well-characterized protein and functions as a carrier for polysaccharides and haptens, making them immunogenic.  The Company has developed unique CRM197 production strains based on its Pfēnex Expression Technology platform. As a result of these development efforts, the Company previously entered into commercial licenses for production strains capable of producing CRM197 with both Merck & Co., Inc. and Serum Institute of India Private Ltd. Merck and SIIPL are using the CRM197 produced via the licensed production strain in multiple clinical stage products. Those products currently include Merck’s 15-valent pneumococcal conjugate vaccine, PCV-15 (V114) currently in several ongoing Phase 3 clinical studies and SIIPL’s 10-valent pneumococcal conjugate vaccine Pneumosil® currently in WHO Prequalification and a pentavalent meningococcal conjugate vaccine currently in a Phase 3 clinical study. The CRM197 production strains utilized by both Merck and SIIPL are unique and exclusively licensed to each party. These commercial license agreements with Merck and SIIPL contemplate potential maintenance and milestone fees as well as royalties on net sales. Additionally, as part of the SIIPL commercial license agreement, SIIPL supplies both reagent grade and cGMP CRM197 to Pfenex, which supplies the product to vaccine development-focused pharmaceutical partners.   Arcellx Development, Evaluation and License Agreement The Company previously entered into a development, evaluation and license agreement with Arcellx which provides access to the Pfēnex Expression Technology platform to advance Arcellx’s proprietary sparX proteins that activate, silence and reprogram Antigen- Receptor Complex T cell-based therapies. Under the terms of the agreement, Pfenex is eligible to receive development funding in addition to development, regulatory and commercial milestones ranging from $2.6 million to $18 million for each product incorporating a sparX protein expressed using the Pfēnex Expression Technology, as well as royalties on worldwide sales of any such products. The Company currently has two sparX proteins in development with Arcellx.  As of September 30, 2019, the Company has recorded $1.8 million in revenue related to development for Arcellx. Additional Novel Vaccine and Biosimilar Pipeline Products The Company’s pipeline includes biosimilar candidates to certain reference products, including biosimilar candidates to Lucentis (PF582) and Neulasta (PF529) and two novel anthrax vaccine candidates, Px563L and RPA563, which are funded by the Biomedical Advanced Research and Development Authority (BARDA). In November of 2017, the Company paused development on both PF582 and PF529 and it does not intend to advance PF582 or PF529 without development and commercial collaboration partners. In March 2019 the Company received a notice from BARDA advising it of BARDA’s decision not to exercise development options for cGMP manufacturing, preclinical studies and Phase 1/2b study readiness in connection with the Company’s Px563L and RPA563 novel anthrax vaccine program. Following the receipt of the notice from BARDA and pursuant to discussions with BARDA, the Company deprioritized this program in its portfolio. At the Market Offering Program In March 2018, the Company entered into an equity sales agreement (Sales Agreement) with William Blair & Company, L.L.C. (William Blair) to sell shares of the Company’s common stock having aggregate sales proceeds of up to $20.0 million, from time to time, through an “at the market” equity offering program under which William Blair will act as sales agent. Under the Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. As of September 30, 2019, the Company had not sold any shares under the Sales Agreement. Follow-on Public Offering In May 2018, the Company completed a public offering of common stock in which it sold 7,820,000 shares of its common stock at an offering price of $5.50 per share, which included the full exercise by the underwriters of their option to purchase an additional 1,020,000 shares, pursuant to the Company’s prior shelf registration statement. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $39.5 million. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. Use of Estimates The preparation of the accompanying unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates. Risk and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the performance of the Company’s commercial partner Alvogen, uncertainty of results of clinical trials and reaching milestones, uncertainty of timing and types of regulatory approval of the Company’s product candidates, uncertainty of market acceptance of the Company’s products if approved for sale, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals. Products developed by the Company require clearances from international and domestic regulatory agencies prior to commercial sales in such jurisdictions. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. As of September 30, 2019, the Company had an accumulated deficit of $209.5 million and expects to incur substantial operating losses for the next several years. The Company believes that its existing cash and cash equivalents and cash inflow from operations will be sufficient to meet its anticipated cash needs for at least the next 12 months from the date these unaudited consolidated financial statements are issued. The Company will require substantial cash to achieve its objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. The Company may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. It will need to obtain significant funds under its existing collaborations and license agreements, under new collaboration, licensing or other commercial agreements for one or more of its product candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that it does not obtain additional funding, the Company will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on its ability to achieve its intended business objectives. Cash and Cash Equivalents The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash amounts that are restricted as to withdrawal or usage are presented as restricted cash. In January 2017, the Company entered into a Borrower’s Pledge Agreement, which required $0.2 million in restricted cash to be provided as security for its commercial credit card arrangement with one of the Company’s banks. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at three major financial institutions as of September 30, 2019 and December 31, 2018. For the Company’s cash position of $32.7 million as of September 30, 2019, which included restricted cash of $0.2 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance. Additional credit risk is related to the Company’s concentration of receivables. As of September 30, 2019, and December 31, 2018, receivables were concentrated among two and three customers representing 91% and 87% of total net receivables, respectively. No allowance for doubtful accounts was recorded at September 30, 2019 or December 31, 2018. For the three months ended September 30, 2019 and 2018, revenue was concentrated among two customers and/or collaboration partners representing 89% of total revenues for both periods.  Revenue from two customers and/or collaboration partners represented 70% and 87% of total revenue for the nine months ended September 30, 2019 and 2018, respectively. A portion of revenue is earned from entities located outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s revenue from U.S. and non-U.S. based sources for the nine months ended September 30, 2019 and 2018 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,172</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,877</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-US Revenue</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,371</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,199</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,629</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,248</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,570</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,421</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,506</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   During the three and nine months ended September 30, 2019, entities located in Ireland and Malta accounted for more than 10% of the Company’s revenue. During the three and nine months ended September 30, 2018, entities located in Ireland accounted for more than 10% of the Company’s revenue.    </div> Fair Value of Financial Instruments Financial instruments, including cash, cash equivalents, restricted cash and the lines of credit, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> •</td> <td valign="top"> Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at September 30, 2019 and December 31, 2018 included the Company’s cash, cash equivalents and restricted cash. There were no Level 1 liabilities; </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> •</td> <td valign="top"> Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at September 30, 2019 or December 31, 2018; and </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:4.54%;white-space:nowrap"> •</td> <td valign="top"> Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at September 30, 2019 or December 31, 2018. </td></tr></table></div> Revenue The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, license agreements, government contracts and sales of reagent protein products, which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving development and sales milestones and for product royalties. The specifics of the Company’s significant agreements are detailed in Note 7—Significant Research and Development Agreements. The Company’s revenue is reported into one of three categories, including: license revenue, service revenue, and product revenue.  License revenue generally includes providing customers with access to the Company’s intellectual property and achievement of development milestones during the period or a portion of contractual payments that are recognized during the reporting period. Service revenue is derived from performing activities for customers related to the Company’s Pfēnex Expression Technology platform.  Product revenue generally includes sales of CMR197 and other materials.  The three-months ended September 30, 2019 is the first period revenue has been reported into these three categories, and prior periods have been disaggregated to conform to this current presentation. The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement. On a quarterly basis, the Company evaluates the period of performance to determine if a change should be made. Upfront, nonrefundable licensing payments are assessed to determine whether or not the licensee is able to obtain standalone value from the license. Where the license does not have standalone value, non-refundable license fees are recorded as deferred revenue and recognized as revenue as the Company performs under the applicable agreement. Where the level of effort is relatively consistent over the performance period, the Company recognizes fixed or determined revenue on a straight-line basis over the estimated period of performance. Where the license has standalone value, the Company recognizes total license revenue at the time all revenue recognition criteria have been met. Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed. Revenue under service agreements are recorded as services are performed. These agreements do not require development achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement. The Company recognizes revenue for its cost-plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under the Company’s government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred. The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. For the three and nine months ended September 30, 2019, $11.0 million and $17.1 million in revenue was recognized in connection with the achievement of milestones, respectively.   The Company’s reagent protein products are primarily comprised of internally developed reagent protein products. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. As of September 30, 2019, the Company has had minimal product returns related to reagent protein product sales. Therefore, no reserve for warranty and return rights was recorded as of September 30, 2019 and December 31, 2018. Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent. Recently Issued Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Numerous updates were issued in 2016 that provide clarification on a number of specific issues as well as requiring additional disclosures. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of January 1, 2019 in that filing. However, the Company will continue to account for revenue recognition under ASC Topic 605 for interim periods in 2019 and will not be required to amend its Form 10-Q filings filed throughout 2019 to reflect the January 1, 2019 adoption date. The guidance allows for the use of one of two retrospective application methods: the full retrospective method or the modified retrospective method. The Company plans to adopt the standard in fiscal year 2019 using the modified retrospective method. The Company does not expect the new standard to have a material impact on the recognition of revenue from its services or reagent protein product sales. The Company is currently evaluating the impact of the new standard on historical revenue recorded for its collaboration agreements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which was subsequently amended by ASU No. 2018-10, ASU No. 2018-11, ASU No. 2018-20 and ASU No. 2019-01. This ASU, as amended, increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as right-of-use assets and lease liabilities. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification dictates whether lease expense is to be recognized based on an effective interest method or on a straight-line basis over the term of the lease. Additional qualitative and quantitative disclosures will be required to give financial statement users information on the amount, timing and judgments related to a reporting entity’s cash flows arising from leases. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of January 1, 2019 in that filing. However, the Company will continue to account for leases under ASC Topic 840 for interim periods in 2019 and will not be required to amend its Form 10-Q filings filed throughout 2019 to reflect the January 1, 2019 adoption date. The Company plans on adopting this standard using the modified retrospective transition approach by applying the new standard to leases existing at the date of initial adoption. The Company plans to use the package of practical expedients, which permit the Company to not reassess prior conclusions about lease identification, lease classification and initial direct costs determined under ASC Topic 840. In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. This updated guidance eliminates Step 2 from the current two-step quantitative model for goodwill impairment tests. Step 2 required an entity to calculate an implied fair value, which included a hypothetical purchase price allocation requirement, for reporting units that failed Step 1. Per this updated guidance, a goodwill impairment will instead be measured as the amount by which a reporting unit’s carrying value exceeds its fair value as identified in Step 1. This guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this guidance is not expected to have a material impact on the consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718), which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of January 1, 2019 in that filing. The adoption of this guidance is not expected to have a material impact on the consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. ASU 2018-15 is effective for the Company beginning in the first quarter of fiscal year 2020, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact on its financial statements and related disclosures. In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. ASU No. 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in ASU No. 2018-18 are required to be applied retrospectively to the date of initial application of ASC 606. The Company is currently evaluating the impact of ASU No. 2018-08 on its consolidated financial statements.

5. Intangible Assets Intangible assets consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,750</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,750</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,400</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,400</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade names</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">920</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">920</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intangible assets, gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated amortization</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,211</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total intangible assets, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,859</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,248</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Amortization expense related to intangible assets was $0.1 million for both the three months ended September 30, 2019 and 2018, and $0.4 million for both the nine months ended September 30, 2019 and 2018. Amortization expense is included within selling, general and administrative expense in the accompanying consolidated statements of operations. As of September 30, 2019, estimated amortization expense for the next five years amounts to approximately $0.5 million per year.

7. Significant Research and Development Agreements The Company has two types of research and development agreements (i) those for which the Company co-develops or assists customers in developing their products (Collaboration Agreements), and (ii) those for which the Company receives funding to advance its own products (Funding Agreements). Collaboration Agreements Alvogen In June 2018, the Company entered into an agreement with Alvogen in which the Company granted Alvogen exclusive rights to commercialize and manufacture PF708 in the United States. The Company expects Alvogen to launch the FDA-approved PF708 product in the U.S. upon an FDA rating decision on the therapeutic equivalence evaluation of the product. Prior to the FDA approval of the NDA for PF708, the Company was responsible for development and registration of PF708, while Alvogen was and continues to provide additional regulatory and development expertise. Following the FDA approval of the NDA for PF708, Alvogen has assumed responsibility for costs related to litigation, commercial manufacturing and supply chain, and commercialization of the FDA-approved PF708 product and the Company is currently in the process of transferring the NDA to Alvogen. In consideration for the licenses and other rights granted to Alvogen under the agreement, the Company received an upfront payment of $2.5 million, achieved two development milestone for $2.5 million each, one of which was the milestone achievement for FDA approval of PF708 in October 2019, and may be eligible to receive an additional $20 million in support and regulatory milestone payments. The Company may also be eligible to receive a 50% gross profit split on sales if the product is rated as Therapeutically Equivalent (AP) to Forteo and up to 40% if rated differently. The Company deems that the support and regulatory milestones are substantive. In February 2019, the Company and Alvogen entered into agreements expanding the Company’s and Alvogen’s collaboration to develop and commercialize PF708 to the EU, to certain countries in the MENA and to the ROW territories (the latter defined as all countries outside of the EU, US and MENA, excluding Mainland China, Hong Kong, Singapore, Malaysia and Thailand). Under the agreements, Alvogen has exclusive rights to develop, commercialize and manufacture PF708 in such territories. As of September 30, 2019, the Company has earned $1.0 million in upfront and milestone payments and may be eligible to receive an additional $1.5 million in milestone payments under the terms of the expanded agreements with Alvogen. For EU, MENA and ROW, Pfenex may also be eligible to receive up to 60% of Alvogen’s gross profit derived from product sales, depending on geography and cost of goods sold. In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the Alvogen Agreement. The significant deliverables were determined to be the development and regulatory services up through the NDA filing and ultimate approval related to the PF708 product and the exclusive license granted to Alvogen to commercialize PF708 in the United States. The Company has determined that the license and the development and regulatory activities meet the separation criteria; therefore, they are each treated as separate units of accounting. To determine the stand-alone value of the license, the Company considered its negotiation discussions with Alvogen that led to the final terms of the agreement and other information. The Company determined a selling price for the services by estimating costs expected to be incurred for internal labor, burden rates, internal margins, and subcontractors. The upfront payment of $2.5 million received in 2018 is not fixed and determinable due to a contract clause that $2.5 million may be payable to Alvogen if the NDA approval is not transferred to Alvogen by a specified date; therefore, the upfront payment has been recorded as deferred revenue in the accompanying consolidated balance sheet as of September 30, 2019. In the nine months ended September 30, 2019, a one-time support payment of $2.5 million was received by the Company from Alvogen upon FDA acceptance of the NDA in consideration of the Company’s production of consistency batches of PF708 product and related development and support activities. The payment was recorded as revenue during the first quarter of 2019. In February 2019, Alvogen also agreed to support certain costs incurred by the Company for PF708 related to the preparation and filing of the NDA and costs related to regulatory affairs, quality, manufacturing and supply chain during 2019. Alvogen agreed to pay a total of $1.6 million for said costs, and the Company recognized the entire $1.6 million as an offset to R&D expense in 2019. As of September 30, 2019, the Company invoiced Alvogen approximately $1.2 million, and the remaining $0.4 million is recorded as an unbilled receivable. The Company is currently in the process of transferring internally managed manufacturing activities to Alvogen. In April 2019, the Company entered into an agreement with Alvogen where the Company acted as the liaison between Alvogen and the Company’s established raw materials supplier/manufacturer. In May 2019, the Company received a $1.7 million cash payment from Alvogen for raw materials. As of September 30, 2019, the Company had shipped approximately $1.0 million of raw materials due to Alvogen related to this agreement which was recorded as an offset to R&D expense, and the remaining $0.7 million is recorded as part of accrued liabilities. In May 2019, the Company entered into an agreement with Alvogen for the Company to provide PF708 drug substance batches and pen components in exchange for $2.3 million.  This product sold to Alvogen was initially manufactured by Company’s CMO for manufacturing process validation purposes as part of the PF708 NDA submission to the FDA for approval. The Company does not expect to have similar transactions with its collaboration partners in the future.  The $2.3 million was recorded as product revenue in the accompanying consolidated statements of operations during the three and nine months ended September 30, 2019.   In October 2019, the FDA approved the NDA for PF708 under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug.  In connection with the FDA approval of PF708, the Company earned a $2.5 million milestone payment under the collaboration agreement with Alvogen, payable upon Alvogen’s receipt of notice of NDA approval, and will be recognized as revenue in the fourth quarter of 2019.   NT Pharma In April 2018, the Company entered into an agreement with NT Pharma under which the Company granted NT Pharma non-exclusive development and exclusive commercialization rights to PF708 in Mainland China, Hong Kong, Singapore, Malaysia and Thailand. In accordance with the agreement, the Company received an upfront payment of $2.5 million and may be eligible to receive up to $22.5 million in payments based on the achievement of certain development, regulatory, and sales-related milestones. In addition, the Company is eligible to receive double-digit royalties on net product sales. NT Pharma is responsible for any further development required to achieve regulatory approval as well as commercialization activities in the applicable territories. The Company deems that none of the non-sales milestones are substantive. Milestones that are not considered substantive would be recognized as revenue over the remaining period of performance, assuming all other revenue recognition criteria are met. In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the NT Pharma Agreement. The significant deliverables were determined to be the license and research and development services up through the NDA filing related to the PF708 product. The Company has determined that these deliverables meet the separation criteria and therefore are each treated as separate units of accounting. The upfront payment of $2.5 million was not fixed and determinable. Due to a contract clause, the $2.5 million could be payable to NT Pharma if the NDA was not filed by a specified date and additional deliverables were required after NDA submission. Therefore, the upfront payment was recorded as deferred revenue as of December 31, 2018. The deliverables were satisfied during the first quarter of 2019, at which time the upfront payment was recognized as revenue.   Jazz In July 2016, the Company entered into a development and license agreement with Jazz Pharmaceuticals for the development and commercialization of multiple early stage hematology/oncology product candidates, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. Jazz has the exclusive right to manufacture and commercialize such products throughout the world. In addition, pursuant to the agreement, the Company has granted Jazz certain other rights to negotiate the exclusive right to develop, manufacture and commercialize throughout the world other hematology/oncology products that are currently or in the future may be developed by the Company. In the third quarter of 2017, the Company achieved a process development milestone associated with this collaboration. In December 2017, the Company and Jazz entered into an amended and restated agreement (as amended, the Amended Jazz Agreement).  As part of the Amended Jazz Agreement, the Company received a total payment of $18.5 million, consisting of an upfront payment of $5.0 million and a payment of $13.5 million for development achievement. In 2018, the Company achieved two development milestones and received $0.8 million in recognized revenue for successful achievement of process development milestones for PF745. In September 2019, the Company achieved a development milestone and recognized $11.0 million in revenue for successful achievement of a process development milestone for PF745.  In October 2019, the Company received an $11.0 million cash payment for this PF745 milestone achievement. The Company may be eligible to receive additional payments under the Amended Jazz Agreement of up to $177.5 million based on achievement of certain research and development, regulatory and sales-related milestones. As of September 30, 2019, the total remaining milestones are categorized as follows: $18.5 million based on achievement of certain research and development milestones; $34.0 million for certain regulatory milestones; and $125.0 million for sales milestones. For the non-sales-related milestones totaling $52.5 million, the Company conducted an evaluation as to whether they will be recorded using the milestone method and, as a result of this evaluation, estimates approximately $18.5 million of these non-sales-related milestones are deemed to be substantive. The Company may also be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement. Both Jazz and the Company are contributing to the development efforts. Unless terminated earlier, the Amended Jazz Agreement will continue on a product-by-product basis for as long as Jazz is commercializing or having commercialized the products under the Amended Jazz Agreement. In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the Jazz Agreement and again upon entering into the Amended Jazz Agreement. The deliverables have not changed under the amendment. The significant deliverables were determined to be the research and development services related to the pegaspargase product candidate option and for license and research and development activities of the other hematology/oncology products. The Company has determined that the license, together with the research and development activities, represent one unit of accounting for each product under license, as the license does not have standalone value from the respective development activities. The research and development activities related to the pegaspargase option were determined to have standalone value apart from the license and development activities for the other hematology/oncology products. The estimated selling price for the pegaspargase product candidate and the hematology/oncology products was determined using an income approach. In determining the estimated selling price, the Company considered costs expected to be incurred for internal labor, burden rates, internal margins, and subcontractors. Based on the Company’s considerations of estimated selling price, the Company allocated the original $15.0 million upfront and option payment as follows: $10.0 million to the pegaspargase product candidate and $2.5 million to each of the hematology/oncology products. For the $5.0 million upfront payment received under the terms of the Amended Jazz Agreement, the Company determined that $0.8 million represented development services performed prior to the amendment, which had been reimbursable under the original agreement. The remaining $4.2 million of the upfront payment was allocated to the remaining hematology product; the amount was deferred and is being recognized over the period of performance. The Amended Jazz Agreement provisions allow for Jazz to halt the advancement of one of the products under development and replace with others wherein the Company could potentially earn milestone revenue on those products. However, the Company believes it is unlikely Jazz would halt the advancement of the product under development and replace with other products. Therefore, none of the upfront payments were allocated to this option. The upfront and option payment for the original Jazz agreement and the amendment were being deferred and being recognized as revenue ratably over the period in which the Company expects services to be rendered for each respective unit of accounting, concluded by June 30, 2019. As previously disclosed, the estimated period of revenue recognition approximates a range of 15 to 32 months. Based on changes to this estimate that occurred during the quarter ended June 30, 2017, the Company modified the period of revenue recognition to range from 15 to 35 months. During the year ended December 31, 2017, the Company completed the service period related to one of the hematology products. During the three months ended September 30, 2019 and 2018, the Company recorded revenue of approximately $11.0 million and $1.8 million related to the Jazz Collaboration, respectively. During the nine months ended September 30, 2019 and 2018, the Company recorded revenue of approximately $13.7 million and $6.3 million related to the Jazz collaboration, respectively. As of December 31, 2018, deferred revenue associated with the Jazz collaboration was $2.7 million. As of September 30, 2019, all deferred revenue related to the collaboration had been recognized.   Funding Agreements The U.S. Department of Health and Human Services In August 2015, the Company completed a development contract with the BARDA within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services for Px563L and RPA563 as a novel vaccine candidate for the prevention of anthrax infection. The Company entered into a follow-on contract with BARDA in August 2015 for the advanced development of Px563L and RPA563. This agreement is a cost-plus fixed fee development contract valued at up to approximately $143.5 million, including a 30-month base period of performance of approximately $15.9 million, and eight option periods valued at a total of approximately $127.6 million. The base period of performance was initially from August 2015 through February 2018 and later extended through September 2018. BARDA exercised additional phases of the development contract effective January 2017, totaling $4.9 million and allowing for the continuing development of Px563L and RPA563. The period of performance for the two option periods was extended through September 2018 and December 2019. In May 2018, BARDA increased the funding for one of the option periods by approximately $1.7 million. On March 29, 2019, the Company received notice from BARDA advising the Company of its decision not to exercise development options for cGMP manufacturing and potential Phase 1/2b study readiness for Px563L and RPA563. Following the receipt of the notice from BARDA and pursuant to discussions with BARDA, the Company deprioritized this program in its portfolio. Revenue is recognized in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under this government contract primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under the BARDA contract, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under this BARDA contract, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred and become billable. The billing of any overage in indirect cost rates over the approved provisional rates in the contract is not allowed. Any such overage is expensed as incurred. When and if final rates with Defense Contract Audit Agency are approved, the Company will recognize any change in revenue resulting from the rate change in the period such revised rates are approved and as such this would be considered a change in estimate. This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 whereupon BARDA may immediately terminate the agreement early for convenience or request the Company to stop all or any part of the work for a period of at least 90 days. During the three months ended September 30, 2019 and 2018, revenue from BARDA was $0.2 million and $1.3 million, respectively. During the nine months ended September 30, 2019 and 2018, revenue from BARDA was $1.2 million and $3.8 million, respectively.

9. Stock-Based Compensation Summary Stock-Based Compensation Information The following table summarizes stock-based compensation expense:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,149</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,259</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">793</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,381</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,551</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation from:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">752</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,320</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">793</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,381</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,551</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,155</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,282</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.57</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.47</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled (forfeited)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(522</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.52</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,795</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.73</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.92</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,431</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at September 30, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,245</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.92</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.66</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,156</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,458</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.08</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,865</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> The Company received approximately $0.4 million and $0.1 million from stock option exercises during the nine months ended September 30, 2019 and September 30, 2018, respectively. Options outstanding at September 30, 2019 have a weighted average remaining contractual term of 6.92 years. The exercise price of all options granted during the nine months ended September 30, 2019 and 2018 was equal to the closing price of the Company’s common stock on the date of grant. The fair value of each stock option granted is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair values of the stock option, including the effect of estimated forfeitures, are then expensed over the requisite service period which is generally the vesting period. The table below sets forth the weighted-average assumptions used to estimate the fair value of stock options:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of options in years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> The weighted-average grant date fair value of options granted during the nine months ended September 30, 2019 and 2018 was $3.01 and $2.37, respectively. As of September 30, 2019, there was unrecognized compensation cost of approximately $5.8 million related to unvested stock option awards, and the weighted-average period over which this cost is expected to be recognized is 2.7 years.

12. Subsequent Events In October 2019, the FDA approved the NDA for PF708 under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug.  In connection with the FDA approval of PF708, the Company earned a $2.5 million milestone payment under the collaboration agreement with Alvogen, payable upon Alvogen’s receipt of notice of NDA approval. The Company recognized this $2.5 million as license revenue in the fourth quarter of 2019.    In October 2019, the Company received an $11 million cash payment for the September 2019 achievement of a development milestone for PF745 associated to the Jazz collaboration. The Company recognized this $11.0 million as license revenue in the third quarter of 2019. In October 2019, the Company announced the successful completion of its PF708 comparative use human factors study and its submission of the final study report to the FDA.  An estimate of the financial effect of this subsequent event cannot be determined as of the report release date.

Business Activities and Organization Pfenex Inc. (the Company or Pfenex) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of potential therapeutic equivalents, vaccines, biologics, and biosimilars. On October 4, 2019, the U.S. Food and Drug Administration (FDA) approved the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo® (teriparatide injection) as the reference drug. Like Forteo, this FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. Marketing authorization applications are pending in other jurisdictions. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals Ireland Limited (Jazz) including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. Both PF743 and PF745 are being developed for the treatment of Acute Lymphoblastic Leukemia (ALL) and other hematological malignancies. The Company also uses its Pfēnex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccine candidates under development by Merck & Co, Inc. (Merck) and Serum Institute of India Private Ltd. (SIIPL). Both have licenses to the Pfēnex Expression Technology for the production of CRM197 for use in conjugate vaccine products.  The Company is focused developing its portfolio of partnered as well as wholly-owned peptides and complex proteins.  Currently, the Company is exploring opportunities to develop novel modalities through an assessment program designed to evaluate and pursue validated biologic pathways that are differentially druggable via a selected modality in specific diseases. In addition, the Company is exploring a range of modality platforms and targets that are potentially compatible with its Pfēnex Expression Technology. FDA-Approved PF708 Product On October 4, 2019, the FDA approved the NDA for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo  (teriparatide injection) as the reference drug.  The FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture.  The Company is currently in the process of transferring the NDA to Alvogen pursuant to the Alvogen Agreement, described below, between the companies.  In addition, the Company has been continuing its efforts to obtain an “A” therapeutic equivalence designation for the product relative to its reference drug, Forteo. A determination of therapeutic equivalence may permit the FDA-approved PF708 product to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states.  Consistent with the Company’s interactions with the FDA and the agency’s draft guidance document on demonstrating the therapeutic equivalence of drug-device combination products, the Company has completed a comparative human factors study comparing the FDA-approved PF708 product and Forteo.  This human factors study was designed to further support a finding that the FDA-approved PF708 product is therapeutically equivalent to Forteo. On October 14, 2019, the Company announced the successful completion of its PF708 comparative use human factors study and its submission of the final study report to the FDA.  The study data demonstrate that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo for each critical user task evaluated in the study based on pre-specified statistical analysis of critical patient and caregiver tasks.    The Company believes this submission completes the information package required by the FDA to evaluate the therapeutic equivalence of the PF708 product.  The Company’s collaboration partner, Alvogen, intends to launch the FDA-approved PF708 product in the U.S. upon an FDA decision on the therapeutic equivalence evaluation of the product.   In April 2018, the Company and China NT Pharma Group Company Ltd. (NT Pharma) entered into a Development and License Agreement (NT Pharma Agreement), pursuant to which the Company granted an exclusive license to NT Pharma to commercialize PF708 in Mainland China, Hong Kong, Singapore, Malaysia and Thailand and a non-exclusive license to conduct development activities in such territories with respect to PF708. The Company will be responsible for commercial manufacturing and providing product for commercial sale to NT Pharma. The Company will facilitate this obligation via its commercial partner Alvogen. NT Pharma is responsible for all regulatory submissions, development costs and costs associated with regulatory approvals in such territories. In June 2018, the Company and Alvogen Malta Operations Ltd. (Alvogen) entered into a Development and License Agreement (Alvogen Agreement) pursuant to which Alvogen has the exclusive right to commercialize and manufacture PF708 in the United States. The Company expects Alvogen to launch FDA-approved PF708 in the U.S. upon an FDA rating decision on the therapeutic equivalence evaluation of the product. Following the FDA approval of the NDA for PF708, the FDA-approved PF708 product will be commercialized and manufactured in the U.S. by Alvogen. The Company is currently in the process of transferring the NDA to Alvogen pursuant to its collaboration agreement.   In February 2019, the Company and Alvogen entered into additional agreements, extending Alvogen’s rights to commercialize and manufacture PF708 to include the European Union (EU), certain countries in the Middle East and North Africa (MENA) and to the rest of world (ROW) territories (excluding certain Asian countries granted to NT Pharma). Alvogen is responsible for local activities and for overseeing any clinical development, regulatory, litigation, commercial manufacturing and commercialization activities in these jurisdictions. Collaboration Partner: Jazz Pharmaceuticals Ireland Limited In July 2016, the Company and Jazz announced an agreement under which the Company granted Jazz worldwide rights to develop and commercialize multiple early stage hematology/oncology product candidates, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. In December 2017, the parties amended the Jazz agreement, bringing the total value of payments and potential payments associated with the collaboration to $224.5 million. In addition, the Company may be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement. Pfēnex Expression Technology Licenses: CRM197 The Company has both licenses and supply agreements in place for CRM197, which is a non-toxic mutant of diphtheria toxin.  It is a well-characterized protein and functions as a carrier for polysaccharides and haptens, making them immunogenic.  The Company has developed unique CRM197 production strains based on its Pfēnex Expression Technology platform. As a result of these development efforts, the Company previously entered into commercial licenses for production strains capable of producing CRM197 with both Merck & Co., Inc. and Serum Institute of India Private Ltd. Merck and SIIPL are using the CRM197 produced via the licensed production strain in multiple clinical stage products. Those products currently include Merck’s 15-valent pneumococcal conjugate vaccine, PCV-15 (V114) currently in several ongoing Phase 3 clinical studies and SIIPL’s 10-valent pneumococcal conjugate vaccine Pneumosil® currently in WHO Prequalification and a pentavalent meningococcal conjugate vaccine currently in a Phase 3 clinical study. The CRM197 production strains utilized by both Merck and SIIPL are unique and exclusively licensed to each party. These commercial license agreements with Merck and SIIPL contemplate potential maintenance and milestone fees as well as royalties on net sales. Additionally, as part of the SIIPL commercial license agreement, SIIPL supplies both reagent grade and cGMP CRM197 to Pfenex, which supplies the product to vaccine development-focused pharmaceutical partners.   Arcellx Development, Evaluation and License Agreement The Company previously entered into a development, evaluation and license agreement with Arcellx which provides access to the Pfēnex Expression Technology platform to advance Arcellx’s proprietary sparX proteins that activate, silence and reprogram Antigen- Receptor Complex T cell-based therapies. Under the terms of the agreement, Pfenex is eligible to receive development funding in addition to development, regulatory and commercial milestones ranging from $2.6 million to $18 million for each product incorporating a sparX protein expressed using the Pfēnex Expression Technology, as well as royalties on worldwide sales of any such products. The Company currently has two sparX proteins in development with Arcellx.  As of September 30, 2019, the Company has recorded $1.8 million in revenue related to development for Arcellx. Additional Novel Vaccine and Biosimilar Pipeline Products The Company’s pipeline includes biosimilar candidates to certain reference products, including biosimilar candidates to Lucentis (PF582) and Neulasta (PF529) and two novel anthrax vaccine candidates, Px563L and RPA563, which are funded by the Biomedical Advanced Research and Development Authority (BARDA). In November of 2017, the Company paused development on both PF582 and PF529 and it does not intend to advance PF582 or PF529 without development and commercial collaboration partners. In March 2019 the Company received a notice from BARDA advising it of BARDA’s decision not to exercise development options for cGMP manufacturing, preclinical studies and Phase 1/2b study readiness in connection with the Company’s Px563L and RPA563 novel anthrax vaccine program. Following the receipt of the notice from BARDA and pursuant to discussions with BARDA, the Company deprioritized this program in its portfolio. At the Market Offering Program In March 2018, the Company entered into an equity sales agreement (Sales Agreement) with William Blair & Company, L.L.C. (William Blair) to sell shares of the Company’s common stock having aggregate sales proceeds of up to $20.0 million, from time to time, through an “at the market” equity offering program under which William Blair will act as sales agent. Under the Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. As of September 30, 2019, the Company had not sold any shares under the Sales Agreement. Follow-on Public Offering In May 2018, the Company completed a public offering of common stock in which it sold 7,820,000 shares of its common stock at an offering price of $5.50 per share, which included the full exercise by the underwriters of their option to purchase an additional 1,020,000 shares, pursuant to the Company’s prior shelf registration statement. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $39.5 million.

A portion of revenue is earned from entities located outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s revenue from U.S. and non-U.S. based sources for the nine months ended September 30, 2019 and 2018 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US Revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">877</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,172</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,877</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-US Revenue</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,371</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,199</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,629</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,248</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,570</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,421</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,506</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of September 30, 2019 and December 31, 2018, were determined using the inputs described above and are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Using</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in Active <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and money market funds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,718</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,718</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,718</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,718</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and money market funds</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,420</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,420</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,420</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,420</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,518</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,220</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   the statement of cash flows</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,718</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,420</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Property and equipment consisted of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">372</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and IT equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">451</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchased software</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab and research equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,801</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,154</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">951</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">876</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,128</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other fixed assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, gross</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,297</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,634</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,923</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,963</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,374</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,671</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Total property and equipment assets under capital lease were $1.0 million at both September 30, 2019 and December 31, 2018. Accumulated depreciation related to assets under capital lease as of both dates was $0.2 million. For the three and nine months ended September 30, 2019 and 2018, total depreciation and amortization expense is included in research and development, selling, general and administrative expenses and cost of sales in the accompanying consolidated statements of operations was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">664</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total depreciation and amortization expense</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">968</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">849</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Payment commitments for the Company’s capital leases are summarized as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes stock-based compensation expense:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">999</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,149</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,259</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">793</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,381</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,551</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation from:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">752</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,320</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">793</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,381</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,551</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,155</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,282</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.57</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.47</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled (forfeited)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(522</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.52</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,795</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.73</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.92</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,431</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at September 30, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,245</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.92</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.66</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,156</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at September 30, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,458</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.08</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,865</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The table below sets forth the weighted-average assumptions used to estimate the fair value of stock options:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of options in years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes the computation of basic and diluted net income (loss) per share attributable to common stockholders of the Company:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,082</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,662</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,208</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,770</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute basic and <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   diluted net income (loss) per share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,595</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,437</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,534</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,288</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilutive effect of employee stock option plans</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">903</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dilutive weighted-average common shares outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,498</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,437</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,534</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,288</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per common share</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.34</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.26</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Diluted net income (loss) per common share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.34</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.26</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>

The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding because of their anti-dilutive impact to earnings per share:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,795</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,119</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,854</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,189</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

224500000 18000000 2600000

1800000

20000000

7820000

5.50

1020000 39500000

200000

32700000

200000

3 3 2 3

0.91

0.87

2 2

0.89

2 2

0.70

0.87

877000

1371000

4172000

3877000

14371000

2199000

24249000

7629000

15248000

3570000

28421000

11506000

0.10

11000000

17100000

32718000

56420000

32718000

56420000

372000

367000

498000

451000

464000

375000

9801000

9154000

951000

876000

1128000

328000

83000

13297000

11634000

4923000

3963000

1000000

200000

88000

8000

105000

23000

197000

242000

664000

709000

53000

41000

199000

117000

338000

291000

3750000

4400000

920000

9070000

5211000

4822000

100000

500000

522000

493000

549000

589000

1618000

1748000

525000

302000

855000

1524000

615000 387000 1949000 4265000 713000

1006000

504000

1700000

1000000

700000

2500000 20000000 2 2500000 0.50 0.40

1000000

1500000 0.60 2500000

2500000

2500000 1600000 1600000

400000

1200000

700000 2300000

2300000

2500000

2500000 22500000 2500000

2500000

18500000 5000000 13500000

800000

11000000

177500000 18500000 34000000 125000000 52500000 18500000

The estimated selling price for the pegaspargase product candidate and the hematology/oncology products was determined using an income approach. In determining the estimated selling price, the Company considered costs expected to be incurred for internal labor, burden rates, internal margins, and subcontractors

15000000

10000000

2500000

800000 4200000 P15M P32M P15M P35M

11000000

1800000

13700000

6300000

2700000

P30M

This agreement is a cost-plus fixed fee development contract valued at up to approximately $143.5 million, including a 30-month base period of performance of approximately $15.9 million, and eight option periods valued at a total of approximately $127.6 million. The base period of performance was initially from August 2015 through February 2018 and later extended through September 2018. BARDA exercised additional phases of the development contract effective January 2017, totaling $4.9 million and allowing for the continuing development of Px563L and RPA563. The period of performance for the two option periods was extended through September 2018 and December 2019.

1700000

143500000

15900000

4900000

127600000

This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 whereupon BARDA may immediately terminate the agreement early for convenience or request the Company to stop all or any part of the work for a period of at least 90 days.

200000

1300000

1200000

3800000

92000

202000

1000

295000

various dates through 2021

44000

50000

133000

143000

219000

339000

999000

1149000

408000

404000

1249000

1259000

671000

793000

2381000

2551000

646000

752000

2320000

2395000

25000

41000

61000

156000

4155000

1282000

120000

522000

4795000

4245000

2458000

6.13

4.57

3.47

6.52

5.73

5.92

7.04

P6Y11M1D

P6Y7M28D

P5Y29D

15431000

13156000

5865000

400000

100000

0.015

0.028

0.024

0.027

0.727

0.728

0.726

0.711

0.00

P5Y10M24D

P6Y3M18D

P6Y2M12D

P6Y3M18D

3.01

2.37

5800000

P2Y8M12D

903000

4795000

4119000

59000

70000

4854000

4189000

2500000

11000000

EX-101.SCH 6 pfnx-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Organization and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Cash, Cash Equivalents and Restricted Cash link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Accrued Liabilities link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Significant Research and Development Agreements link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Net Income (Loss) Per Share of Common Stock link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Accrued Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Net Income (Loss) Per Share of Common Stock (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Organization and Summary of Significant Accounting Policies - Summary of Sales Revenue (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Property and Equipment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Property and Equipment - Depreciation and Amortization Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Accrued Liabilities - Components of Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Accrued Liabilities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Significant Research and Development Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Commitments and Contingencies - Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Non-cancelable Leasing Arrangements, Including Facilities Lease (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions used to Estimate Fair Value of Stock Options (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Net Income (Loss) Per Share of Common Stock - Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Net Income (Loss) Per Share of Common Stock - Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 pfnx-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 pfnx-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 pfnx-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Small Business Entity Small Business Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Interactive Data Current Entity Interactive Data Current Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Accounts And Unbilled Receivable Net Current Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Restricted cash Restricted Cash And Cash Equivalents At Carrying Value Accounts and unbilled receivables, net Accounts And Unbilled Receivable Net Current Income tax receivable Income Taxes Receivable Other current assets Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Other long-term assets Other Assets Noncurrent Intangible assets, net Intangible Assets Net Excluding Goodwill Goodwill Goodwill Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Current portion of deferred revenue Deferred Revenue Current Current portion of capital lease obligations Capital Lease Obligations Current Total current liabilities Liabilities Current Deferred revenue, less current portion Deferred Revenue Noncurrent Capital lease obligations, less current portion Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Stockholders’ equity Stockholders Equity [Abstract] Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding Preferred Stock Value Common stock, par value $0.001, 200,000,000 shares authorized; 31,622,914 and 31,467,580 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, outstanding Common Stock Shares Outstanding Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] License License And Service [Member] Service Technology Service [Member] Product Product [Member] Statement [Line Items] Statement [Line Items] Revenue Revenues [Abstract] Total revenue Revenues Cost of revenue Cost Of Revenue Gross profit Gross Profit Operating expense Operating Expenses [Abstract] Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total operating expense Operating Expenses Net income (loss) from operations Operating Income Loss Other income, net Nonoperating Income Expense Net income (loss) Net Income Loss Net income (loss) per common share: Earnings Per Share Basic And Diluted [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Weighted-average common shares used in calculating net income (loss) per share: Weighted Average Number Of Shares Outstanding [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Restricted stock issuance for bonus accrual. Statement Of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Amortization of intangible assets Amortization Of Intangible Assets Stock-based compensation expense Share Based Compensation Loss on disposal of property and equipment Gain Loss On Sale Of Property Plant Equipment Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Accounts and unbilled receivables Increase Decrease In Receivables Other assets Increase Decrease In Other Current Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Deferred revenue Increase Decrease In Deferred Revenue Income tax receivable Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities Net Cash Provided By Used In Investing Activities [Abstract] Acquisitions of property and equipment Payments To Acquire Property Plant And Equipment Purchase of intangible asset Payments To Acquire Intangible Assets Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Repayments of capital lease obligations Repayments Of Long Term Capital Lease Obligations Proceeds from exercise of stock options and other stock issuances Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Payment for taxes related to net share settlement of equity award Payments Related To Tax Withholding For Share Based Compensation Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net (decrease) increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations [Abstract] Beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations End of period Supplemental disclosures of non-cash investing and financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Asset acquisitions in accounts payable and accrued expenses Capital Expenditures Incurred But Not Yet Paid Acquisitions under capital lease obligations Capital Lease Obligations Incurred Restricted stock issuance for bonus accrual Restricted Stock Issuance For Bonus Accrual Supplemental schedule of cash flow information Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Cash paid for taxes Income Taxes Paid Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid in Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Beginning Balance Beginning Balance, Shares Shares Outstanding Restricted stock units, value Stock Issued During Period Value Restricted Stock Award Gross Restricted stock units, shares Stock Issued During Period Shares Restricted Stock Award Gross Issuance of common stock, net of offering costs Stock Issued During Period Value New Issues Issuance of common stock, net of offering costs, shares Stock Issued During Period Shares New Issues Exercise of stock options Stock Issued During Period Value Stock Options Exercised Exercise of stock options, shares Stock Issued During Period Shares Stock Options Exercised Issuance of common stock under employee stock purchase plan Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock under employee stock purchase plan, shares Stock Issued During Period Shares Employee Stock Purchase Plans Stock-based compensation expense Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Offering costs Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Net income (loss) Ending Balance Ending Balance, Shares Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Summary of Significant Accounting Policies Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Cash, cash equivalents and restricted cash. Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract] Cash, Cash Equivalents and Restricted Cash Cash Cash Equivalents And Restricted Cash [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Intangible Assets Intangible Assets Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Liabilities Accounts Payable And Accrued Liabilities Disclosure [Text Block] Research And Development [Abstract] Significant Research and Development Agreements Research Development And Computer Software Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Net Income (Loss) Per Share of Common Stock Earnings Per Share [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Business Activities and Organization Business Description And Accounting Policies [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Use of Estimates Use Of Estimates Risks And Uncertainties [Policy Text Block] Risk and Uncertainties Risks And Uncertainties Policy [Text Block] Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Concentrations Concentration Risk Credit Risk Fair Value Measurements Fair Value Measurement Policy Policy [Text Block] Revenue Revenue Recognition Policy [Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Summary of Sales Revenue Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block] Schedule of Assets Measured at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of cash cash equivalents and restricted cash. Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Summary of Property and Equipment Property Plant And Equipment [Text Block] Summary of Intangible Assets Schedule Of Finite Lived Intangible Assets Table [Text Block] Components of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Summary of Capital Lease Schedule Of Future Minimum Lease Payments For Capital Leases Table [Text Block] Summary of Stock-Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Company's Stock Option Activity EX-101.PRE 10 pfnx-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R25.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2019

Payables And Accruals [Abstract]

Components of Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2019		December 31, 2018
	(in thousands)
Accrued vacation	$	522	$	493
Deferred rent		549		589
Accrued bonuses		1,618		1,748
Other accrued employee-related liabilities		525		302
Accrued professional fees		855		1,524
Accrued supplier liability		615		387
Accrued subcontractor costs		1,949		4,265
Obligation to Alvogen for raw materials		713		—
Other accrued liabilities		1,006		504
Total accrued liabilities	$	8,352	$	9,812

XML 12 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Assets Measured at Fair Value on Recurring Basis

			Fair Value Measurements at Reporting Date Using
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(in thousands)
September 30, 2019
Cash and money market funds	$	32,718	$	32,718	$	—	$	—
Total assets measured at fair value	$	32,718	$	32,718	$	—	$	—
December 31, 2018
Cash and money market funds	$	56,420	$	56,420	$	—	$	—
Total assets measured at fair value	$	56,420	$	56,420	$	—	$	—

XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R29.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2019 USD ($) Financial_Institution Customer	Sep. 30, 2018 USD ($) Customer	Sep. 30, 2019 USD ($) Financial_Institution Customer	Sep. 30, 2018 USD ($) Customer	Dec. 31, 2018 USD ($) Financial_Institution Customer	Jan. 31, 2017 USD ($)
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proceeds from sale of common stock							$ 39,522,000
Accumulated deficit				$ (209,508,000)		$ (209,508,000)		$ (201,300,000)
Restricted cash collateral									$ 200,000
Restricted cash				$ 200,000		$ 200,000		$ 200,000
Number of financial institutions cash and cash equivalents held \| Financial_Institution				3		3		3
Number of customers accounted for receivables \| Customer				2		2		3
Allowance for doubtful accounts receivable				$ 0		$ 0		$ 0
Revenue recognized				17,100,000		11,000,000
Reagent Protein Product [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Warranty reserve accrual				0		0		0
Level 1 [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Liabilities				0		0		0
Level 2 [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Liabilities				0		0		0
Assets				0		0		0
Level 3 [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Liabilities				0		0		0
Assets				$ 0		$ 0		$ 0
Sales Revenue, Net [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Number of customers accounted for revenue \| Customer				2	2	2	2
Credit Availability Concentration Risk [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Cash				$ 32,700,000		$ 32,700,000
Restricted cash				$ 200,000		$ 200,000
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage						91.00%		87.00%
Customer Concentration Risk [Member] \| Sales Revenue, Net [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage				89.00%	89.00%	70.00%	87.00%
Follow On Public Offering [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues \| shares	7,820,000
Offering price \| $ / shares	$ 5.50
Option to purchase an additional shares to underwriters \| shares	1,020,000
Net proceeds from public offering, after underwriting discounts and commissions and offering costs	$ 39,500,000
Jazz Pharmaceuticals Ireland Limited [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Collaboration agreement potential payments			$ 224,500,000
Revenue recognized from milestone				$ 11,000,000	$ 1,800,000	$ 13,700,000	$ 6,300,000
Revenue recognized								$ 2,700,000
Arcellx [Member] \| Development, Evaluation and License Agreement [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Revenue recognized from milestone						1,800,000
Maximum [Member] \| Arcellx [Member] \| Development, Evaluation and License Agreement [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Amount of development fund eligible to receive						$ 2,600,000
Maximum [Member] \| William Blair Company LLC [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Proceeds from sale of common stock		$ 20,000,000
Minimum [Member] \| Geographic Concentration Risk [Member] \| Sales Revenue, Net [Member] \| Malta [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage				10.00%		10.00%
Minimum [Member] \| Geographic Concentration Risk [Member] \| Sales Revenue, Net [Member] \| Ireland [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Concentration of risk percentage				10.00%	10.00%	10.00%	10.00%
Minimum [Member] \| Arcellx [Member] \| Development, Evaluation and License Agreement [Member]
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Amount of development fund eligible to receive						$ 18,000,000

XML 15 R48.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 0	$ 0

XML 16 R40.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Additional Information (Detail) - Liasion Agreeement With Alvogen [Member] - Alvogen Malta Operations Ltd [Member] - USD ($) $ in Millions	1 Months Ended	9 Months Ended
	May 31, 2019	Sep. 30, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment received for raw materials	$ 1.7
Raw materials shipped to Alvogen		$ 1.0
Balance due to Alvogen		$ 0.7

XML 17 R44.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$ 671	$ 793	$ 2,381	$ 2,551
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	44	50	133	143
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	219	339	999	1,149
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	408	404	1,249	1,259
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	646	752	2,320	2,395
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation expense	$ 25	$ 41	$ 61	$ 156

XML 18 R51.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
	Oct. 31, 2019	Dec. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Subsequent Event [Line Items]
Revenue			$ 15,248	$ 3,570	$ 28,421	$ 11,506
License
Subsequent Event [Line Items]
Revenue			11,562	1,874	20,430	6,869
Alvogen Malta Operations Ltd [Member]
Subsequent Event [Line Items]
Revenue					1,000
Alvogen Malta Operations Ltd [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Revenue recognized from milestone	$ 2,500
Alvogen Malta Operations Ltd [Member] \| License \| Forecast [Member]
Subsequent Event [Line Items]
Revenue		$ 2,500
Jazz Pharmaceuticals Ireland Limited [Member]
Subsequent Event [Line Items]
Revenue recognized from milestone			11,000	$ 1,800	$ 13,700	$ 6,300
Jazz Pharmaceuticals Ireland Limited [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Payment received for achievement of development milestone	$ 11,000
Jazz Pharmaceuticals Ireland Limited [Member] \| License
Subsequent Event [Line Items]
Revenue			$ 11,000

XML 19 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2017	$ 57,763	$ 24	$ 219,446	$ (161,707)
Beginning Balance, Shares at Dec. 31, 2017		23,548,000
Restricted stock units, value	57		57
Restricted stock units, shares		17,000
Issuance of common stock under employee stock purchase plan	55		55
Issuance of common stock under employee stock purchase plan, shares		19,000
Stock-based compensation expense	909		909
Net income (loss)	(11,027)			(11,027)
Ending Balance at Mar. 31, 2018	47,757	$ 24	220,467	(172,734)
Ending Balance, Shares at Mar. 31, 2018		23,584,000
Beginning Balance at Dec. 31, 2017	57,763	$ 24	219,446	(161,707)
Beginning Balance, Shares at Dec. 31, 2017		23,548,000
Net income (loss)	(32,770)
Ending Balance at Sep. 30, 2018	67,319	$ 32	261,764	(194,477)
Ending Balance, Shares at Sep. 30, 2018		31,461,000
Beginning Balance at Mar. 31, 2018	47,757	$ 24	220,467	(172,734)
Beginning Balance, Shares at Mar. 31, 2018		23,584,000
Issuance of common stock, net of offering costs	39,522	$ 8	39,514
Issuance of common stock, net of offering costs, shares		7,820,000
Exercise of stock options	14		14
Exercise of stock options, shares		17,000
Stock-based compensation expense	849		849
Net income (loss)	(11,081)			(11,081)
Ending Balance at Jun. 30, 2018	77,061	$ 32	260,844	(183,815)
Ending Balance, Shares at Jun. 30, 2018		31,421,000
Exercise of stock options	65		65
Exercise of stock options, shares		20,000
Issuance of common stock under employee stock purchase plan	60		60
Issuance of common stock under employee stock purchase plan, shares		20,000
Stock-based compensation expense	794		794
Offering costs	1		1
Net income (loss)	(10,662)			(10,662)
Ending Balance at Sep. 30, 2018	67,319	$ 32	261,764	(194,477)
Ending Balance, Shares at Sep. 30, 2018		31,461,000
Beginning Balance at Dec. 31, 2018	61,137	$ 32	262,405	(201,300)
Beginning Balance, Shares at Dec. 31, 2018		31,468,000
Exercise of stock options	60		60
Exercise of stock options, shares		15,000
Issuance of common stock under employee stock purchase plan	53		53
Issuance of common stock under employee stock purchase plan, shares		17,000
Stock-based compensation expense	880		880
Net income (loss)	(3,661)			(3,661)
Ending Balance at Mar. 31, 2019	58,469	$ 32	263,398	(204,961)
Ending Balance, Shares at Mar. 31, 2019		31,500,000
Beginning Balance at Dec. 31, 2018	$ 61,137	$ 32	262,405	(201,300)
Beginning Balance, Shares at Dec. 31, 2018		31,468,000
Exercise of stock options, shares	120,000
Net income (loss)	$ (8,208)
Ending Balance at Sep. 30, 2019	55,835	$ 32	265,311	(209,508)
Ending Balance, Shares at Sep. 30, 2019		31,623,000
Beginning Balance at Mar. 31, 2019	58,469	$ 32	263,398	(204,961)
Beginning Balance, Shares at Mar. 31, 2019		31,500,000
Exercise of stock options	142		142
Exercise of stock options, shares		58,000
Stock-based compensation expense	830		830
Net income (loss)	(7,629)			(7,629)
Ending Balance at Jun. 30, 2019	51,812	$ 32	264,370	(212,590)
Ending Balance, Shares at Jun. 30, 2019		31,558,000
Exercise of stock options	214		214
Exercise of stock options, shares		47,000
Issuance of common stock under employee stock purchase plan	56		56
Issuance of common stock under employee stock purchase plan, shares		18,000
Stock-based compensation expense	671		671
Net income (loss)	3,082			3,082
Ending Balance at Sep. 30, 2019	$ 55,835	$ 32	$ 265,311	$ (209,508)
Ending Balance, Shares at Sep. 30, 2019		31,623,000

XML 20 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 32,518	$ 56,220
Restricted cash	200	200
Accounts and unbilled receivables, net	16,215	5,171
Income tax receivable	53	207
Other current assets	2,357	1,851
Total current assets	51,343	63,649
Property and equipment, net	8,374	7,671
Other long-term assets	170	133
Intangible assets, net	3,859	4,248
Goodwill	5,577	5,577
Total assets	69,323	81,278
Current liabilities
Accounts payable	2,233	2,005
Accrued liabilities	8,352	9,812
Current portion of deferred revenue	105	5,317
Current portion of capital lease obligations	269	316
Total current liabilities	10,959	17,450
Deferred revenue, less current portion	2,500	2,500
Capital lease obligations, less current portion	29	191
Total liabilities	13,488	20,141
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $0.001, 200,000,000 shares authorized; 31,622,914 and 31,467,580 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	32	32
Additional paid-in capital	265,311	262,405
Accumulated deficit	(209,508)	(201,300)
Total stockholders’ equity	55,835	61,137
Total liabilities and stockholders’ equity	$ 69,323	$ 81,278

XML 21 R17.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Share of Common Stock

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Net Income (Loss) Per Share of Common Stock

11. Net Income (Loss) Per Share of Common Stock

The following table summarizes the computation of basic and diluted net income (loss) per share attributable to common stockholders of the Company:

	Three Months Ended September 30,					Nine months Ended September 30,
(in thousands, except per share data)	2019		2018			2019			2018
Net income (loss)	$	3,082	$	(10,662	)	$	(8,208	)	$	(32,770	)
Weighted average shares used to compute basic and diluted net income (loss) per share		31,595		31,437			31,534			27,288
Dilutive effect of employee stock option plans		903		—			—			—
Dilutive weighted-average common shares outstanding		32,498		31,437			31,534			27,288
Basic net income (loss) per common share	$	0.10	$	(0.34	)	$	(0.26	)	$	(1.20	)
Diluted net income (loss) per common share	$	0.09	$	(0.34	)	$	(0.26	)	$	(1.20	)

	September 30,
	2019		2018
	(in thousands)
Options to purchase common stock		4,795		4,119
Employee stock purchase plan		59		70
Total		4,854		4,189

XML 22 R13.htm IDEA: XBRL DOCUMENT

Significant Research and Development Agreements

9 Months Ended

Sep. 30, 2019

Research And Development [Abstract]

Significant Research and Development Agreements

7. Significant Research and Development Agreements

Collaboration Agreements

Alvogen

NT Pharma

The upfront payment of $2.5 million was not fixed and determinable. Due to a contract clause, the $2.5 million could be payable to NT Pharma if the NDA was not filed by a specified date and additional deliverables were required after NDA submission. Therefore, the upfront payment was recorded as deferred revenue as of December 31, 2018. The deliverables were satisfied during the first quarter of 2019, at which time the upfront payment was recognized as revenue.

Jazz

Funding Agreements

The U.S. Department of Health and Human Services

XML 23 R38.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 100	$ 100	$ 389	$ 400
Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months	500		500
Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two	500		500
Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three	500		500
Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four	500		500
Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five	$ 500		$ 500

XML 24 R30.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Summary of Sales Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Concentration Risk [Line Items]
Revenue	$ 15,248	$ 3,570	$ 28,421	$ 11,506
Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue	15,248	3,570	28,421	11,506
Geographic Concentration Risk [Member] \| US [Member]
Concentration Risk [Line Items]
Revenue	877	1,371	4,172	3,877
Geographic Concentration Risk [Member] \| Non - US [Member]
Concentration Risk [Line Items]
Revenue	$ 14,371	$ 2,199	$ 24,249	$ 7,629

XML 25 R34.htm IDEA: XBRL DOCUMENT

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 13,297	$ 11,634
Less: accumulated depreciation and amortization	(4,923)	(3,963)
Property and equipment, net	8,374	7,671
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	372	367
Computers and IT equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	498	451
Purchased Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	464	375
Lab and Research Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	9,801	9,154
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	951	876
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	1,128	328
Other Fixed Assets [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 83	$ 83

XML 26 R50.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Share of Common Stock - Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding (Detail) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from the computation of diluted shares	4,854	4,189
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from the computation of diluted shares	4,795	4,119
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from the computation of diluted shares	59	70

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

10. Income Taxes

XML 28 R12.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

9 Months Ended

Sep. 30, 2019

Payables And Accruals [Abstract]

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2019		December 31, 2018
	(in thousands)
Accrued vacation	$	522	$	493
Deferred rent		549		589
Accrued bonuses		1,618		1,748
Other accrued employee-related liabilities		525		302
Accrued professional fees		855		1,524
Accrued supplier liability		615		387
Accrued subcontractor costs		1,949		4,265
Obligation to Alvogen for raw materials		713		—
Other accrued liabilities		1,006		504
Total accrued liabilities	$	8,352	$	9,812

XML 29 R7.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Business Activities and Organization

Pfenex Inc. (the Company or Pfenex) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology^® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of potential therapeutic equivalents, vaccines, biologics, and biosimilars. On October 4, 2019, the U.S. Food and Drug Administration (FDA) approved the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo^® (teriparatide injection) as the reference drug. Like Forteo, this FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. Marketing authorization applications are pending in other jurisdictions. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals Ireland Limited (Jazz) including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. Both PF743 and PF745 are being developed for the treatment of Acute Lymphoblastic Leukemia (ALL) and other hematological malignancies. The Company also uses its Pfēnex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccine candidates under development by Merck & Co, Inc. (Merck) and Serum Institute of India Private Ltd. (SIIPL). Both have licenses to the Pfēnex Expression Technology for the production of CRM197 for use in conjugate vaccine products. The Company is focused developing its portfolio of partnered as well as wholly-owned peptides and complex proteins. Currently, the Company is exploring opportunities to develop novel modalities through an assessment program designed to evaluate and pursue validated biologic pathways that are differentially druggable via a selected modality in specific diseases. In addition, the Company is exploring a range of modality platforms and targets that are potentially compatible with its Pfēnex Expression Technology.

FDA-Approved PF708 Product

In February 2019, the Company and Alvogen entered into additional agreements, extending Alvogen’s rights to commercialize and manufacture PF708 to include the European Union (EU), certain countries in the Middle East and North Africa (MENA) and to the rest of world (ROW) territories (excluding certain Asian countries granted to NT Pharma). Alvogen is responsible for local activities and for overseeing any clinical development, regulatory, litigation, commercial manufacturing and commercialization activities in these jurisdictions.

Collaboration Partner: Jazz Pharmaceuticals Ireland Limited

Pfēnex Expression Technology Licenses: CRM197

Arcellx Development, Evaluation and License Agreement

Additional Novel Vaccine and Biosimilar Pipeline Products

At the Market Offering Program

Follow-on Public Offering

Basis of Presentation

Use of Estimates

Risk and Uncertainties

Cash and Cash Equivalents

Concentrations

	Three Months Ended September 30,				Nine months Ended September 30,
(in thousands)	2019		2018		2019		2018
US Revenue	$	877	$	1,371	$	4,172	$	3,877
Non-US Revenue		14,371		2,199		24,249		7,629
	$	15,248	$	3,570	$	28,421	$	11,506

Fair Value of Financial Instruments

•

Revenue

Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.

The Company’s reagent protein products are primarily comprised of internally developed reagent protein products. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. As of September 30, 2019, the Company has had minimal product returns related to reagent protein product sales. Therefore, no reserve for warranty and return rights was recorded as of September 30, 2019 and December 31, 2018.

Recently Issued Accounting Pronouncements Not Yet Adopted

XML 30 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 221 320 1 false 66 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.pfenex.com/20190930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.pfenex.com/20190930/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.pfenex.com/20190930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://www.pfenex.com/20190930/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Cash Flows Sheet http://www.pfenex.com/20190930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.pfenex.com/20190930/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 100060 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Fair Value Measurements Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 8 false false R9.htm 100080 - Disclosure - Cash, Cash Equivalents and Restricted Cash Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureCashCashEquivalentsAndRestrictedCash Cash, Cash Equivalents and Restricted Cash Notes 9 false false R10.htm 100090 - Disclosure - Property and Equipment Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment Notes 10 false false R11.htm 100100 - Disclosure - Intangible Assets Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureIntangibleAssets Intangible Assets Notes 11 false false R12.htm 100110 - Disclosure - Accrued Liabilities Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureAccruedLiabilities Accrued Liabilities Notes 12 false false R13.htm 100120 - Disclosure - Significant Research and Development Agreements Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureSignificantResearchAndDevelopmentAgreements Significant Research and Development Agreements Notes 13 false false R14.htm 100130 - Disclosure - Commitments and Contingencies Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 100140 - Disclosure - Stock-Based Compensation Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 100150 - Disclosure - Income Taxes Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 100160 - Disclosure - Net Income (Loss) Per Share of Common Stock Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureNetIncomeLossPerShareOfCommonStock Net Income (Loss) Per Share of Common Stock Notes 17 false false R18.htm 100170 - Disclosure - Subsequent Events Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 18 false false R19.htm 100180 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.pfenex.com/20190930/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 100190 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosureFairValueMeasurements 21 false false R22.htm 100210 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureCashCashEquivalentsAndRestrictedCashTables Cash, Cash Equivalents and Restricted Cash (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosureCashCashEquivalentsAndRestrictedCash 22 false false R23.htm 100220 - Disclosure - Property and Equipment (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosurePropertyAndEquipment 23 false false R24.htm 100230 - Disclosure - Intangible Assets (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosureIntangibleAssets 24 false false R25.htm 100240 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureAccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosureAccruedLiabilities 25 false false R26.htm 100250 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosureCommitmentsAndContingencies 26 false false R27.htm 100260 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosureStockBasedCompensation 27 false false R28.htm 100270 - Disclosure - Net Income (Loss) Per Share of Common Stock (Tables) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureNetIncomeLossPerShareOfCommonStockTables Net Income (Loss) Per Share of Common Stock (Tables) Tables http://www.pfenex.com/20190930/taxonomy/role/DisclosureNetIncomeLossPerShareOfCommonStock 28 false false R29.htm 100280 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Organization and Summary of Significant Accounting Policies - Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - Organization and Summary of Significant Accounting Policies - Summary of Sales Revenue (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSummaryOfSalesRevenueDetail Organization and Summary of Significant Accounting Policies - Summary of Sales Revenue (Detail) Details 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) Details 31 false false R32.htm 100310 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureCashCashEquivalentsAndRestrictedCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Details 32 false false R33.htm 100320 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureCashCashEquivalentsAndRestrictedCashAdditionalInformationDetail Cash, Cash Equivalents and Restricted Cash - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail Property and Equipment - Summary of Property and Equipment (Detail) Details 34 false false R35.htm 100340 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Property and Equipment - Depreciation and Amortization Expense (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosurePropertyAndEquipmentDepreciationAndAmortizationExpenseDetail Property and Equipment - Depreciation and Amortization Expense (Detail) Details 36 false false R37.htm 100360 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureIntangibleAssetsSummaryOfIntangibleAssetsDetail Intangible Assets - Summary of Intangible Assets (Detail) Details 37 false false R38.htm 100370 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail Intangible Assets - Additional Information (Detail) Details 38 false false R39.htm 100380 - Disclosure - Accrued Liabilities - Components of Accrued Liabilities (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureAccruedLiabilitiesComponentsOfAccruedLiabilitiesDetail Accrued Liabilities - Components of Accrued Liabilities (Detail) Details 39 false false R40.htm 100390 - Disclosure - Accrued Liabilities - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureAccruedLiabilitiesAdditionalInformationDetail Accrued Liabilities - Additional Information (Detail) Details 40 false false R41.htm 100400 - Disclosure - Significant Research and Development Agreements - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureSignificantResearchAndDevelopmentAgreementsAdditionalInformationDetail Significant Research and Development Agreements - Additional Information (Detail) Details 41 false false R42.htm 100410 - Disclosure - Commitments and Contingencies - Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Non-cancelable Leasing Arrangements, Including Facilities Lease (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfEstimatedFutureAnnualMinimumLeasePaymentObligationsUnderNonCancelableLeasingArrangementsIncludingFacilitiesLeaseDetail Commitments and Contingencies - Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Non-cancelable Leasing Arrangements, Including Facilities Lease (Detail) Details 42 false false R43.htm 100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 43 false false R44.htm 100430 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) Details 44 false false R45.htm 100440 - Disclosure - Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfCompanySStockOptionActivityDetail Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail) Details 45 false false R46.htm 100450 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 46 false false R47.htm 100460 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions used to Estimate Fair Value of Stock Options (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsDetail Stock-Based Compensation - Weighted-Average Assumptions used to Estimate Fair Value of Stock Options (Detail) Details 47 false false R48.htm 100470 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 48 false false R49.htm 100480 - Disclosure - Net Income (Loss) Per Share of Common Stock - Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureNetIncomeLossPerShareOfCommonStockComputationOfBasicAndDilutedNetIncomeLossPerShareAttributableToCommonStockholdersDetail Net Income (Loss) Per Share of Common Stock - Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) Details http://www.pfenex.com/20190930/taxonomy/role/DisclosureNetIncomeLossPerShareOfCommonStockTables 49 false false R50.htm 100490 - Disclosure - Net Income (Loss) Per Share of Common Stock - Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureNetIncomeLossPerShareOfCommonStockSummaryOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationOfDilutedSharesOutstandingDetail Net Income (Loss) Per Share of Common Stock - Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding (Detail) Details http://www.pfenex.com/20190930/taxonomy/role/DisclosureNetIncomeLossPerShareOfCommonStockTables 50 false false R51.htm 100500 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.pfenex.com/20190930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 51 false false All Reports Book All Reports pfnx-20190930.xml pfnx-20190930.xsd pfnx-20190930_cal.xml pfnx-20190930_def.xml pfnx-20190930_lab.xml pfnx-20190930_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true XML 31 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	200,000,000	200,000,000
Common stock, shares issued	31,622,914	31,467,580
Common stock, outstanding	31,622,914	31,467,580

XML 32 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and money market funds	$ 32,718,000	$ 56,420,000
Total assets measured at fair value	32,718,000	56,420,000
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and money market funds	32,718,000	56,420,000
Total assets measured at fair value	32,718,000	56,420,000
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	$ 0	$ 0

XML 33 R35.htm IDEA: XBRL DOCUMENT

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Property and equipment assets under capital lease	$ 1.0	$ 1.0
Accumulated depreciation related to assets under capital lease	$ 0.2	$ 0.2

EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 35 R39.htm IDEA: XBRL DOCUMENT v3.19.3

Accrued Liabilities - Components of Accrued Liabilities (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Other Liabilities Disclosure [Abstract]

Accrued vacation $ 522 $ 493

Deferred rent 549 589

Accrued bonuses 1,618 1,748

Other accrued employee-related liabilities 525 302

Accrued professional fees 855 1,524

Accrued supplier liability 615 387

Accrued subcontractor costs 1,949 4,265

Obligation to Alvogen for raw materials 713

Other accrued liabilities 1,006 504

Total accrued liabilities $ 8,352 $ 9,812

X

- Definition
Accrued Liabilities To Suppliers Current
+ References
No definition available.
+ Details

Name: pfnx_AccruedLiabilitiesToSuppliersCurrent

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Subcontractor Fees
+ References
No definition available.
+ Details

Name: pfnx_AccruedSubcontractorFees

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued supplier obligation current.
+ References
No definition available.
+ Details

Name: pfnx_AccruedSupplierObligationCurrent

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765
+ Details

Name: us-gaap_AccruedBonusesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-SubTopic 10
-Section 25
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765
+ Details

Name: us-gaap_AccruedVacationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 25
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707
+ Details

Name: us-gaap_DeferredRentCreditCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherEmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R28.htm IDEA: XBRL DOCUMENT v3.19.3

Net Income (Loss) Per Share of Common Stock (Tables)
9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders
The following table summarizes the computation of basic and diluted net income (loss) per share attributable to common stockholders of the Company:

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands, except per share data)

2019

2018

2019

2018

Net income (loss)

$

3,082

$

(10,662

)

$

(8,208

)

$

(32,770

)

Weighted average shares used to compute basic and

 diluted net income (loss) per share

31,595

31,437

31,534

27,288

Dilutive effect of employee stock option plans

903

—

—

—

Dilutive weighted-average common shares outstanding

32,498

31,437

31,534

27,288

Basic net income (loss) per common share

$

0.10

$

(0.34

)

$

(0.26

)

$

(1.20

)

Diluted net income (loss) per common share

$

0.09

$

(0.34

)

$

(0.26

)

$

(1.20

)

Summary of Potentially Dilutive Securities Outstanding Excluded From Computation of Diluted Shares Outstanding
The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding because of their anti-dilutive impact to earnings per share:

September 30,

2019

2018

(in thousands)

Options to purchase common stock

4,795

4,119

Employee stock purchase plan

59

70

Total

4,854

4,189

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R24.htm IDEA: XBRL DOCUMENT v3.19.3

Intangible Assets (Tables)
9 Months Ended

Sep. 30, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets
Intangible assets consisted of the following:

September 30,

2019

December 31,

2018

(in thousands)

Customer relationships

$

3,750

$

3,750

Developed technology

4,400

4,400

Trade names

920

920

Total intangible assets, gross

9,070

9,070

Less: Accumulated amortization

(5,211

)

(4,822

)

Total intangible assets, net

$

3,859

$

4,248

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Organization and Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Sales Revenue
A portion of revenue is earned from entities located outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s revenue from U.S. and non-U.S. based sources for the nine months ended September 30, 2019 and 2018 is as follows:

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands)

2019

2018

2019

2018

US Revenue

$

877

$

1,371

$

4,172

$

3,877

Non-US Revenue

14,371

2,199

24,249

7,629

$

15,248

$

3,570

$

28,421

$

11,506

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R41.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Research and Development Agreements - Additional Information (Detail)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended

Oct. 31, 2019

USD ($)

Sep. 30, 2019

USD ($)

May 31, 2019

USD ($)

Feb. 28, 2019

Jun. 30, 2018

USD ($)

Milestone

Apr. 30, 2018

USD ($)

Dec. 31, 2017

USD ($)

Jan. 31, 2017

USD ($)

Aug. 31, 2015

USD ($)

Sep. 30, 2019

USD ($)

Sep. 30, 2018

USD ($)

Jun. 30, 2017

Sep. 30, 2019

USD ($)

Sep. 30, 2018

USD ($)

Dec. 31, 2018

USD ($)

May 31, 2018

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue $ 15,248 $ 3,570 $ 28,421 $ 11,506

Obligation to Alvogen for raw materials $ 713 713 713

Deferred revenue recognized 17,100 11,000

Biomedical Advanced Research And Development Authority [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue 200 1,300 $ 1,200 3,800

Funding Agreement [Member] | U.S. Department of Health and Human Services [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Base program period 30 months

Agreement description This agreement is a cost-plus fixed fee development contract valued at up to approximately $143.5 million, including a 30-month base period of performance of approximately $15.9 million, and eight option periods valued at a total of approximately $127.6 million. The base period of performance was initially from August 2015 through February 2018 and later extended through September 2018. BARDA exercised additional phases of the development contract effective January 2017, totaling $4.9 million and allowing for the continuing development of Px563L and RPA563. The period of performance for the two option periods was extended through September 2018 and December 2019.

Amount of contract eligible for payments $ 1,700

Total amount of contract $ 143,500

Agreement termination description This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 whereupon BARDA may immediately terminate the agreement early for convenience or request the Company to stop all or any part of the work for a period of at least 90 days.

PF708 Drug Substance Batches and Pen Components [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue 2,953 357 $ 4,836 816

Base Period Performance Contracts [Member] | Funding Agreement [Member] | U.S. Department of Health and Human Services [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total amount of contract $ 4,900 15,900

Option Period Contracts [Member] | Funding Agreement [Member] | U.S. Department of Health and Human Services [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Total amount of contract $ 127,600

Alvogen Malta Operations Ltd [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment $ 2,500

Number of development milestone | Milestone 2

Upfront payments from development milestone $ 2,500

Percentage of gross profit received from rating of therapeutic equivalent 50.00%

Percentage of gross profit received without rating of therapeutic equivalent 40.00%

Revenue 1,000

Upfront and Milestone Payments 1,500

Percentage of gross profit received from geography basis 60.00%

Expected Reimbursable Costs 1,600 1,600

Alvogen Malta Operations Ltd [Member] | PF708 Drug Substance Batches and Pen Components [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue 2,300 2,300

Collaboration agreement, transaction amount $ 2,300

Alvogen Malta Operations Ltd [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue recognized from milestone $ 2,500

Alvogen Malta Operations Ltd [Member] | Unbilled Revenues [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Unbilled Receivables, Current 400 400 400

Alvogen Malta Operations Ltd [Member] | Billed Revenues [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Invoiced bills receivable 1,200 1,200 1,200

Alvogen Malta Operations Ltd [Member] | NDA [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment $ 2,500

Deferred revenue 2,500

One Time Support Payment 2,500

Alvogen Malta Operations Ltd [Member] | NDA [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue recognized from milestone 2,500

Alvogen Malta Operations Ltd [Member] | Support And Regulatory Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional payment $ 20,000

Alvogen Malta Operations Ltd [Member] | Liasion Agreeement With Alvogen [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment Received for Raw Materials $ 1,700

Raw Materials Shipped To Alvogen 1,000

Obligation to Alvogen for raw materials 700 700 700

NT Pharma Agreement [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment $ 2,500

NT Pharma Agreement [Member] | NDA [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment 2,500

Deferred revenue 2,500

NT Pharma Agreement [Member] | Research and Development, Regulatory and Sales Related Milestones [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional payment $ 22,500

Jazz Pharmaceuticals Ireland Limited [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment $ 5,000

Revenue recognized from milestone 11,000 $ 1,800 $ 13,700 $ 6,300

Upfront and milestone payment total 18,500

Payments of development achievement 13,500

Estimated selling price determination method The estimated selling price for the pegaspargase product candidate and the hematology/oncology products was determined using an income approach. In determining the estimated selling price, the Company considered costs expected to be incurred for internal labor, burden rates, internal margins, and subcontractors

Upfront and option payment 15,000

Deferred revenue recognized $ 2,700

Jazz Pharmaceuticals Ireland Limited [Member] | Minimum [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Product development period 15 months 15 months

Jazz Pharmaceuticals Ireland Limited [Member] | Maximum [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Product development period 35 months 32 months

Jazz Pharmaceuticals Ireland Limited [Member] | Pegaspargase Product [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue recognition, selling price 10,000

Jazz Pharmaceuticals Ireland Limited [Member] | Hematology Product [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenue recognition, selling price 2,500

Remaining upfront payment 4,200 $ 4,200 $ 4,200

Jazz Pharmaceuticals Ireland Limited [Member] | Research and Development, Regulatory and Sales Related Milestones [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Additional payment 177,500

Jazz Pharmaceuticals Ireland Limited [Member] | Research and Development Milestones [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payment $ 800

Revenue recognized from milestone $ 11,000 $ 800

Milestone payments 18,500

Jazz Pharmaceuticals Ireland Limited [Member] | Research and Development Milestones [Member] | Subsequent Event [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Payment Received for Raw Materials $ 11,000

Jazz Pharmaceuticals Ireland Limited [Member] | Regulatory Milestones [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments 34,000

Jazz Pharmaceuticals Ireland Limited [Member] | Sales Milestones [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments 125,000

Jazz Pharmaceuticals Ireland Limited [Member] | Non-sales-related Milestones [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments 52,500

Jazz Pharmaceuticals Ireland Limited [Member] | Substantive Non Sales Related Milestone [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Milestone payments $ 18,500

X

- Definition
Accrued supplier obligation current.
+ References
No definition available.
+ Details

Name: pfnx_AccruedSupplierObligationCurrent

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Additional milestone payments upon achievement of certain development and regulatory milestones.
+ References
No definition available.
+ Details

Name: pfnx_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Base program period.
+ References
No definition available.
+ Details

Name: pfnx_BaseProgramPeriod

Namespace Prefix: pfnx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Collaboration agreement transaction amount.
+ References
No definition available.
+ Details

Name: pfnx_CollaborationAgreementTransactionAmount

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Expected reimbursable costs.
+ References
No definition available.
+ Details

Name: pfnx_ExpectedReimbursableCosts

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Milestone payments upon achievement of certain development milestone.
+ References
No definition available.
+ Details

Name: pfnx_MilestonePaymentsUponAchievementOfCertainDevelopmentMilestone

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of development milestone.
+ References
No definition available.
+ Details

Name: pfnx_NumberOfDevelopmentMilestone

Namespace Prefix: pfnx_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
One time support payment.
+ References
No definition available.
+ Details

Name: pfnx_OneTimeSupportPayment

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Payments upon achievement of development.
+ References
No definition available.
+ Details

Name: pfnx_PaymentsUponAchievementOfDevelopment

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Percentage of gross profit received from geography basis.
+ References
No definition available.
+ Details

Name: pfnx_PercentageOfGrossProfitReceivedFromGeographyBasis

Namespace Prefix: pfnx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of gross profit received from rating of therapeutic equivalent.
+ References
No definition available.
+ Details

Name: pfnx_PercentageOfGrossProfitReceivedFromRatingOfTherapeuticEquivalent

Namespace Prefix: pfnx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of gross profit received without rating of therapeutic equivalent.
+ References
No definition available.
+ Details

Name: pfnx_PercentageOfGrossProfitReceivedWithoutRatingOfTherapeuticEquivalent

Namespace Prefix: pfnx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Product development period.
+ References
No definition available.
+ Details

Name: pfnx_ProductDevelopmentPeriod

Namespace Prefix: pfnx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Remaining upfront payments.
+ References
No definition available.
+ Details

Name: pfnx_RemainingUpfrontPayments

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Upfront and milestone payment.
+ References
No definition available.
+ Details

Name: pfnx_UpfrontAndMilestonePayment

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount provides upfront payment and mile stone payments.
+ References
No definition available.
+ Details

Name: pfnx_UpfrontAndMilestonePayments

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Upfront and option payment.
+ References
No definition available.
+ Details

Name: pfnx_UpfrontAndOptionPayment

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Upfront payments.
+ References
No definition available.
+ Details

Name: pfnx_UpfrontPayments

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Upfront payments from development milestone.
+ References
No definition available.
+ Details

Name: pfnx_UpfrontPaymentsFromDevelopmentMilestone

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
General description of claims, deemed to be reimbursable and included in accounts receivable, relating to the termination of long-term government contracts and programs. Includes claims associated with terminated war and defense contracts. If a reasonable estimate of a termination claim is undeterminable or impossible to make, disclosure is made to discuss the status and circumstances related to the undeterminable claim.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 310
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84167097&loc=d3e55541-109407

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 310
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84167097&loc=d3e55538-109407

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 275
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84167019&loc=d3e54672-109401

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 405
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84167112&loc=d3e56414-109416

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 275
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=84167019&loc=d3e54708-109401

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 405
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84167112&loc=d3e56417-109416

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 275
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84167019&loc=d3e54658-109401
+ Details

Name: us-gaap_ContractTerminationClaimsDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cost of material used for good produced and service rendered.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(2))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostDirectMaterial

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of the offset related to government or other customer advances received on a contract when the expected advances will be applied in payment to those particular charges of the receivable.
+ References
No definition available.
+ Details

Name: us-gaap_CustomerAdvancesAndProgressPaymentsForLongTermContractsOrPrograms

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously reported as deferred or unearned revenue.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow from operating activities classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromOtherOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the method (vendor-specific objective evidence, third-party evidence, estimated selling price) used to establish the selling price of the significant unit of accounting for allocation of the consideration of the multiple-deliverable arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_UnbilledReceivablesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=pfnx_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfnx_FundingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=pfnx_UsDepartmentOfHealthAndHumanServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=pfnx_BasePeriodPerformanceContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=pfnx_OptionPeriodContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=pfnx_AlvogenMaltaOperationsLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=pfnx_NewDrugApplicationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=pfnx_SupportAndRegulatoryMilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=pfnx_LiasionAgreeementWithAlvogenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=pfnx_NTPharmaAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=pfnx_ResearchAndDevelopmentRegulatoryAndSalesRelatedMilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=pfnx_JazzPharmaceuticalsIrelandLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=pfnx_PegaspargaseProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=pfnx_HematologyProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=pfnx_ResearchAndDevelopmentMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=pfnx_RegulatoryMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=pfnx_SalesMilestonesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=pfnx_NonSalesRelatedMilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=pfnx_SubstantiveNonSalesRelatedMilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R45.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
9 Months Ended

Sep. 30, 2019

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]

Number of Options, beginning balance 4,155

Number of Options, Granted 1,282

Number of Options, Exercised (120)

Number of Options, Cancelled (forfeited) (522)

Number of Options, ending balance 4,795

Number of Options, Vested and expected to vest at September 30, 2019 4,245

Number of Options, Vested and exercisable at September 30, 2019 2,458

Weighted Average Exercise Price, Outstanding, beginning balance $ 6.13

Weighted Average Exercise Price, Granted 4.57

Weighted Average Exercise Price, Exercised 3.47

Weighted Average Exercise Price, Cancelled (forfeited) 6.52

Weighted Average Exercise Price, Outstanding, ending balance 5.73

Weighted Average Exercise Price, Vested and expected to vest at September 30, 2019 5.92

Weighted Average Exercise Price, Vested and exercisable at September 30, 2019 $ 7.04

Weighted Average Remaining Contractual Term (in years), Outstanding 6 years 11 months 1 day

Weighted Average Remaining Contractual Term (in years), Vested and expected to vest at September 30, 2019 6 years 7 months 28 days

Weighted Average Remaining Contractual Term (in years), Vested and exercisable at September 30, 2019 5 years 29 days

Aggregate Intrinsic Value, Outstanding $ 15,431

Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2019 13,156

Aggregate Intrinsic Value, Vested and exercisable at September 30, 2019 $ 5,865

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 41 R49.htm IDEA: XBRL DOCUMENT v3.19.3

Net Income (Loss) Per Share of Common Stock - Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Sep. 30, 2019

Sep. 30, 2018

Earnings Per Share [Abstract]

Net income (loss) $ 3,082 $ (7,629) $ (3,661) $ (10,662) $ (11,081) $ (11,027) $ (8,208) $ (32,770)

Weighted average shares used to compute basic and diluted net income (loss) per share 31,595 31,437 31,534 27,288

Dilutive effect of employee stock option plans 903

Dilutive weighted-average common shares outstanding 32,498 31,437 31,534 27,288

Basic net income (loss) per common share $ 0.10 $ (0.34) $ (0.26) $ (1.20)

Diluted net income (loss) per common share $ 0.09 $ (0.34) $ (0.26) $ (1.20)

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 28A
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

ZIP 43 0001564590-19-041772-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-041772-xbrl.zip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�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end XML 44 R33.htm IDEA: XBRL DOCUMENT v3.19.3

Cash, Cash Equivalents and Restricted Cash - Additional Information (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Restricted Cash And Cash Equivalents Items [Line Items]

Restricted cash balance $ 200 $ 200

Credit Availability Concentration Risk [Member]

Restricted Cash And Cash Equivalents Items [Line Items]

Restricted cash balance $ 200

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditAvailabilityConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R37.htm IDEA: XBRL DOCUMENT v3.19.3

Intangible Assets - Summary of Intangible Assets (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]

Total intangible assets, gross $ 9,070 $ 9,070

Less: Accumulated amortization (5,211) (4,822)

Total intangible assets, net 3,859 4,248

Trade Names [Member]

Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]

Total intangible assets, gross 920 920

Customer Relationships [Member]

Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]

Total intangible assets, gross 3,750 3,750

Developed Technology [Member]

Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]

Total intangible assets, gross $ 4,400 $ 4,400

X

- Definition
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
+ References
No definition available.
+ Details

Name: pfnx_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsLineItems

Namespace Prefix: pfnx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated amortization of intangible assets, excluding goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R14.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies
9 Months Ended

Sep. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies
8. Commitments and Contingencies

Capital Lease Agreements

Payment commitments for the Company’s capital leases are summarized as follows:

September 30,

2019

(in thousands)

2019

$

92

2020

202

2021

1

Total future minimum lease payments

$

295

The Company has operating and capital lease agreements for office and lab equipment that expire at various dates through 2021.

Clinical Study and Development Activity Commitments

The Company has entered into agreements with contract research organizations and subcontractors to further develop its product candidates. These contracts can be cancelled at any time, with some having certain cancellation fees associated with the termination of the contract, and others that only obligate the Company through the termination date.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R9.htm IDEA: XBRL DOCUMENT v3.19.3

Cash, Cash Equivalents and Restricted Cash
9 Months Ended

Sep. 30, 2019

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]

Cash, Cash Equivalents and Restricted Cash
3. Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows.

September 30,

2019

December 31,

2018

(in thousands)

Cash and cash equivalents

$

32,518

$

56,220

Restricted cash

200

200

Total cash, cash equivalents and restricted cash shown in

 the statement of cash flows

$

32,718

$

56,420

The Company’s restricted cash balance of $0.2 million is bank collateral for its corporate credit card program.

X

- Definition
Cash, cash equivalents and restricted cash.
+ References
No definition available.
+ Details

Name: pfnx_CashCashEquivalentsAndRestrictedCashTextBlock

Namespace Prefix: pfnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R10.htm IDEA: XBRL DOCUMENT v3.19.3

Property and Equipment
9 Months Ended

Sep. 30, 2019

Property Plant And Equipment [Abstract]

Property and Equipment
4. Property and Equipment

Property and equipment consisted of the following:

September 30,

2019

December 31,

2018

(in thousands)

Furniture and equipment

$

372

$

367

Computers and IT equipment

498

451

Purchased software

464

375

Lab and research equipment

9,801

9,154

Leasehold improvements

951

876

Construction in progress

1,128

328

Other fixed assets

83

83

Total property and equipment, gross

13,297

11,634

Less: accumulated depreciation and amortization

(4,923

)

(3,963

)

Total property and equipment, net

$

8,374

$

7,671

Total property and equipment assets under capital lease were $1.0 million at both September 30, 2019 and December 31, 2018. Accumulated depreciation related to assets under capital lease as of both dates was $0.2 million. For the three and nine months ended September 30, 2019 and 2018, total depreciation and amortization expense is included in research and development, selling, general and administrative expenses and cost of sales in the accompanying consolidated statements of operations was as follows:

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands)

2019

2018

2019

2018

Cost of revenue

$

88

$

8

$

105

$

23

Research and development

197

242

664

709

Selling, general and administrative

53

41

199

117

Total depreciation and amortization expense

$

338

$

291

$

968

$

849

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R5.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Cash flows from operating activities

Net loss $ (8,208) $ (32,770)

Adjustments to reconcile net loss to net cash used in operating activities

Depreciation and amortization 968 849

Amortization of intangible assets 389 400

Stock-based compensation expense 2,381 2,551

Loss on disposal of property and equipment 8

Changes in operating assets and liabilities

Accounts and unbilled receivables (11,044) (439)

Other assets (596) (268)

Accounts payable 100 (560)

Accrued liabilities (1,887) 2,031

Deferred revenue (5,212) (522)

Income tax receivable 207 432

Net cash used in operating activities (22,902) (28,288)

Cash flows from investing activities

Acquisitions of property and equipment (1,076) (1,010)

Purchase of intangible asset (10)

Net cash used in investing activities (1,076) (1,020)

Cash flows from financing activities

Proceeds from issuance of common stock 39,522

Repayments of capital lease obligations (249) (212)

Proceeds from exercise of stock options and other stock issuances 525 197

Payment for taxes related to net share settlement of equity award 0 (38)

Net cash provided by financing activities 276 39,469

Net (decrease) increase in cash, cash equivalents and restricted cash (23,702) 10,161

Cash, cash equivalents and restricted cash

Beginning of period 56,420 57,864

End of period 32,718 68,025

Supplemental disclosures of non-cash investing and financing activities

Asset acquisitions in accounts payable and accrued expenses 747 92

Acquisitions under capital lease obligations 0 154

Restricted stock issuance for bonus accrual 0 56

Supplemental schedule of cash flow information

Cash paid for interest 18 36

Cash paid for taxes $ 1 $ 48

X

- Definition
Restricted stock issuance for bonus accrual.
+ References
No definition available.
+ Details

Name: pfnx_RestrictedStockIssuanceForBonusAccrual

Namespace Prefix: pfnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in lease obligation from new lease.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalLeaseObligationsIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in current assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfLongTermCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R18.htm IDEA: XBRL DOCUMENT v3.19.3

Subsequent Events
9 Months Ended

Sep. 30, 2019

Subsequent Events [Abstract]

Subsequent Events
12. Subsequent Events

In October 2019, the FDA approved the NDA for PF708 under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug. In connection with the FDA approval of PF708, the Company earned a $2.5 million milestone payment under the collaboration agreement with Alvogen, payable upon Alvogen’s receipt of notice of NDA approval. The Company recognized this $2.5 million as license revenue in the fourth quarter of 2019.

 In October 2019, the Company received an $11 million cash payment for the September 2019 achievement of a development milestone for PF745 associated to the Jazz collaboration. The Company recognized this $11.0 million as license revenue in the third quarter of 2019.

In October 2019, the Company announced the successful completion of its PF708 comparative use human factors study and its submission of the final study report to the FDA. An estimate of the financial effect of this subsequent event cannot be determined as of the report release date.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2019

Nov. 01, 2019

Cover [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q3

Entity Registrant Name Pfenex Inc.

Entity Central Index Key 0001478121

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Emerging Growth Company true

Entity Ex Transition Period false

Entity Small Business true

Entity Common Stock, Shares Outstanding 31,675,903

Entity Interactive Data Current Yes

Entity Current Reporting Status Yes

Entity Shell Company false

Entity File Number 001-36540

Entity Incorporation, State or Country Code DE

Entity Tax Identification Number 27-1356759

Entity Address, Address Line One 10790 Roselle Street

Entity Address, City or Town San Diego

Entity Address, State or Province CA

Entity Address, Postal Zip Code 92121

City Area Code 858

Local Phone Number 352-4400

Document Quarterly Report true

Document Transition Report false

Title of 12(b) Security Common Stock, par value $0.001 per share

Trading Symbol PFNX

Security Exchange Name NYSEAMER

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an quarterly report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-Q
-Number 240
-Section 13
-Subsection a-13
+ Details

Name: dei_DocumentQuarterlyReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1-
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 52 R26.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies (Tables)
9 Months Ended

Sep. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Summary of Capital Lease
Payment commitments for the Company’s capital leases are summarized as follows:

September 30,

2019

(in thousands)

2019

$

92

2020

202

2021

1

Total future minimum lease payments

$

295

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737
+ Details

Name: us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R22.htm IDEA: XBRL DOCUMENT v3.19.3

Cash, Cash Equivalents and Restricted Cash (Tables)
9 Months Ended

Sep. 30, 2019

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]

Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the statement of cash flows.

September 30,

2019

December 31,

2018

(in thousands)

Cash and cash equivalents

$

32,518

$

56,220

Restricted cash

200

200

Total cash, cash equivalents and restricted cash shown in

 the statement of cash flows

$

32,718

$

56,420

X

- Definition
Schedule of cash cash equivalents and restricted cash.
+ References
No definition available.
+ Details

Name: pfnx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock

Namespace Prefix: pfnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R43.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies - Additional Information (Detail)
9 Months Ended

Sep. 30, 2019

Office and Lab Equipment [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Operating and capital lease expiration dates various dates through 2021

X

- Definition
Lease expiration description.
+ References
No definition available.
+ Details

Name: pfnx_LeaseExpirationDescription

Namespace Prefix: pfnx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=pfnx_OfficeAndLaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R47.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation - Weighted-Average Assumptions used to Estimate Fair Value of Stock Options (Detail)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]

Risk-free interest rate 1.50% 2.80% 2.40% 2.70%

Expected volatility 72.70% 72.80% 72.60% 71.10%

Expected dividend yield 0.00% 0.00% 0.00% 0.00%

Expected life of options in years 5 years 10 months 24 days 6 years 3 months 18 days 6 years 2 months 12 days 6 years 3 months 18 days

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 56 R27.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock-Based Compensation Expense
The following table summarizes stock-based compensation expense:

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands)

2019

2018

2019

2018

Cost of revenue

$

44

$

50

$

133

$

143

Research and development

219

339

999

1,149

Selling, general and administrative

408

404

1,249

1,259

Total

$

671

$

793

$

2,381

$

2,551

Stock-based compensation from:

Stock options

$

646

$

752

$

2,320

$

2,395

Employee stock purchase plan

25

41

61

156

Total

$

671

$

793

$

2,381

$

2,551

Summary of Company's Stock Option Activity
The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2019:

Number of

Options

(in thousands)

Weighted

Average

Exercise Price

Weighted

Average

Remaining

Contractual

Term (in years)

Aggregate

Intrinsic Value

(in thousands)

Outstanding at December 31, 2018

4,155

$

6.13

Granted

1,282

4.57

Exercised

(120

)

3.47

Cancelled (forfeited)

(522

)

6.52

Outstanding at September 30, 2019

4,795

$

5.73

6.92

$

15,431

Vested and expected to vest at September 30, 2019

4,245

$

5.92

6.66

$

13,156

Vested and exercisable at September 30, 2019

2,458

$

7.04

5.08

$

5,865

Weighted-Average Assumptions used to Estimate Fair Value of Stock Options The table below sets forth the weighted-average assumptions used to estimate the fair value of stock options:

Three Months Ended

September 30,

Nine months Ended

September 30,

2019

2018

2019

2018

Risk-free interest rate

1.5

%

2.8

%

2.4

%

2.7

%

Expected volatility

72.7

%

72.8

%

72.6

%

71.1

%

Expected dividend yield

0

%

0

%

0

%

0

%

Expected life of options in years

5.9

6.3

6.2

6.3

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R23.htm IDEA: XBRL DOCUMENT v3.19.3

Property and Equipment (Tables)
9 Months Ended

Sep. 30, 2019

Property Plant And Equipment [Abstract]

Summary of Property and Equipment
Property and equipment consisted of the following:

September 30,

2019

December 31,

2018

(in thousands)

Furniture and equipment

$

372

$

367

Computers and IT equipment

498

451

Purchased software

464

375

Lab and research equipment

9,801

9,154

Leasehold improvements

951

876

Construction in progress

1,128

328

Other fixed assets

83

83

Total property and equipment, gross

13,297

11,634

Less: accumulated depreciation and amortization

(4,923

)

(3,963

)

Total property and equipment, net

$

8,374

$

7,671

Total property and equipment assets under capital lease were $1.0 million at both September 30, 2019 and December 31, 2018. Accumulated depreciation related to assets under capital lease as of both dates was $0.2 million. For the three and nine months ended September 30, 2019 and 2018, total depreciation and amortization expense is included in research and development, selling, general and administrative expenses and cost of sales in the accompanying consolidated statements of operations was as follows:

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands)

2019

2018

2019

2018

Cost of revenue

$

88

$

8

$

105

$

23

Research and development

197

242

664

709

Selling, general and administrative

53

41

199

117

Total depreciation and amortization expense

$

338

$

291

$

968

$

849

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 R42.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies - Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Non-cancelable Leasing Arrangements, Including Facilities Lease (Detail)
$ in Thousands

Sep. 30, 2019

USD ($)

Commitments And Contingencies Disclosure [Abstract]

Capital Leases, 2019 $ 92

Capital Leases, 2020 202

Capital Leases, 2021 1

Total future minimum lease payments $ 295

X

- Definition
Amount of minimum lease payments for capital leases.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737
+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737
+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737
+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of minimum lease payments for capital leases due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R46.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Compensation Related Costs [Abstract]

Proceeds from exercise of stock options $ 0.4 $ 0.1

Weighted average remaining contractual term 6 years 11 months 1 day

Weighted average grant date fair value, granted $ 3.01 $ 2.37

Unrecognized compensation cost related to unvested stock options $ 5.8

Unrecognized compensation cost related to unvested stock options, weighted average period for recognition 2 years 8 months 12 days

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationRelatedCostsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 61 R32.htm IDEA: XBRL DOCUMENT v3.19.3

Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]

Cash and cash equivalents $ 32,518 $ 56,220

Restricted cash 200 200

Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 32,718 $ 56,420

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 62 R36.htm IDEA: XBRL DOCUMENT v3.19.3

Property and Equipment - Depreciation and Amortization Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Property, Plant and Equipment [Line Items]

Total depreciation and amortization expense $ 338 $ 291 $ 968 $ 849

Cost of revenue [Member]

Property, Plant and Equipment [Line Items]

Total depreciation and amortization expense 88 8 105 23

Research and development [Member]

Property, Plant and Equipment [Line Items]

Total depreciation and amortization expense 197 242 664 709

Selling, general and administrative [Member]

Property, Plant and Equipment [Line Items]

Total depreciation and amortization expense $ 53 $ 41 $ 199 $ 117

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Revenue

Total revenue $ 15,248 $ 3,570 $ 28,421 $ 11,506

Cost of revenue 1,143 1,479 3,837 3,923

Gross profit 14,105 2,091 24,584 7,583

Operating expense

Research and development 6,931 9,045 19,691 28,590

Selling, general and administrative 4,147 3,823 13,296 11,920

Total operating expense 11,078 12,868 32,987 40,510

Net income (loss) from operations 3,027 (10,777) (8,403) (32,927)

Other income, net 55 115 195 157

Net income (loss) $ 3,082 $ (10,662) $ (8,208) $ (32,770)

Net income (loss) per common share:

Basic $ 0.10 $ (0.34) $ (0.26) $ (1.20)

Diluted $ 0.09 $ (0.34) $ (0.26) $ (1.20)

Weighted-average common shares used in calculating net income (loss) per share:

Basic 31,595 31,437 31,534 27,288

Diluted 32,498 31,437 31,534 27,288

License

Revenue

Total revenue $ 11,562 $ 1,874 $ 20,430 $ 6,869

Service

Revenue

Total revenue 733 1,339 3,155 3,821

Product

Revenue

Total revenue $ 2,953 $ 357 $ 4,836 $ 816

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_TechnologyServiceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R19.htm IDEA: XBRL DOCUMENT v3.19.3

Organization and Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Business Activities and Organization
Business Activities and Organization

Pfenex Inc. (the Company or Pfenex) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology^® to develop and improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, the Company has created an advanced pipeline of potential therapeutic equivalents, vaccines, biologics, and biosimilars. On October 4, 2019, the U.S. Food and Drug Administration (FDA) approved the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo^® (teriparatide injection) as the reference drug. Like Forteo, this FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. Marketing authorization applications are pending in other jurisdictions. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals Ireland Limited (Jazz) including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. Both PF743 and PF745 are being developed for the treatment of Acute Lymphoblastic Leukemia (ALL) and other hematological malignancies. The Company also uses its Pfēnex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccine candidates under development by Merck & Co, Inc. (Merck) and Serum Institute of India Private Ltd. (SIIPL). Both have licenses to the Pfēnex Expression Technology for the production of CRM197 for use in conjugate vaccine products. The Company is focused developing its portfolio of partnered as well as wholly-owned peptides and complex proteins. Currently, the Company is exploring opportunities to develop novel modalities through an assessment program designed to evaluate and pursue validated biologic pathways that are differentially druggable via a selected modality in specific diseases. In addition, the Company is exploring a range of modality platforms and targets that are potentially compatible with its Pfēnex Expression Technology.

FDA-Approved PF708 Product

On October 4, 2019, the FDA approved the NDA for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo (teriparatide injection) as the reference drug. The FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. The Company is currently in the process of transferring the NDA to Alvogen pursuant to the Alvogen Agreement, described below, between the companies. In addition, the Company has been continuing its efforts to obtain an “A” therapeutic equivalence designation for the product relative to its reference drug, Forteo. A determination of therapeutic equivalence may permit the FDA-approved PF708 product to be automatically substituted for Forteo, depending on applicable laws and policies within each of the 50 states. Consistent with the Company’s interactions with the FDA and the agency’s draft guidance document on demonstrating the therapeutic equivalence of drug-device combination products, the Company has completed a comparative human factors study comparing the FDA-approved PF708 product and Forteo. This human factors study was designed to further support a finding that the FDA-approved PF708 product is therapeutically equivalent to Forteo. On October 14, 2019, the Company announced the successful completion of its PF708 comparative use human factors study and its submission of the final study report to the FDA. The study data demonstrate that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo for each critical user task evaluated in the study based on pre-specified statistical analysis of critical patient and caregiver tasks. The Company believes this submission completes the information package required by the FDA to evaluate the therapeutic equivalence of the PF708 product. The Company’s collaboration partner, Alvogen, intends to launch the FDA-approved PF708 product in the U.S. upon an FDA decision on the therapeutic equivalence evaluation of the product.

In April 2018, the Company and China NT Pharma Group Company Ltd. (NT Pharma) entered into a Development and License Agreement (NT Pharma Agreement), pursuant to which the Company granted an exclusive license to NT Pharma to commercialize PF708 in Mainland China, Hong Kong, Singapore, Malaysia and Thailand and a non-exclusive license to conduct development activities in such territories with respect to PF708. The Company will be responsible for commercial manufacturing and providing product for commercial sale to NT Pharma. The Company will facilitate this obligation via its commercial partner Alvogen. NT Pharma is responsible for all regulatory submissions, development costs and costs associated with regulatory approvals in such territories.

In June 2018, the Company and Alvogen Malta Operations Ltd. (Alvogen) entered into a Development and License Agreement (Alvogen Agreement) pursuant to which Alvogen has the exclusive right to commercialize and manufacture PF708 in the United States. The Company expects Alvogen to launch FDA-approved PF708 in the U.S. upon an FDA rating decision on the therapeutic equivalence evaluation of the product. Following the FDA approval of the NDA for PF708, the FDA-approved PF708 product will be commercialized and manufactured in the U.S. by Alvogen. The Company is currently in the process of transferring the NDA to Alvogen pursuant to its collaboration agreement.

In February 2019, the Company and Alvogen entered into additional agreements, extending Alvogen’s rights to commercialize and manufacture PF708 to include the European Union (EU), certain countries in the Middle East and North Africa (MENA) and to the rest of world (ROW) territories (excluding certain Asian countries granted to NT Pharma). Alvogen is responsible for local activities and for overseeing any clinical development, regulatory, litigation, commercial manufacturing and commercialization activities in these jurisdictions.

Collaboration Partner: Jazz Pharmaceuticals Ireland Limited

In July 2016, the Company and Jazz announced an agreement under which the Company granted Jazz worldwide rights to develop and commercialize multiple early stage hematology/oncology product candidates, including PF743 (JZP-458), a recombinant Erwinia asparaginase, and PF745 (JZP-341), a long-acting Erwinia asparaginase. In December 2017, the parties amended the Jazz agreement, bringing the total value of payments and potential payments associated with the collaboration to $224.5 million. In addition, the Company may be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration at rates reduced from those under the 2016 agreement.

Pfēnex Expression Technology Licenses: CRM197

The Company has both licenses and supply agreements in place for CRM197, which is a non-toxic mutant of diphtheria toxin. It is a well-characterized protein and functions as a carrier for polysaccharides and haptens, making them immunogenic. The Company has developed unique CRM197 production strains based on its Pfēnex Expression Technology platform. As a result of these development efforts, the Company previously entered into commercial licenses for production strains capable of producing CRM197 with both Merck & Co., Inc. and Serum Institute of India Private Ltd. Merck and SIIPL are using the CRM197 produced via the licensed production strain in multiple clinical stage products. Those products currently include Merck’s 15-valent pneumococcal conjugate vaccine, PCV-15 (V114) currently in several ongoing Phase 3 clinical studies and SIIPL’s 10-valent pneumococcal conjugate vaccine Pneumosil® currently in WHO Prequalification and a pentavalent meningococcal conjugate vaccine currently in a Phase 3 clinical study. The CRM197 production strains utilized by both Merck and SIIPL are unique and exclusively licensed to each party. These commercial license agreements with Merck and SIIPL contemplate potential maintenance and milestone fees as well as royalties on net sales. Additionally, as part of the SIIPL commercial license agreement, SIIPL supplies both reagent grade and cGMP CRM197 to Pfenex, which supplies the product to vaccine development-focused pharmaceutical partners.

Arcellx Development, Evaluation and License Agreement

The Company previously entered into a development, evaluation and license agreement with Arcellx which provides access to the Pfēnex Expression Technology platform to advance Arcellx’s proprietary sparX proteins that activate, silence and reprogram Antigen- Receptor Complex T cell-based therapies. Under the terms of the agreement, Pfenex is eligible to receive development funding in addition to development, regulatory and commercial milestones ranging from $2.6 million to $18 million for each product incorporating a sparX protein expressed using the Pfēnex Expression Technology, as well as royalties on worldwide sales of any such products. The Company currently has two sparX proteins in development with Arcellx. As of September 30, 2019, the Company has recorded $1.8 million in revenue related to development for Arcellx.

Additional Novel Vaccine and Biosimilar Pipeline Products

The Company’s pipeline includes biosimilar candidates to certain reference products, including biosimilar candidates to Lucentis (PF582) and Neulasta (PF529) and two novel anthrax vaccine candidates, Px563L and RPA563, which are funded by the Biomedical Advanced Research and Development Authority (BARDA). In November of 2017, the Company paused development on both PF582 and PF529 and it does not intend to advance PF582 or PF529 without development and commercial collaboration partners. In March 2019 the Company received a notice from BARDA advising it of BARDA’s decision not to exercise development options for cGMP manufacturing, preclinical studies and Phase 1/2b study readiness in connection with the Company’s Px563L and RPA563 novel anthrax vaccine program. Following the receipt of the notice from BARDA and pursuant to discussions with BARDA, the Company deprioritized this program in its portfolio.

At the Market Offering Program

In March 2018, the Company entered into an equity sales agreement (Sales Agreement) with William Blair & Company, L.L.C. (William Blair) to sell shares of the Company’s common stock having aggregate sales proceeds of up to $20.0 million, from time to time, through an “at the market” equity offering program under which William Blair will act as sales agent. Under the Sales Agreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. As of September 30, 2019, the Company had not sold any shares under the Sales Agreement.

Follow-on Public Offering

In May 2018, the Company completed a public offering of common stock in which it sold 7,820,000 shares of its common stock at an offering price of $5.50 per share, which included the full exercise by the underwriters of their option to purchase an additional 1,020,000 shares, pursuant to the Company’s prior shelf registration statement. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $39.5 million.

Basis of Presentation
Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

Use of Estimates
Use of Estimates

The preparation of the accompanying unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Estimates have been prepared on the basis of the most current and best available information. However, actual results could differ from those estimates.

Risk and Uncertainties
Risk and Uncertainties

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the performance of the Company’s commercial partner Alvogen, uncertainty of results of clinical trials and reaching milestones, uncertainty of timing and types of regulatory approval of the Company’s product candidates, uncertainty of market acceptance of the Company’s products if approved for sale, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals.

Products developed by the Company require clearances from international and domestic regulatory agencies prior to commercial sales in such jurisdictions. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company.

As of September 30, 2019, the Company had an accumulated deficit of $209.5 million and expects to incur substantial operating losses for the next several years. The Company believes that its existing cash and cash equivalents and cash inflow from operations will be sufficient to meet its anticipated cash needs for at least the next 12 months from the date these unaudited consolidated financial statements are issued.

The Company will require substantial cash to achieve its objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. The Company may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. It will need to obtain significant funds under its existing collaborations and license agreements, under new collaboration, licensing or other commercial agreements for one or more of its product candidates and programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that it does not obtain additional funding, the Company will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on its ability to achieve its intended business objectives.

Cash and Cash Equivalents
Cash and Cash Equivalents

The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash amounts that are restricted as to withdrawal or usage are presented as restricted cash. In January 2017, the Company entered into a Borrower’s Pledge Agreement, which required $0.2 million in restricted cash to be provided as security for its commercial credit card arrangement with one of the Company’s banks.

Concentrations
Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts and unbilled receivables. The Company has established guidelines intended to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio and placing investments with maturities that help maintain safety and liquidity. All cash and cash equivalents were held at three major financial institutions as of September 30, 2019 and December 31, 2018. For the Company’s cash position of $32.7 million as of September 30, 2019, which included restricted cash of $0.2 million, the Company has exposure to credit loss for amounts in excess of insured limits in the event of non-performance by the institutions; however, the Company does not anticipate non-performance. Additional credit risk is related to the Company’s concentration of receivables. As of September 30, 2019, and December 31, 2018, receivables were concentrated among two and three customers representing 91% and 87% of total net receivables, respectively. No allowance for doubtful accounts was recorded at September 30, 2019 or December 31, 2018. For the three months ended September 30, 2019 and 2018, revenue was concentrated among two customers and/or collaboration partners representing 89% of total revenues for both periods. Revenue from two customers and/or collaboration partners represented 70% and 87% of total revenue for the nine months ended September 30, 2019 and 2018, respectively.

A portion of revenue is earned from entities located outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s revenue from U.S. and non-U.S. based sources for the nine months ended September 30, 2019 and 2018 is as follows:

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands)

2019

2018

2019

2018

US Revenue

$

877

$

1,371

$

4,172

$

3,877

Non-US Revenue

14,371

2,199

24,249

7,629

$

15,248

$

3,570

$

28,421

$

11,506

During the three and nine months ended September 30, 2019, entities located in Ireland and Malta accounted for more than 10% of the Company’s revenue. During the three and nine months ended September 30, 2018, entities located in Ireland accounted for more than 10% of the Company’s revenue.

Fair Value Measurements
Fair Value of Financial Instruments

Financial instruments, including cash, cash equivalents, restricted cash and the lines of credit, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:

•

Level 1—Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 1 assets at September 30, 2019 and December 31, 2018 included the Company’s cash, cash equivalents and restricted cash. There were no Level 1 liabilities;

•

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. The Company had no Level 2 assets or liabilities at September 30, 2019 or December 31, 2018; and

•

Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities in which there is little or no market data. The Company had no Level 3 assets or liabilities at September 30, 2019 or December 31, 2018.

Revenue
Revenue

The Company’s revenue is related to the monetization of its protein production platform through collaboration agreements, service agreements, license agreements, government contracts and sales of reagent protein products, which may provide for various types of payments, including upfront payments, funding of research and development, milestone payments, intellectual property access fees and licensing fees. The Company’s revenue generating agreements also include potential revenues for achieving development and sales milestones and for product royalties. The specifics of the Company’s significant agreements are detailed in Note 7—Significant Research and Development Agreements.

The Company’s revenue is reported into one of three categories, including: license revenue, service revenue, and product revenue. License revenue generally includes providing customers with access to the Company’s intellectual property and achievement of development milestones during the period or a portion of contractual payments that are recognized during the reporting period. Service revenue is derived from performing activities for customers related to the Company’s Pfēnex Expression Technology platform. Product revenue generally includes sales of CMR197 and other materials. The three-months ended September 30, 2019 is the first period revenue has been reported into these three categories, and prior periods have been disaggregated to conform to this current presentation.

The Company considers a variety of factors in determining the appropriate method of accounting for its collaboration agreements, including whether multiple deliverables can be separated and accounted for individually as separate units of accounting. Where there are multiple deliverables within a collaboration agreement that cannot be separated and therefore are combined into a single unit of accounting, revenues are deferred and recognized using the relevant guidance over the estimated period of performance. If the deliverables can be separated, the Company applies the relevant revenue recognition guidance to each individual deliverable. The specific methodology for the recognition of the underlying revenue is determined on a case-by-case basis according to the facts and circumstances applicable to each agreement. On a quarterly basis, the Company evaluates the period of performance to determine if a change should be made.

Upfront, nonrefundable licensing payments are assessed to determine whether or not the licensee is able to obtain standalone value from the license. Where the license does not have standalone value, non-refundable license fees are recorded as deferred revenue and recognized as revenue as the Company performs under the applicable agreement. Where the level of effort is relatively consistent over the performance period, the Company recognizes fixed or determined revenue on a straight-line basis over the estimated period of performance. Where the license has standalone value, the Company recognizes total license revenue at the time all revenue recognition criteria have been met.

Nonrefundable payments for research funding are generally recognized as revenue over the period the underlying research activities are performed.

Revenue under service agreements are recorded as services are performed. These agreements do not require development achievement as a performance obligation and provide for payment when services are rendered. All such revenue is nonrefundable. Upfront, nonrefundable payments for license fees, exclusivity and feasibility services received in excess of amounts earned are classified as deferred revenue and recognized as income over the contract term or period of performance based on the nature of the related agreement.

The Company recognizes revenue for its cost-plus fixed fee government contracts in accordance with the authoritative guidance for revenue recognition including the authoritative guidance specific to federal government contractors. Reimbursable costs under the Company’s government contracts primarily include direct labor, materials, subcontracts, accountable property and indirect costs. In addition, the Company receives a fixed fee under its government contracts, which is unconditionally earned as allowable costs are incurred and is not contingent on success factors. Reimbursable costs under the Company’s government contracts, including the fixed fee, are generally recognized as revenue in the period the reimbursable costs are incurred.

The Company assesses milestone payments on an individual basis and recognizes revenue from nonrefundable milestone payments when the earnings process is complete and the payment is reasonably assured. Nonrefundable milestone payments related to arrangements under which the Company has continuing performance obligations are recognized as revenue upon achievement of the associated milestone, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, and (ii) the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with the milestone event. For the three and nine months ended September 30, 2019, $11.0 million and $17.1 million in revenue was recognized in connection with the achievement of milestones, respectively.

The Company’s reagent protein products are primarily comprised of internally developed reagent protein products. Revenues for reagent product sales are reflected net of attributable sales tax. The Company generally offers a 30 day return policy. The Company recognizes reagent product revenue from product sales when it is realized or realizable and earned. As of September 30, 2019, the Company has had minimal product returns related to reagent protein product sales. Therefore, no reserve for warranty and return rights was recorded as of September 30, 2019 and December 31, 2018.

Revenue under arrangements where the Company outsources the cost of fulfillment to third parties is evaluated as to whether the related amounts should be recorded gross or net. The Company records amounts collected from the customer as revenue, and the amounts paid to suppliers as cost of revenue when it holds all or substantially all of the risks and benefits related to the product or service. For transactions where the Company does not hold all or substantially all the risk, the Company uses net reporting and therefore records the transaction as if the end-user made a purchase from the supplier with the Company acting as a sales agent.

Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Numerous updates were issued in 2016 that provide clarification on a number of specific issues as well as requiring additional disclosures. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of January 1, 2019 in that filing. However, the Company will continue to account for revenue recognition under ASC Topic 605 for interim periods in 2019 and will not be required to amend its Form 10-Q filings filed throughout 2019 to reflect the January 1, 2019 adoption date. The guidance allows for the use of one of two retrospective application methods: the full retrospective method or the modified retrospective method. The Company plans to adopt the standard in fiscal year 2019 using the modified retrospective method. The Company does not expect the new standard to have a material impact on the recognition of revenue from its services or reagent protein product sales. The Company is currently evaluating the impact of the new standard on historical revenue recorded for its collaboration agreements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which was subsequently amended by ASU No. 2018-10, ASU No. 2018-11, ASU No. 2018-20 and ASU No. 2019-01. This ASU, as amended, increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as right-of-use assets and lease liabilities. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification dictates whether lease expense is to be recognized based on an effective interest method or on a straight-line basis over the term of the lease. Additional qualitative and quantitative disclosures will be required to give financial statement users information on the amount, timing and judgments related to a reporting entity’s cash flows arising from leases. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of January 1, 2019 in that filing. However, the Company will continue to account for leases under ASC Topic 840 for interim periods in 2019 and will not be required to amend its Form 10-Q filings filed throughout 2019 to reflect the January 1, 2019 adoption date. The Company plans on adopting this standard using the modified retrospective transition approach by applying the new standard to leases existing at the date of initial adoption. The Company plans to use the package of practical expedients, which permit the Company to not reassess prior conclusions about lease identification, lease classification and initial direct costs determined under ASC Topic 840.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. This updated guidance eliminates Step 2 from the current two-step quantitative model for goodwill impairment tests. Step 2 required an entity to calculate an implied fair value, which included a hypothetical purchase price allocation requirement, for reporting units that failed Step 1. Per this updated guidance, a goodwill impairment will instead be measured as the amount by which a reporting unit’s carrying value exceeds its fair value as identified in Step 1. This guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that reporting period. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this guidance is not expected to have a material impact on the consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718), which simplifies the accounting for nonemployee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The financial information included in the Company’s 2019 Form 10-K will be updated for the January 1, 2019 adoption date; this new guidance will be reflected for the first time in the Company’s 2019 Form 10-K but effective as of January 1, 2019 in that filing. The adoption of this guidance is not expected to have a material impact on the consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles—Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. ASU 2018-15 is effective for the Company beginning in the first quarter of fiscal year 2020, with early adoption permitted. The Company is currently evaluating this guidance to determine the impact on its financial statements and related disclosures.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606. The amendments in ASU No. 2018-18 make targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in ASC 808 was aligned with the guidance in ASC 606 when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606. ASU No. 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in ASU No. 2018-18 are required to be applied retrospectively to the date of initial application of ASC 606. The Company is currently evaluating the impact of ASU No. 2018-08 on its consolidated financial statements.

X

- Definition
Risks And Uncertainties [Policy Text Block]
+ References
No definition available.
+ Details

Name: pfnx_RisksAndUncertaintiesPolicyTextBlock

Namespace Prefix: pfnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R15.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation
9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation
9. Stock-Based Compensation

Summary Stock-Based Compensation Information

The following table summarizes stock-based compensation expense:

Three Months Ended

September 30,

Nine months Ended

September 30,

(in thousands)

2019

2018

2019

2018

Cost of revenue

$

44

$

50

$

133

$

143

Research and development

219

339

999

1,149

Selling, general and administrative

408

404

1,249

1,259

Total

$

671

$

793

$

2,381

$

2,551

Stock-based compensation from:

Stock options

$

646

$

752

$

2,320

$

2,395

Employee stock purchase plan

25

41

61

156

Total

$

671

$

793

$

2,381

$

2,551

The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2019:

Number of

Options

(in thousands)

Weighted

Average

Exercise Price

Weighted

Average

Remaining

Contractual

Term (in years)

Aggregate

Intrinsic Value

(in thousands)

Outstanding at December 31, 2018

4,155

$

6.13

Granted

1,282

4.57

Exercised

(120

)

3.47

Cancelled (forfeited)

(522

)

6.52

Outstanding at September 30, 2019

4,795

$

5.73

6.92

$

15,431

Vested and expected to vest at September 30, 2019

4,245

$

5.92

6.66

$

13,156

Vested and exercisable at September 30, 2019

2,458

$

7.04

5.08

$

5,865

The Company received approximately $0.4 million and $0.1 million from stock option exercises during the nine months ended September 30, 2019 and September 30, 2018, respectively. Options outstanding at September 30, 2019 have a weighted average remaining contractual term of 6.92 years.

The exercise price of all options granted during the nine months ended September 30, 2019 and 2018 was equal to the closing price of the Company’s common stock on the date of grant. The fair value of each stock option granted is estimated on the grant date under the fair value method using the Black-Scholes model. The estimated fair values of the stock option, including the effect of estimated forfeitures, are then expensed over the requisite service period which is generally the vesting period. The table below sets forth the weighted-average assumptions used to estimate the fair value of stock options:

Three Months Ended

September 30,

Nine months Ended

September 30,

2019

2018

2019

2018

Risk-free interest rate

1.5

%

2.8

%

2.4

%

2.7

%

Expected volatility

72.7

%

72.8

%

72.6

%

71.1

%

Expected dividend yield

0

%

0

%

0

%

0

%

Expected life of options in years

5.9

6.3

6.2

6.3

The weighted-average grant date fair value of options granted during the nine months ended September 30, 2019 and 2018 was $3.01 and $2.37, respectively. As of September 30, 2019, there was unrecognized compensation cost of approximately $5.8 million related to unvested stock option awards, and the weighted-average period over which this cost is expected to be recognized is 2.7 years.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 66 R8.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements
9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements
2. Fair Value Measurements

The fair value measurements of the Company’s cash equivalents and investments, which are measured at fair value on a recurring basis as of September 30, 2019 and December 31, 2018, were determined using the inputs described above and are as follows:

Fair Value Measurements at Reporting

Date Using

Total

Quoted Prices

in Active

Markets for

Identical Assets

(Level 1)

Significant

Other

Observable

Inputs

(Level 2)

Significant

Unobservable

Inputs

(Level 3)

(in thousands)

September 30, 2019

Cash and money market funds

$

32,718

$

32,718

$

—

$

—

Total assets measured at fair value

$

32,718

$

32,718

$

—

$

—

December 31, 2018

Cash and money market funds

$

56,420

$

56,420

$

—

$

—

Total assets measured at fair value

$

56,420

$

56,420

$

—

$

—

Cash and money market funds at September 30, 2019 and December 31, 2018 include restricted cash, which is included in current assets on the balance sheet.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R11.htm IDEA: XBRL DOCUMENT v3.19.3

Intangible Assets
9 Months Ended

Sep. 30, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets
5. Intangible Assets

Intangible assets consisted of the following:

September 30,

2019

December 31,

2018

(in thousands)

Customer relationships

$

3,750

$

3,750

Developed technology

4,400

4,400

Trade names

920

920

Total intangible assets, gross

9,070

9,070

Less: Accumulated amortization

(5,211

)

(4,822

)

Total intangible assets, net

$

3,859

$

4,248

Amortization expense related to intangible assets was $0.1 million for both the three months ended September 30, 2019 and 2018, and $0.4 million for both the nine months ended September 30, 2019 and 2018. Amortization expense is included within selling, general and administrative expense in the accompanying consolidated statements of operations. As of September 30, 2019, estimated amortization expense for the next five years amounts to approximately $0.5 million per year.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Accrued Liabilities - Components of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Other Liabilities Disclosure [Abstract]
Accrued vacation	$ 522	$ 493
Deferred rent	549	589
Accrued bonuses	1,618	1,748
Other accrued employee-related liabilities	525	302
Accrued professional fees	855	1,524
Accrued supplier liability	615	387
Accrued subcontractor costs	1,949	4,265
Obligation to Alvogen for raw materials	713
Other accrued liabilities	1,006	504
Total accrued liabilities	$ 8,352	$ 9,812

Significant Research and Development Agreements - Additional Information (Detail) $ in Thousands	1 Months Ended									3 Months Ended			9 Months Ended		12 Months Ended
	Oct. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	May 31, 2019 USD ($)	Feb. 28, 2019	Jun. 30, 2018 USD ($) Milestone	Apr. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jan. 31, 2017 USD ($)	Aug. 31, 2015 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2017	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	May 31, 2018 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue										$ 15,248	$ 3,570		$ 28,421	$ 11,506
Obligation to Alvogen for raw materials		$ 713								713			713
Deferred revenue recognized										17,100			11,000
Biomedical Advanced Research And Development Authority [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue										200	1,300		$ 1,200	3,800
Funding Agreement [Member] \| U.S. Department of Health and Human Services [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Base program period									30 months
Agreement description													This agreement is a cost-plus fixed fee development contract valued at up to approximately $143.5 million, including a 30-month base period of performance of approximately $15.9 million, and eight option periods valued at a total of approximately $127.6 million. The base period of performance was initially from August 2015 through February 2018 and later extended through September 2018. BARDA exercised additional phases of the development contract effective January 2017, totaling $4.9 million and allowing for the continuing development of Px563L and RPA563. The period of performance for the two option periods was extended through September 2018 and December 2019.
Amount of contract eligible for payments																$ 1,700
Total amount of contract									$ 143,500
Agreement termination description													This agreement is subject to early termination and stop-work order in conformance with Federal Acquisition Regulations 52.249-6 and 52.242-15 whereupon BARDA may immediately terminate the agreement early for convenience or request the Company to stop all or any part of the work for a period of at least 90 days.
PF708 Drug Substance Batches and Pen Components [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue										2,953	357		$ 4,836	816
Base Period Performance Contracts [Member] \| Funding Agreement [Member] \| U.S. Department of Health and Human Services [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total amount of contract								$ 4,900	15,900
Option Period Contracts [Member] \| Funding Agreement [Member] \| U.S. Department of Health and Human Services [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total amount of contract									$ 127,600
Alvogen Malta Operations Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment					$ 2,500
Number of development milestone \| Milestone					2
Upfront payments from development milestone					$ 2,500
Percentage of gross profit received from rating of therapeutic equivalent					50.00%
Percentage of gross profit received without rating of therapeutic equivalent					40.00%
Revenue													1,000
Upfront and Milestone Payments													1,500
Percentage of gross profit received from geography basis				60.00%
Expected Reimbursable Costs											1,600		1,600
Alvogen Malta Operations Ltd [Member] \| PF708 Drug Substance Batches and Pen Components [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue										2,300			2,300
Collaboration agreement, transaction amount			$ 2,300
Alvogen Malta Operations Ltd [Member] \| Subsequent Event [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized from milestone	$ 2,500
Alvogen Malta Operations Ltd [Member] \| Unbilled Revenues [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Unbilled Receivables, Current		400								400			400
Alvogen Malta Operations Ltd [Member] \| Billed Revenues [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Invoiced bills receivable		1,200								1,200			1,200
Alvogen Malta Operations Ltd [Member] \| NDA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment					$ 2,500
Deferred revenue					2,500
One Time Support Payment													2,500
Alvogen Malta Operations Ltd [Member] \| NDA [Member] \| Subsequent Event [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized from milestone	2,500
Alvogen Malta Operations Ltd [Member] \| Support And Regulatory Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Additional payment					$ 20,000
Alvogen Malta Operations Ltd [Member] \| Liasion Agreeement With Alvogen [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment Received for Raw Materials			$ 1,700
Raw Materials Shipped To Alvogen													1,000
Obligation to Alvogen for raw materials		700								700			700
NT Pharma Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment						$ 2,500
NT Pharma Agreement [Member] \| NDA [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment						2,500
Deferred revenue						2,500
NT Pharma Agreement [Member] \| Research and Development, Regulatory and Sales Related Milestones [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Additional payment						$ 22,500
Jazz Pharmaceuticals Ireland Limited [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment							$ 5,000
Revenue recognized from milestone										11,000	$ 1,800		$ 13,700	$ 6,300
Upfront and milestone payment total							18,500
Payments of development achievement							13,500
Estimated selling price determination method													The estimated selling price for the pegaspargase product candidate and the hematology/oncology products was determined using an income approach. In determining the estimated selling price, the Company considered costs expected to be incurred for internal labor, burden rates, internal margins, and subcontractors
Upfront and option payment							15,000
Deferred revenue recognized															$ 2,700
Jazz Pharmaceuticals Ireland Limited [Member] \| Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Product development period												15 months	15 months
Jazz Pharmaceuticals Ireland Limited [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Product development period												35 months	32 months
Jazz Pharmaceuticals Ireland Limited [Member] \| Pegaspargase Product [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition, selling price							10,000
Jazz Pharmaceuticals Ireland Limited [Member] \| Hematology Product [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognition, selling price							2,500
Remaining upfront payment		4,200								$ 4,200			$ 4,200
Jazz Pharmaceuticals Ireland Limited [Member] \| Research and Development, Regulatory and Sales Related Milestones [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Additional payment							177,500
Jazz Pharmaceuticals Ireland Limited [Member] \| Research and Development Milestones [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment							$ 800
Revenue recognized from milestone		$ 11,000													$ 800
Milestone payments													18,500
Jazz Pharmaceuticals Ireland Limited [Member] \| Research and Development Milestones [Member] \| Subsequent Event [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment Received for Raw Materials	$ 11,000
Jazz Pharmaceuticals Ireland Limited [Member] \| Regulatory Milestones [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments													34,000
Jazz Pharmaceuticals Ireland Limited [Member] \| Sales Milestones [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments													125,000
Jazz Pharmaceuticals Ireland Limited [Member] \| Non-sales-related Milestones [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments													52,500
Jazz Pharmaceuticals Ireland Limited [Member] \| Substantive Non Sales Related Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments													$ 18,500

Stock-Based Compensation - Summary of Company's Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Options, beginning balance	4,155
Number of Options, Granted	1,282
Number of Options, Exercised	(120)
Number of Options, Cancelled (forfeited)	(522)
Number of Options, ending balance	4,795
Number of Options, Vested and expected to vest at September 30, 2019	4,245
Number of Options, Vested and exercisable at September 30, 2019	2,458
Weighted Average Exercise Price, Outstanding, beginning balance	$ 6.13
Weighted Average Exercise Price, Granted	4.57
Weighted Average Exercise Price, Exercised	3.47
Weighted Average Exercise Price, Cancelled (forfeited)	6.52
Weighted Average Exercise Price, Outstanding, ending balance	5.73
Weighted Average Exercise Price, Vested and expected to vest at September 30, 2019	5.92
Weighted Average Exercise Price, Vested and exercisable at September 30, 2019	$ 7.04
Weighted Average Remaining Contractual Term (in years), Outstanding	6 years 11 months 1 day
Weighted Average Remaining Contractual Term (in years), Vested and expected to vest at September 30, 2019	6 years 7 months 28 days
Weighted Average Remaining Contractual Term (in years), Vested and exercisable at September 30, 2019	5 years 29 days
Aggregate Intrinsic Value, Outstanding	$ 15,431
Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2019	13,156
Aggregate Intrinsic Value, Vested and exercisable at September 30, 2019	$ 5,865

Net Income (Loss) Per Share of Common Stock - Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net income (loss)	$ 3,082	$ (7,629)	$ (3,661)	$ (10,662)	$ (11,081)	$ (11,027)	$ (8,208)	$ (32,770)
Weighted average shares used to compute basic and diluted net income (loss) per share	31,595			31,437			31,534	27,288
Dilutive effect of employee stock option plans	903
Dilutive weighted-average common shares outstanding	32,498			31,437			31,534	27,288
Basic net income (loss) per common share	$ 0.10			$ (0.34)			$ (0.26)	$ (1.20)
Diluted net income (loss) per common share	$ 0.09			$ (0.34)			$ (0.26)	$ (1.20)

Cash, Cash Equivalents and Restricted Cash - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Restricted Cash And Cash Equivalents Items [Line Items]
Restricted cash balance	$ 200	$ 200
Credit Availability Concentration Risk [Member]
Restricted Cash And Cash Equivalents Items [Line Items]
Restricted cash balance	$ 200

Intangible Assets - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 9,070	$ 9,070
Less: Accumulated amortization	(5,211)	(4,822)
Total intangible assets, net	3,859	4,248
Trade Names [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total intangible assets, gross	920	920
Customer Relationships [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total intangible assets, gross	3,750	3,750
Developed Technology [Member]
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 4,400	$ 4,400

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities
Net loss	$ (8,208)	$ (32,770)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	968	849
Amortization of intangible assets	389	400
Stock-based compensation expense	2,381	2,551
Loss on disposal of property and equipment		8
Changes in operating assets and liabilities
Accounts and unbilled receivables	(11,044)	(439)
Other assets	(596)	(268)
Accounts payable	100	(560)
Accrued liabilities	(1,887)	2,031
Deferred revenue	(5,212)	(522)
Income tax receivable	207	432
Net cash used in operating activities	(22,902)	(28,288)
Cash flows from investing activities
Acquisitions of property and equipment	(1,076)	(1,010)
Purchase of intangible asset		(10)
Net cash used in investing activities	(1,076)	(1,020)
Cash flows from financing activities
Proceeds from issuance of common stock		39,522
Repayments of capital lease obligations	(249)	(212)
Proceeds from exercise of stock options and other stock issuances	525	197
Payment for taxes related to net share settlement of equity award	0	(38)
Net cash provided by financing activities	276	39,469
Net (decrease) increase in cash, cash equivalents and restricted cash	(23,702)	10,161
Cash, cash equivalents and restricted cash
Beginning of period	56,420	57,864
End of period	32,718	68,025
Supplemental disclosures of non-cash investing and financing activities
Asset acquisitions in accounts payable and accrued expenses	747	92
Acquisitions under capital lease obligations	0	154
Restricted stock issuance for bonus accrual	0	56
Supplemental schedule of cash flow information
Cash paid for interest	18	36
Cash paid for taxes	$ 1	$ 48

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 01, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	Pfenex Inc.
Entity Central Index Key	0001478121
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		31,675,903
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-36540
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-1356759
Entity Address, Address Line One	10790 Roselle Street
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	352-4400
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	PFNX
Security Exchange Name	NYSEAMER

Commitments and Contingencies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2019
Office and Lab Equipment [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Operating and capital lease expiration dates	various dates through 2021

Commitments and Contingencies - Schedule of Estimated Future Annual Minimum Lease Payment Obligations under Non-cancelable Leasing Arrangements, Including Facilities Lease (Detail) $ in Thousands	Sep. 30, 2019 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Capital Leases, 2019	$ 92
Capital Leases, 2020	202
Capital Leases, 2021	1
Total future minimum lease payments	$ 295

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Compensation Related Costs [Abstract]
Proceeds from exercise of stock options	$ 0.4	$ 0.1
Weighted average remaining contractual term	6 years 11 months 1 day
Weighted average grant date fair value, granted	$ 3.01	$ 2.37
Unrecognized compensation cost related to unvested stock options	$ 5.8
Unrecognized compensation cost related to unvested stock options, weighted average period for recognition	2 years 8 months 12 days

Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 32,518	$ 56,220
Restricted cash	200	200
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 32,718	$ 56,420